28:I[426309,["/_next/static/chunks/33t46atd3n2zd.js","/_next/static/chunks/13_5xgo-88-ti.js","/_next/static/chunks/1qdiot3ypuu8p.js","/_next/static/chunks/0k1u_y85kp1nu.js","/_next/static/chunks/3jv9w5luh13-h.js","/_next/static/chunks/2m2orr4p1zthr.js","/_next/static/chunks/396j1ajnr24t2.js","/_next/static/chunks/40_ipnvspmobm.js","/_next/static/chunks/2k8ijum9vhxzb.js","/_next/static/chunks/0x3w32sab_w1g.js","/_next/static/chunks/0dsf1sm79o3h9.js","/_next/static/chunks/0hhry4zljb_l8.js","/_next/static/chunks/3qlj4t73oud8o.js","/_next/static/chunks/2gxjjg41aomlx.js","/_next/static/chunks/0d5_zjj152e85.js","/_next/static/chunks/162klsaeqauz4.js"],"CompanyPage"] 29:T294c,# Dr. Reddy's Biologics Facility: Three Years of USFDA Scrutiny ## The Pattern of Regulatory Observations [Dr. Reddy's Laboratories](isin#INE089A01031) has received Form 483 observations in three consecutive USFDA inspections at its biologics manufacturing facility in Bachupally, Hyderabad. The timeline tells a concerning story: nine observations in October 2023, five in September 2025, and seven in June 2026. The June 2026 inspection was a Pre-License Inspection (PLI) conducted over 10 days, representing a critical hurdle for upcoming biosimilar approvals[web:2]. [lodr:1] The company itself acknowledges this is a continuation of earlier inspections, with disclosures referencing the October 2023 and September 2025 events[web:9]. This isn't just routine regulatory noise—it's a pattern that suggests deeper systemic issues at a facility Dr. Reddy's has identified as its primary growth engine as revenue from generic Revlimid begins to erode[web:1]. [lodr:1] ## What the Numbers Really Mean At first glance, the reduction from nine observations in 2023 to five in 2025 looked like progress—a 44% improvement that suggested corrective measures were working. But the increase to seven in 2026 tells a different story. This regression indicates that previous corrective actions may have been superficial rather than addressing root causes, or that new deficiencies emerged during the interim period[web:1]. The shift from Pre-Approval Inspection (PAI) in 2023 and 2025 to Pre-License Inspection (PLI) in 2026 is significant. A PLI is product-specific and directly halts the approval of targeted biologic drugs if deficiencies aren't resolved[web:1]. The magnitude of risk has shifted from general regulatory oversight to specific pre-license hurdles for upcoming biosimilars[web:1]. ## What's Actually Wrong at the Facility Here's where things get tricky. Dr. Reddy's has not publicly disclosed the specific details of the seven observations from June 2026. The company's public statements confirm only the number, not the nature of the deficiencies[web:2]. However, management has provided some clues. [lodr:1] Management characterizes the observations as related to the "sterile nature of the site" and notes they're primarily focused on the first fill-and-finish line (FFM-1). Some design issues with this line have raised queries "and also last time," suggesting recurring problems. The company describes these as "queries that are addressable" with "nothing specific, per se". [lodr:36] Historical context from October 2023 provides more insight. That inspection found major production equipment not appropriately cleaned, a quality-control unit that didn't investigate consumer complaints, computer systems not properly overseen, production buildings not maintained, and testing methods not established to detect accuracy or reproducibility[web:31]. The regulator also spotted "cleanliness and procedural lapses"[web:34]. ## Why Internal Audits Aren't Catching These Issues The recurring pattern across three inspections points to systemic failures in internal audit mechanisms. Effective internal audit programs should identify where systems are likely to fail before regulators do[web:39]. But at Dr. Reddy's Bachupally facility, USFDA inspectors keep finding issues that internal processes should have caught and resolved. Most GMP audit findings are not isolated issues—they're "repeatable signals of weak system control"[web:39]. Recent FDA warning letters consistently trace systemic weaknesses to poor process control, inadequate documentation, and data integrity gaps[web:39]. The fact that similar design-related queries were raised "last time" suggests Dr. Reddy's internal audits may be addressing symptoms rather than root causes. [lodr:36] Internal audit best practices require risk-based approaches that go beyond checklist confirmation, sampling records deeply, tracing decisions end-to-end, and verifying processes work in daily practice not just on paper[web:39]. Findings should be graded by risk, linked to verified root causes, and include CAPAs with meaningful effectiveness checks. If Dr. Reddy's audits aren't catching what USFDA finds, the program may lack depth, independence, or critical testing of assumptions. ## The Regulatory and Financial Impact The seven observations create immediate regulatory hurdles. Dr. Reddy's has 15 business days to submit a corrective and preventive action (CAPA) plan[web:1]. The Establishment Inspection Report (EIR) classification—expected within 60-90 days—will determine next steps[web:1]. Until the USFDA classifies the inspection as VAI (Voluntary Action Indicated), the biosimilar approval pipeline remains stagnant[web:1]. Direct remediation costs could range from ₹50-100 crore, with potential margin compression if costs exceed this range[web:1]. But the real cost lies in "opportunity loss" from delayed biologics approvals[web:1]. Significant capital has been diverted into the biologics pipeline; delays increase the burn rate on these investments without corresponding revenue realization. The September 2025 inspection already resulted in a Complete Response Letter (CRL) for the Rituximab biosimilar candidate, and by January 2026, the company received a Post-Application Action Letter (PAAL) indicating ongoing resolution challenges. Management expects to respond to comments and anticipates a re-inspection, though the exact timeline remains uncertain. [lodr:34][lodr:35][lodr:64] ## Competitive Positioning at Risk The global biosimilars market is projected to reach USD 102-163 billion by 2033, growing at 14-18% annually[web:69][web:70]. Dr. Reddy's competes against established players like Amgen, Pfizer, Samsung Bioepis, and Celltrion, which collectively held 55% market share in 2025[web:73]. In this market, timing is critical—first entrants typically capture significant market share. The repeat nature of observations "could delay high-margin product approvals in the US market"[web:1]. Competitors with ready manufacturing capacity could gain market share if Dr. Reddy's launches are delayed. The company is "among the leaders in the biosimilar race," making its compliance status a benchmark for the broader industry[web:1]. Dr. Reddy's has implemented geographic diversification to mitigate competitive disadvantages. The Bachupally facility already has European approval, and management expects European sales to grow from less than EUR 100 million in 2018 to potentially "10 times this number" in the next 2-3 years. The company has successfully launched Rituximab across multiple European countries and received European Commission approval for Denosumab biosimilar in Q3FY26. [lodr:83][lodr:40][lodr:78] ## Strategic Investments and Risk Mitigation Dr. Reddy's is making significant strategic investments in manufacturing quality and compliance. The company invests 7-9% of annual revenue in R&D, heavily skewed toward high-barrier segments including complex injectables and biosimilars[web:54]. Significant CAPEX is focused on biologics facilities, including Bachupally and injectable facility FTO-11. [lodr:155] The company has implemented a multi-layered risk mitigation approach. An alternate fill-and-finish line (FFM-2) serves as backup if the primary line faces challenges. A US-based Contract Manufacturing Organization (CMO) partnership for Abatacept production provides regulatory risk mitigation, tariff uncertainty protection, and Day-1 launch capability. Management notes they're "very, very sensitive to margins" and disciplined about investment decisions. [lodr:36][lodr:47][lodr:44][lodr:104] Regulatory performance across facilities shows mixed results. The API facility CTO SEZ in Srikakulam achieved zero observations during USFDA inspection in November 2025, demonstrating the company's capability to achieve USFDA compliance standards when properly executed. This contrasts with the ongoing challenges at Bachupally. [lodr:35] ## Investor Confidence and Cost of Capital Despite regulatory challenges, Dr. Reddy's maintains strong financial fundamentals. The company has a net cash surplus of $342 million as of December 2025, with cash and short-term investments of ₹82.59 billion compared to total debt of ₹67.73 billion[web:54]. Operating margin stood at 15.63% in Q3 FY26, with free cash flow of ₹4.20 billion[web:54]. ROCE was 20.4% annualized in Q3 FY26. [lodr:138][lodr:118] The stock is currently trading near its 52-week high of ₹1,375.90[web:59], with market capitalization around ₹1,08,560 crore[web:1]. While specific stock price movements following the June 2026 observations aren't yet available, historical patterns show Indian pharma stocks are "highly sensitive to regulatory developments"[web:67]. Cipla shares fell approximately 5% following USFDA observations at a partner facility in January 2026[web:67]. Recurring USFDA observations could create a modest valuation discount and increase the cost of capital through higher regulatory risk premiums, cash flow uncertainty, execution risk, and competitive position risk. However, mitigating factors include the strong balance sheet, geographic diversification, proven compliance capability at other facilities, and European market success. ## The Path Forward The immediate focus is addressing the seven observations within the stipulated timeline. Management has stated they will address all observations within the prescribed regulatory timeframe[web:2]. The company's ability to satisfactorily address these observations is the key consideration[web:2]. [lodr:1] Investors should monitor several critical milestones: the CAPA plan submission within 15 business days, EIR classification within 60-90 days, management commentary during Q1 FY27 results scheduled for July 22, 2026, and disclosure about whether observations are primarily related to data integrity or procedural issues[web:1]. The global biosimilars market's projected growth represents a significant opportunity. Dr. Reddy's ability to resolve its USFDA compliance challenges quickly will determine its share of this expanding market and its long-term competitive positioning. With biologics as the company's primary growth engine, timely resolution of these observations is critical for achieving management's 15% plus growth target and maintaining competitive positioning in the global biosimilar market.2a:T1f37,## Dr Reddy's US Generics Push [Dr Reddy's Laboratories](isin#INE089A01031) launched Bosutinib Tablets 400mg in the US on June 13, 2026, as the first-to-market generic equivalent of Pfizer's Bosulif®. The branded product generates approximately $253.8 million in annual US sales[web:11]. With 180 days of generic exclusivity, Dr Reddy's can capture significant market share during this protected period. Industry studies show generic companies generate 60-80% of total lifetime profits for a molecule within this six-month window[web:82]. The launch strengthens Dr Reddy's oncology portfolio and demonstrates its first-to-file capabilities. The company ranks #6 in the US generics market and has achieved 7.6% growth compared to 0.8% for the overall US generics market, excluding Lenalidomide. This launch fits into Dr Reddy's broader strategy of focusing on complex generics with favorable market dynamics, executing through strategic partnerships while maintaining control over commercialization. [lodr:1] ## Adani Green's Battery Storage Bet [Adani Green Energy](isin#INE364U01010) has commissioned 3.37 GWh of battery energy storage at Khavda, Gujarat—the world's largest single-location deployment outside China[web:81]. The company plans to scale this to 14 GWh by fiscal year-end and 50 GWh over five years[web:3]. This investment addresses a critical challenge: India wasted 300 GWh of clean power in Q1 FY26 due to lack of storage infrastructure[web:3]. The 3.37 GWh system can store enough energy to power nearly 1 million homes for a day[web:4]. By absorbing excess generation during peak production and discharging during evening peak hours, Adani Green can reduce curtailment by up to 50% and improve capacity utilization from 65-70% to 80-85%. The economics are compelling—capital costs of ₹1.5 crore/MWh with expected EBITDA of ₹25 lakh/MWh, delivering returns similar to or better than core solar-wind projects. With 75-78% of capacity secured through 25-year fixed tariff PPAs, the storage assets provide both revenue visibility and upside potential from merchant markets. [lodr:2] ## JSW Energy's Thermal Acquisition [JSW Energy](isin#INE121E01018) signed a definitive agreement to acquire 100% equity of Maruti Clean Coal & Power Limited for an enterprise value of ₹1,410 crore[web:16]. The target operates a 300 MW thermal plant in Korba, Chhattisgarh, with 195 MW tied under long-term PPA with Rajasthan discoms for ~14 years[web:15]. The acquisition is immediately EBITDA and PAT-accretive, with estimated FY26 EBITDA of ~₹279 crore[web:15]. The plant's proximity to JSW Energy's existing 3,600 MW KSK Mahanadi thermal plant creates significant operational synergies. JSW Energy has demonstrated its integration capabilities by improving KSK Mahanadi's plant load factor from 67% to 79% within just 25 days of takeover. Similar improvements are expected at MCCPL through shared infrastructure, optimized fuel logistics, and best practices transfer. The acquisition increases JSW Energy's installed thermal capacity from 5,658 MW to 5,958 MW[web:18] and aligns with its disciplined "Build vs. Buy" approach to reach 30 GW capacity by 2030. [lodr:1] ## KIMS Capital Raise and Expansion [Krishna Institute of Medical Sciences](isin#INE967H01025) approved preferential allotment of 77,02,182 warrants at ₹779 per share to promoter group members, aggregating ₹600 crore[web:21]. The warrants are exercisable within 18 months, with 25% payable upfront and 75% upon conversion. This represents 1.89% equity dilution for existing shareholders upon full conversion, increasing promoter shareholding from 34.11% to 35.35%. The warrant price of ₹779 compares closely to the current market price of ₹782.75, indicating strong management confidence despite current margin pressures [stock_agent:3]. KIMS reported 28.2% revenue growth to ₹3,931 crore in FY26, though EBITDA margins declined to 21.1% from 26.6% due to new hospital ramp-ups. Management expects margin recovery as new assets achieve operational maturity and insurance empanelments. The proceeds will strengthen the capital structure, potentially reducing the debt-to-equity ratio from 0.99x to ~0.78x, and fund continued expansion across Telangana, Karnataka, Maharashtra, and Kerala. [lodr:1][lodr:3] ## Nestlé India's Brand Protection [Nestlé India](isin#INE239A01024) faced social media allegations regarding MAGGI noodles infestation in June 2026. The company categorically rejected the claims, stating laboratory tests on batch and market samples confirmed products met all quality and food safety standards[web:45]. The reference sample was tested at an independent FSSAI-notified and NABL-accredited laboratory, which found it free of any infestation[web:48]. Nestlé India maintains comprehensive quality assurance systems including FSSC 22000 Food Safety System Certification and ISO 17025:2017 for testing laboratories. The company has demonstrated strong crisis recovery capabilities, with management noting that "MAGGI came back from the dead literally in 2015 roaring to a 19% growth" following previous challenges. Despite the allegations causing a 3.29% stock decline on June 12, 2026, the company's scientific validation and transparent communication should mitigate long-term brand impact. MAGGI remains the dominant player in India's instant noodles market, which is valued at approximately ₹3,000 crore[web:52]. [lodr:2] ## NLC India's Critical Mineral Entry [NLC India](isin#INE589A01014) emerged as the preferred bidder for the Parvathapur Vanadium, Titanium & Aluminous Laterite block in Sanga Reddy, Telangana, following the Ministry of Mines' critical and strategic mineral block auction in June 2026[web:39]. This marks a strategic diversification beyond traditional lignite mining and power generation into high-value critical minerals essential for defense, energy storage, and aerospace applications[web:37]. The regulatory approval process typically takes 9-12 months based on NLC India's experience with similar blocks in Chhattisgarh, where the process from preferred bidder status to composite licence grant took approximately 11 months. Recent policy changes, including the September 2025 removal of public consultation requirements for critical mineral projects, could potentially accelerate approvals by 2-3 months[web:53]. However, delays in environmental clearances, forest approvals, or mining lease execution could postpone commercial production timelines and capital deployment. NLC India has strengthened its capabilities through partnerships with CSIR-CECRI for beneficiation technologies and IIT(ISM) TEXMiN for exploration research[web:39]. [lodr:1] ## LIC's Competitive Strategy [LIC of India](isin#INE0J1Y01017) is strengthening its leadership position amid rising private sector competition as it approaches its platinum jubilee in 2031. The corporation maintains 56.6% market share in first-year premium income, with individual business at 35.84% and group business at 71.36%. LIC's seven strategic priorities include digital transformation through the DIVE project, product mix optimization focusing on Non-Participating products, distribution channel enhancement, agency transformation, market share recovery, investment yield maximization, and human capital development. Digital initiatives include the MyLIC customer app and ANANDA platform, which processed 23,00,983 policies in FY26, growing 56.08% year-on-year. Active agents grew by 29.56% YoY, reinforcing LIC's "feet on street" distribution advantage. Success metrics include maintaining above 56% overall market share, improving persistency ratios (currently 74.84% on 13-month premium basis), and growing Value of New Business (VNB) while maintaining VNB margins. LIC's strategy emphasizes sustainable growth balanced with profitability, leveraging its 70-year legacy and trust advantage against more agile private players like HDFC Life and SBI Life[web:72]. [lodr:1]2b:T15a2,**Dr Reddy's Q4 FY26: Navigating R&D Setbacks and US Market Headwinds** [Dr Reddys Laboratories Ltd](isin#INE089A01031) reported a sharp 86% decline in consolidated net profit to Rs 221 crore for the quarter ended March 31, 2026, down from Rs 1,593 crore a year earlier. This significant drop was driven by a combination of one-time impairment charges related to discontinued R&D programs, intense pricing pressure in the crucial US market, and substantial regulatory provisions. Despite these headwinds, the company is executing a strategic pivot toward high-growth areas like semaglutide and biosimilars to rebuild momentum. ## R&D Discontinuations and Their Financial Toll The company decided to discontinue certain programs within its Chimeric Antigen Receptor T-cell (CAR-T) therapy portfolio following clinical trial outcomes. While the specific efficacy or safety data from these trials was not publicly disclosed, the decision led to a total impairment charge of Rs 135 crore. This included Rs 129.1 crore towards non-current assets like property, plant, equipment, and intangible assets, alongside Rs 5.9 crore in wind-down costs. Additionally, Dr Reddy's recorded a separate impairment charge of Rs 91.4 crore after discontinuing a late-stage lung cancer study. These R&D write-offs directly contributed to a reported net loss of Rs 135 crore in the global generics segment for the quarter, severely impacting the bottom line. [lodr:38][lodr:39][lodr:41][lodr:40] ## US Market Pressures and Lenalidomide Decline Operational challenges in the US market compounded the impact of these one-time charges. Total revenue from operations fell 11.5% to Rs 7,546 crore, missing analyst estimates of Rs 8,246 crore. This shortfall was primarily attributed to pricing pressure and increasing competition in the US generics market. A major factor was the decline in sales of lenalidomide, a generic version of Bristol-Myers Squibb's cancer drug Revlimid. Following the patent expiry, competition intensified significantly, eroding the sales of a product that had been a strong growth driver for years. Analysts noted that lenalidomide had contributed $550-650 million to Dr Reddy's US revenue, accounting for 35-40% of that segment. The loss of this high-revenue stream fundamentally altered the company's growth trajectory in North America. ## Cumulative Impact of One-Time Provisions Beyond the R&D impairments, Dr Reddy's profitability was weighed down by significant regulatory provisions. For the full fiscal year 2026, the company recorded a VAT liability provision of Rs 70 crore and a provision of Rs 117 crore related to the implementation of new Labour Codes in India. The Labour Codes provision was retrospective in nature, requiring the re-computation of gratuity and leave encashment obligations for employees. These charges, combined with the impairment losses, created a heavy burden on the company's earnings for the period. For the full year, EBITDA margins narrowed sharply to 22.8% from 28.3% in the previous year, reflecting the cumulative effect of these adverse factors. [lodr:83] ## Strategic Pivot: Semaglutide and Future Growth To counter the decline in lenalidomide and US market pressures, Dr Reddy's is aggressively launching new products. In March 2026, the company launched Obeda, its generic semaglutide injection, in India, becoming the first Indian company to receive DCGI approval for the product. The company plans to expand this launch to Canada, Brazil, Turkey, and over 80 other markets as patents expire. Analysts project the Canadian market alone could generate $80-100 million in revenue for Dr Reddy's in FY27, with the global semaglutide market expected to reach $51.95 billion by 2033. This launch is a cornerstone of the company's strategy to fill the revenue gap left by lenalidomide. [lodr:35][lodr:117][lodr:114] ## Building Long-Term Franchises Dr Reddy's is also investing heavily in biosimilars, consumer health, and innovation to ensure sustainable value creation. The company has launched a denosumab biosimilar in Europe and expects to launch an abatacept biosimilar in July 2027, targeting a $2 billion addressable market. The integration of the Nicotine Replacement Therapy (NRT) business, acquired for Rs 5,276 crore, is 95% complete and is contributing to European revenue growth. Management has stated that biosimilars are expected to reach meaningful scale within five years. These strategic pillars are designed to diversify revenue away from commoditized generics and improve long-term margins. [lodr:32][lodr:116][lodr:117] ## Resilience and Margin Improvement Initiatives Despite the Q4 profit decline, the company demonstrated resilience in other areas. Branded businesses in India and Europe showed strong growth, aided by favorable currency tailwinds. India revenue grew 19% year-on-year in Q3, while emerging markets grew 32%. To improve margins, Dr Reddy's is implementing cost efficiencies through AI/ML systems for supply chain optimization, which reduced inventory lead times by 20% in 2024, and leveraging automation in manufacturing. The company has guided for an underlying EBITDA margin of approximately 25% after adjusting for one-time provisions, indicating confidence in its core operational strength. While margin compression remains a challenge due to US pricing pressure, these initiatives aim to stabilize profitability as the new product pipeline ramps up.2c:T1e8c,## The Canadian Breakthrough Health Canada made pharmaceutical history on April 28, 2026, by authorizing the first generic semaglutide injection in any G7 country. [Dr. Reddy's Laboratories](isin#INE089A01031) secured this landmark approval for its generic version of Ozempic, positioning the Hyderabad-based company as a first-mover in what analysts project could be a $1.5-2.5 billion annual Canadian market . This approval didn't happen by chance—it resulted from Novo Nordisk's failure to pay a $450 annual patent maintenance fee in 2019, causing the patent to lapse irreversibly under Canada's Patent Act . Only data exclusivity, which expired on January 4, 2026, had kept generics off the market until now. The timing couldn't be better for Dr. Reddy's. The company has built an inventory of 12 million pens, with capacity to scale to 15 million based on market demand . Analysts expect six to nine months of no competition in the Canadian market, with the street working with revenue projections between $80 million and $100 million for financial year 2027 . In a bullish scenario, HSBC forecasts potential sales reaching $280 million, contributing approximately 18% of the company's earnings per share . ## Competitive Positioning and Pricing Strategy The Canadian GLP-1 market is about to get crowded. Nine generic manufacturers are in the Health Canada review pipeline, including major players like Sandoz, Apotex, Teva, and others . This competitive landscape forces Dr. Reddy's to navigate a complex trade-off between market share capture and margin preservation. Canada's pan-Canadian Tiered Pricing Framework mandates specific pricing tiers based on market competition . As a single-source generic, Dr. Reddy's faces an automatic price reduction to 55% of brand reference price within three months of public funding . With mandatory generic discounts of 65%, the company plans to price at the lower end of $20-80 per unit range—substantially below branded Ozempic's current monthly cost of $300-450 . Novo Nordisk hasn't sat idle. The Danish pharmaceutical giant launched two authorized generics—Plosbrio (Ozempic equivalent) and Poviztra (Wegovy equivalent)—in December 2025 . These are identical to the branded products in formulation and manufacturing but sold under different names at lower prices . This strategy mirrors Novo Nordisk's approach in India, where it cut Wegovy's price by 37% ahead of the generic wave . ## Regulatory Pathways and First-Mover Advantages Dr. Reddy's path to approval wasn't smooth. In October 2025, Health Canada's Pharmaceutical Drugs Directorate issued a Notice of Non-Compliance, delaying the timeline by 8-12 months . The company submitted its response in January 2026, planning for launch between February and May . On April 22, 2026, Dr. Reddy's received Drug Identification Numbers from Health Canada—a critical step before final approval . The regulatory journey highlights the complexity of bringing complex synthetic products to market. Semaglutide is a 31-amino-acid peptide with a fatty acid side chain, making it harder to manufacture and evaluate than standard small-molecule generics . Health Canada's target review timeline for generic drug submissions is 180 days, and the agency met this target 84% of the time in its most recent reporting year . Historical data from the Canadian generic drug market between 1998-2006 demonstrates the enduring value of first-mover advantages. For about two-thirds of molecules, the first entrant was able to maintain market leadership even after additional competitors entered . This suggests Dr. Reddy's 6-9 month window of exclusivity could translate into lasting market share. ## Financial Impact and Analyst Perspectives The semaglutide opportunity represents a meaningful contribution to Dr. Reddy's overall financial performance. For context, the company reported FY25 revenue of ₹32,553.4 crores (~$3.9 billion) . Even the conservative $80-100 million revenue projection represents 2.2-2.6% of total company revenue, while HSBC's bullish $280 million scenario would contribute 7.2%. Analyst perspectives diverge significantly. HSBC upgraded Dr. Reddy's to "buy" from "hold" in June 2025, raising its price target to ₹1,445 from ₹1,235 . The brokerage forecasts $280 million in semaglutide revenues for 2027, with $224 million expected from Canada alone, assuming mid-single-digit to low-double-digit unit market share . In a bullish case, HSBC sees potential sales reaching $500 million . Conversely, Goldman Sachs downgraded the stock to "sell" from "neutral," cutting its price target to ₹1,075 from ₹1,225 . Goldman believes the Ozempic opportunity will be short-lived and cut FY26-28 EPS estimates by 8-26% . Citi maintains a "sell" rating with a target of ₹1,070, projecting $50 million in revenue for FY28 in a six-player market . The current stock price of ₹1,347.40 reflects this risk-adjusted assessment . The 12-month analyst consensus ranges from ₹1,350-1,550, with a bull case of ₹1,800 and bear case of ₹850 . This 20% discount scenario from current levels reflects market concerns about execution risks, regulatory delays, and intense competition from eight other generic manufacturers . ## Broader Competitive Landscape Implications Dr. Reddy's approval signals broader shifts in the GLP-1 competitive landscape toward increased genericization and price competition. The Canadian market serves as a harbinger of global changes as foundational GLP-1 patents expire across multiple jurisdictions. The entry of generics creates a two-tier market structure. The generic/biosimilar tier targets high-volume markets with emphasis on affordability and patient volume . The innovation tier features next-generation therapies like retatrutide and MariTide that command premium pricing exceeding $1,000/month by proving superior outcomes in cardiovascular events or metabolic liver disease . This transformation is driving massive industry restructuring. Industry analysts estimate coming cardiometabolic acquisitions could exceed $100 billion over the next several years as companies race to secure next-generation therapies . Both Eli Lilly and Novo Nordisk are investing heavily in manufacturing—Eli Lilly spent approximately $7.8 billion in 2025, while Novo Nordisk announced capital expenditure plans exceeding DKK 45 billion for 2026 . ## Strategic Outlook and Execution Challenges The next 6-9 months represent a critical window for Dr. Reddy's to establish market leadership. The company's 12-15 million pen inventory provides manufacturing scale advantages, but success will require more than just capacity . Key execution risks include regulatory complexity, competitive intensity, and market access uncertainty. The stock has experienced significant volatility around semaglutide developments—dropping nearly 6% in October 2025 after a regulatory setback, then gaining 8% in April 2026 on approval anticipation . Looking beyond Canada, Dr. Reddy's has outlined ambitions to launch semaglutide generics in 87 countries, leveraging the Canadian approval as a foundation . The company secured a Certificate of Pharmaceutical Product enabling exports to over 80 international markets, with Brazil and Turkey identified as significant opportunities where the molecule goes off-patent in July 2026 . The Canadian semaglutide approval marks a new chapter for Dr. Reddy's, positioning the company to capitalize on the $100+ billion global GLP-1 market while establishing a template for complex generic entry into other G7 markets . Success will depend on execution excellence during the first-mover window, cost leadership in an increasingly competitive environment, and the ability to navigate both sides of the emerging two-tier GLP-1 economy.1e:[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"Corporation\",\"name\":\"Dr Reddys Laboratories\",\"url\":\"https://askfuzz.ai/company/dr-reddys-laboratories-ltd\",\"industry\":\"Pharmaceuticals\"}"}}],["$","$L28",null,{"slug":"dr-reddys-laboratories-ltd","data":{"ABOUT_COMPANY":null,"BALANCE_SHEET":{"BALANCE_SHEET_CONSOLIDATED_FORMATTED":{"periods":["FY26","FY25","FY24","FY23","FY22","FY21","FY20","FY19","FY18","FY17","FY16","FY15"],"parameters":[{"key":"EbitRoce","label":"EbitRoce"},{"key":"EquityForROE","label":"EquityForROE"},{"key":"TotalAssets","label":"TotalAssets","children":[3,13]},{"key":"TotalCurrentAssets","label":"TotalCurrentAssets","parent":2,"children":[4,5,6,7]},{"key":"CurrentTaxAssets","label":"CurrentTaxAssets","parent":3},{"key":"Inventories","label":"Inventories","parent":3},{"key":"OtherAssets","label":"OtherAssets","parent":3},{"key":"TotalFinancialAssets","label":"TotalFinancialAssets","parent":3,"children":[8,9,10,11,12]},{"key":"CashEquivalent","label":"CashEquivalent","parent":7},{"key":"Investment","label":"Investment","parent":7},{"key":"Loans","label":"Loans","parent":7},{"key":"OtherFinancialAssets","label":"OtherFinancialAssets","parent":7},{"key":"TradeReceivables","label":"TradeReceivables","parent":7},{"key":"TotalNonCurrentAssets","label":"TotalNonCurrentAssets","parent":2,"children":[14,15,16,17,18,19]},{"key":"CapitalWorkInProgress","label":"CapitalWorkInProgress","parent":13},{"key":"DeferredTaxAssets","label":"DeferredTaxAssets","parent":13},{"key":"IntangibleAssets","label":"IntangibleAssets","parent":13},{"key":"PropertyPlantAndEquipments","label":"PropertyPlantAndEquipments","parent":13},{"key":"RightOfUseAssets","label":"RightOfUseAssets","parent":13},{"key":"TotalFinancialAssets","label":"TotalFinancialAssets","parent":13,"children":[20,21,22,23]},{"key":"Investment","label":"Investment","parent":19},{"key":"Loans","label":"Loans","parent":19},{"key":"OtherFinancialAssets","label":"OtherFinancialAssets","parent":19},{"key":"SubAssociatedJointVentures","label":"SubAssociatedJointVentures","parent":19},{"key":"TotalAssetsROCE","label":"TotalAssetsROCE"},{"key":"TotalBorrowings","label":"TotalBorrowings"},{"key":"TotalCurrentLiabilitiesROCE","label":"TotalCurrentLiabilitiesROCE"},{"key":"TotalEquity","label":"TotalEquity","children":[28,29]},{"key":"NonControllingInterest","label":"NonControllingInterest","parent":27},{"key":"TotalStockHolderEquity","label":"TotalStockHolderEquity","parent":27,"children":[30,31]},{"key":"EquityShareCapital","label":"EquityShareCapital","parent":29},{"key":"OtherEquity","label":"OtherEquity","parent":29},{"key":"TotalLiabilities","label":"TotalLiabilities","children":[33,42]},{"key":"TotalCurrentLiabilities","label":"TotalCurrentLiabilities","parent":32,"children":[34,35,36,37]},{"key":"CurrentTaxLiability","label":"CurrentTaxLiability","parent":33},{"key":"OtherCurrentLiabilities","label":"OtherCurrentLiabilities","parent":33},{"key":"Provisions","label":"Provisions","parent":33},{"key":"TotalFinancialLiabilities","label":"TotalFinancialLiabilities","parent":33,"children":[38,39,40,41]},{"key":"Borrowing","label":"Borrowing","parent":37},{"key":"LeaseLiabilities","label":"LeaseLiabilities","parent":37},{"key":"OtherFinancialLiabilities","label":"OtherFinancialLiabilities","parent":37},{"key":"TradePayables","label":"TradePayables","parent":37},{"key":"TotalNonCurrentLiabilities","label":"TotalNonCurrentLiabilities","parent":32,"children":[43,44,45,46]},{"key":"DeferredTaxLiabilities","label":"DeferredTaxLiabilities","parent":42},{"key":"OtherNonCurrentLiabilities","label":"OtherNonCurrentLiabilities","parent":42},{"key":"Provisions","label":"Provisions","parent":42},{"key":"TotalFinancialLiabilities","label":"TotalFinancialLiabilities","parent":42,"children":[47,48,49]},{"key":"Borrowing","label":"Borrowing","parent":46},{"key":"LeaseLiabilities","label":"LeaseLiabilities","parent":46},{"key":"OtherFinancialLiabilities","label":"OtherFinancialLiabilities","parent":46},{"key":"TotalNetProfitForROE","label":"TotalNetProfitForROE"}],"values":[[5860,8031.1,7452.1,6197,3158.2,2980.8,1954.3,2408.4,1507.4,1732.3,3038.9,3122.7],[37891.5,33549.6,28254.8,23286.1,19212.4,17641.7,15598.8,14023.6,12571.6,12262.1,12569.8,9853.1],[58123.4,49426.6,38863.8,32285.1,29746.9,26616.8,23225.3,22465.6,22544.3,21816.5,20384.1,18597.8],[30179.3,25018.1,24805.3,20425.5,17782.3,14550.3,12599.1,11110.1,10498.4,9683.7,11794,11876.7],[0,0,0,0,0,0,0,0,0,0,0,0],[7653.4,7108.5,6355.2,4867,5088.4,4541.2,3506.7,3357.9,2908.9,2852.8,2557.9,2569.9],[2989.5,2706.8,2018,1512,1233,1265,1042.4,1042.4,1276.2,1049.1,964.8,0],[17724.5,14208,15415.1,12894.2,10526.9,8133.1,8050,6709.8,6313.3,5781.8,8271.3,6203.4],[1536.8,1465.4,710.7,577.9,1485.2,1482.9,205.3,222.8,263.8,386.5,492.1,0],[3823.3,3330.7,4405,4449.6,2017.3,1378.5,2368.7,2252.9,1833,1427.1,3503.4,2102.2],[0,0,0,0,0,0,0,0,0,0,0,0],[2241,369.9,2269.6,618.2,348,307.6,448.2,247.2,163.8,169.6,150.8,0],[10123.4,9042,8029.8,7248.5,6676.4,4964.1,5027.8,3986.9,4052.7,3798.6,4125,4101.2],[27944.1,24408.5,14058.5,11859.6,11964.6,12066.5,10626.2,11355.5,12045.9,12132.8,8590.1,6721.1],[1460.2,2399.4,1351,975.2,1279.6,953.9,436.4,472.5,767.8,609.5,662.6,529],[2219,1832.5,1057.8,705.2,1277,1068.6,1219.9,431.7,540.5,678.4,590.5,245],[11985.5,10928,4176.9,3564.9,3234.6,3473.5,2072.4,2278.3,1994.7,1902.6,1950,1193.3],[10077.8,7298.4,6248.7,5654.2,4886.9,4732.2,4777.9,4912.7,4973.3,5028.1,4613,4183.7],[0,0,0,0,0,0,0,0,0,0,0,0],[1753.2,1607.9,646.7,608.9,881.3,921.9,562.1,418.6,557.8,786.5,408.5,0],[894.2,239.3,105.9,66,166.8,495.8,32.8,81.3,254.9,522.3,198.6,0],[0,0,0,0,0,0,0,0,0,0,0,0],[291.7,887.5,121.2,72.7,282.7,88.6,253,84.4,92.5,103.9,78.8,0],[567.3,481.1,419.6,470.2,431.8,337.5,276.3,252.9,210.4,160.3,131.1,0],[58123.4,49426.6,38863.8,32285.1,29746.9,26616.8,23225.3,22465.6,22544.3,21816.5,20384.1,18597.8],[0,380,380,0,380,380,130.4,2200,2508.9,544.9,1068.5,1431.5],[16747.4,13033.8,9588,8572.1,9765.8,8103.8,7214.1,5897.3,6893.8,8419.9,6347.1,6821.3],[38230.9,33927.4,28254.8,23286.1,19212.4,17641.7,15598.8,14023.6,12571.6,12262.1,12569.8,9853.1],[339.4,377.8,0,0,0,0,0,0,0,0,0,0],[37891.5,33549.6,28254.8,23286.1,19212.4,17641.7,15598.8,14023.6,12571.6,12262.1,12569.8,9853.1],[83.5,83.4,83.4,83.3,83.2,83.2,83.1,83,83,82.9,85.3,85.2],[37808,33466.2,28171.4,23202.8,19129.2,17558.5,15515.7,13940.6,12488.6,12179.2,12484.5,9767.9],[19892.5,15499.2,10609,8999,10534.5,8975.1,7626.5,8442,9972.7,9554.4,7814.3,8744.7],[16747.4,13033.8,9588,8572.1,9765.8,8103.8,7214.1,5897.3,6893.8,8419.9,6347.1,6821.3],[435.3,302.8,234.1,214.3,544.2,138.8,57.2,18.1,153,148.2,230.4,0],[1192.1,1319,1143.7,1286.3,1027.8,877.4,651.2,546.9,453.2,464.7,358.9,3768.3],[870,775.6,692,652.5,586.6,501.5,466.9,478.9,438.7,512.5,529,0],[14250,10636.4,7518.2,6419,7607.2,6586.1,6038.8,4853.4,5848.9,7294.5,5228.8,3053],[6293.5,3804.5,1272.3,1119,2708.2,2314.5,1653.2,1212.5,2556.2,4362.6,2271.8,2185.7],[220.3,85.7,130.7,100.4,101.7,86.4,0,0,0,0,0,0],[4698.3,4098.4,3500.8,2931.2,2531.1,2374.3,2860.8,2273.8,1958.2,1875,2050.2,0],[3037.9,2647.8,2614.4,2268.4,2266.2,1810.9,1524.8,1367.1,1334.5,1056.9,906.8,867.3],[3145.1,2465.4,1021,426.9,768.7,871.3,412.4,2544.7,3078.9,1134.5,1467.2,1923.4],[1546.7,1403.8,84.1,76,1.4,28.9,2,47.3,195,162,53.7,140.7],[301.1,225.6,314,203.2,166.9,161.7,205.5,207.9,278.9,325.1,226,273.3],[33.8,29.8,23.9,19.9,25.8,50.8,74.5,79.3,81.7,84.2,94.7,77.9],[1263.5,806.2,599,127.8,574.6,629.9,130.4,2210.2,2523.3,563.2,1092.8,1431.5],[0,380,380,0,380,380,130.4,2200,2508.9,544.9,1068.5,1431.5],[1220.3,406.4,219,127.8,194.6,249.9,0,0,0,0,0,0],[43.2,19.8,0,0,0,0,0,10.2,14.4,18.3,24.3,0],[4157.6,5725.2,5577.9,4507.3,2182.5,1951.6,2026,1950,946.8,1292.1,2130.6,2336.4]]},"BALANCE_SHEET_STANDALONE_FORMATTED":{"periods":["FY26","FY25","FY24","FY23","FY22","FY21","FY20","FY19","FY18","FY17","FY16","FY15"],"parameters":[{"key":"EbitRoce","label":"EbitRoce"},{"key":"EquityForROE","label":"EquityForROE"},{"key":"TotalAssets","label":"TotalAssets","children":[3,13]},{"key":"TotalCurrentAssets","label":"TotalCurrentAssets","parent":2,"children":[4,5,6,7]},{"key":"CurrentTaxAssets","label":"CurrentTaxAssets","parent":3},{"key":"Inventories","label":"Inventories","parent":3},{"key":"OtherAssets","label":"OtherAssets","parent":3},{"key":"TotalFinancialAssets","label":"TotalFinancialAssets","parent":3,"children":[8,9,10,11,12]},{"key":"CashEquivalent","label":"CashEquivalent","parent":7},{"key":"Investment","label":"Investment","parent":7},{"key":"Loans","label":"Loans","parent":7},{"key":"OtherFinancialAssets","label":"OtherFinancialAssets","parent":7},{"key":"TradeReceivables","label":"TradeReceivables","parent":7},{"key":"TotalNonCurrentAssets","label":"TotalNonCurrentAssets","parent":2,"children":[14,15,16,17,18,19]},{"key":"CapitalWorkInProgress","label":"CapitalWorkInProgress","parent":13},{"key":"DeferredTaxAssets","label":"DeferredTaxAssets","parent":13},{"key":"IntangibleAssets","label":"IntangibleAssets","parent":13},{"key":"PropertyPlantAndEquipments","label":"PropertyPlantAndEquipments","parent":13},{"key":"RightOfUseAssets","label":"RightOfUseAssets","parent":13},{"key":"TotalFinancialAssets","label":"TotalFinancialAssets","parent":13,"children":[20,21,22,23]},{"key":"Investment","label":"Investment","parent":19},{"key":"Loans","label":"Loans","parent":19},{"key":"OtherFinancialAssets","label":"OtherFinancialAssets","parent":19},{"key":"SubAssociatedJointVentures","label":"SubAssociatedJointVentures","parent":19},{"key":"TotalAssetsROCE","label":"TotalAssetsROCE"},{"key":"TotalBorrowings","label":"TotalBorrowings"},{"key":"TotalCurrentLiabilitiesROCE","label":"TotalCurrentLiabilitiesROCE"},{"key":"TotalEquity","label":"TotalEquity","children":[28,29]},{"key":"NonControllingInterest","label":"NonControllingInterest","parent":27},{"key":"TotalStockHolderEquity","label":"TotalStockHolderEquity","parent":27,"children":[30,31]},{"key":"EquityShareCapital","label":"EquityShareCapital","parent":29},{"key":"OtherEquity","label":"OtherEquity","parent":29},{"key":"TotalLiabilities","label":"TotalLiabilities","children":[33,42]},{"key":"TotalCurrentLiabilities","label":"TotalCurrentLiabilities","parent":32,"children":[34,35,36,37]},{"key":"CurrentTaxLiability","label":"CurrentTaxLiability","parent":33},{"key":"OtherCurrentLiabilities","label":"OtherCurrentLiabilities","parent":33},{"key":"Provisions","label":"Provisions","parent":33},{"key":"TotalFinancialLiabilities","label":"TotalFinancialLiabilities","parent":33,"children":[38,39,40,41]},{"key":"Borrowing","label":"Borrowing","parent":37},{"key":"LeaseLiabilities","label":"LeaseLiabilities","parent":37},{"key":"OtherFinancialLiabilities","label":"OtherFinancialLiabilities","parent":37},{"key":"TradePayables","label":"TradePayables","parent":37},{"key":"TotalNonCurrentLiabilities","label":"TotalNonCurrentLiabilities","parent":32,"children":[43,44,45,46]},{"key":"DeferredTaxLiabilities","label":"DeferredTaxLiabilities","parent":42},{"key":"OtherNonCurrentLiabilities","label":"OtherNonCurrentLiabilities","parent":42},{"key":"Provisions","label":"Provisions","parent":42},{"key":"TotalFinancialLiabilities","label":"TotalFinancialLiabilities","parent":42,"children":[47,48,49]},{"key":"Borrowing","label":"Borrowing","parent":46},{"key":"LeaseLiabilities","label":"LeaseLiabilities","parent":46},{"key":"OtherFinancialLiabilities","label":"OtherFinancialLiabilities","parent":46},{"key":"TotalNetProfitForROE","label":"TotalNetProfitForROE"}],"values":[[4471.8,7414.4,5892.8,3907.2,2316.9,3143.6,2840.4,1774.5,786.8,1672.8,1797.8,2207.2],[31365.6,28856.6,24240.8,20474.2,18336.2,16983.7,15191.9,12684.1,11807.8,11600.6,12078.4,10634],[43602.1,38290.9,30359.3,25374.8,24495.6,21629.6,19475.8,16247.5,17100.3,16447.2,17585.2,16456],[18523.2,16503,17815.9,13788.3,13491.3,10944.2,10106.7,8933.2,9038.5,8593.8,10211.1,10403.3],[0,0,0,0,0,0,0,0,0,0,0,0],[4955.6,4575.8,4018.9,3043,3347.8,2819.7,2190.4,2015.6,1856.8,1809.7,1699.6,1723.3],[2218.7,1963.5,1614,1218.9,998.1,996.6,852.9,869.6,1121.8,907.1,833,0],[9728.8,9306.6,11167.5,8992.9,8271.8,6787.7,7063.4,6048,6059.9,5877,7678.5,6813.9],[337.5,319.7,201.4,112.3,1159.5,1306.3,39.2,113.2,120.7,66.8,202.1,0],[3233.5,2883,4117.9,4297.8,1912.4,1257,2118.4,2114.4,1682.8,1299.1,3298,2102.2],[100.2,0,0,0,0,0,0,0,0,0,0,0],[1939,144.9,2224.3,293.9,254.5,144.4,267.1,102.7,52.6,105.7,288.9,0],[4118.6,5959,4623.9,4288.9,4945.4,4080,4638.7,3717.7,4203.8,4405.4,3889.5,4711.7],[25078.9,21787.9,12543.4,11586.5,11004.3,10685.4,9369.1,7314.3,8061.8,7853.4,7374.1,6052.7],[1369.1,2156.4,1171.9,899.1,1186.4,877.1,384.1,400.1,675,540,615,488.3],[0,0,0,0,19.4,254.8,612.9,0,93.1,82.1,63.5,0],[2977.4,2367,2479.7,2457.4,2126.5,2265.1,664.1,732.3,738.3,798.8,844.3,120],[7752.7,5865.4,5109.4,4737.9,4024,3579.2,3769.8,3950.4,3979,4043.3,3593.8,3129.4],[0,0,0,0,0,0,0,0,0,0,0,0],[12630.4,11168.1,3356.3,3196.6,3282.3,3454.4,3589.4,1908.3,2213.4,2062.8,2046,0],[691.5,143.9,29.8,1291.7,1222.3,1592.1,1566.8,3.8,138.4,3.6,2.4,0],[0.5,1.4,61.7,1.1,1.2,1.2,1.2,33.2,199.1,193.2,220,0],[268.6,856.2,91.9,53.3,256.8,61,221.1,56,60.6,66.8,47.9,0],[11669.8,10166.6,3172.9,1850.5,1802,1800.1,1800.3,1815.3,1815.3,1799.2,1775.7,0],[43602.1,38290.9,30359.3,25374.8,24495.6,21629.6,19475.8,16247.5,17100.3,16447.2,17585.2,16456],[0,0,0,0,0,0,19.3,345.4,488,485.2,993.9,939.1],[11142.5,8651.8,5538.1,4439.7,6045.1,4560.3,4180.5,3079.3,4719.9,4258,4388.8,4678.6],[31365.6,28856.6,24240.8,20474.2,18336.2,16983.7,15191.9,12684.1,11807.8,11600.6,12078.4,10634],[0,0,0,0,0,0,0,0,0,0,0,0],[31365.6,28856.6,24240.8,20474.2,18336.2,16983.7,15191.9,12684.1,11807.8,11600.6,12078.4,10634],[83.5,83.4,83.4,83.3,83.2,83.2,83.1,83,83,82.9,85.3,85.2],[31282.1,28773.2,24157.4,20390.9,18253,16900.5,15108.8,12601.1,11724.8,11517.7,11993.1,10548.8],[12236.5,9434.3,6118.5,4900.6,6159.4,4645.9,4283.9,3563.4,5292.5,4846.6,5506.8,5822],[11142.5,8651.8,5538.1,4439.7,6045.1,4560.3,4180.5,3079.3,4719.9,4258,4388.8,4678.6],[107.2,79.4,67,0,0,0,0,0,0,0,0,0],[632,700.6,623.3,797.4,608.5,496.8,316,296.2,237.6,245.4,188.6,1776.9],[306.9,339.5,328.3,305.2,322.2,298.7,207.3,184.7,173.4,208.4,170.6,0],[10096.4,7532.3,4519.5,3337.1,5114.4,3764.8,3657.2,2598.4,4308.9,3804.2,4029.6,2901.7],[5419,3385.5,710,0.6,2171.1,1180.9,1043.6,546.3,2100.8,1869.9,2089.6,2185.7],[67.9,30.9,33.4,21.6,14.6,15.9,0,0,0,0,0,0],[2705.3,2122.8,1731.3,1550.4,1262.5,1231.6,1545.2,1020.5,1147.1,1155.6,1220.8,0],[1904.2,1993.1,2044.8,1764.5,1666.2,1336.4,1068.4,1031.6,1061,778.7,719.2,716],[1094,782.5,580.4,460.9,114.3,85.6,103.4,484.1,572.6,588.6,1118,1143.4],[589.9,515.4,416.1,339.2,0,0,0,55.5,0,0,0,129],[242,185.2,105.5,85.2,84.2,42.8,29.6,28.5,31.3,41.1,57.6,25.5],[12,5.4,9.3,7.9,10.4,25.1,54.5,54.7,53.3,62.3,66.5,49.8],[250.1,76.5,49.5,28.6,19.7,17.7,19.3,345.4,488,485.2,993.9,939.1],[0,0,0,0,0,0,19.3,345.4,488,485.2,993.9,939.1],[250.1,76.5,49.5,28.6,19.7,17.7,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0],[3219.7,5349.4,4342,2612.8,1623.2,2186.4,2937.7,1277.3,566.9,1384.1,1374.3,1679.4]]}},"CASH_FLOW":{"CashflowConsolidated":{"periods":["FY26","FY25","FY24","FY23","FY22","FY21","FY20","FY19","FY18","FY17","FY16","FY15"],"parameters":[{"key":"OperatingCashFlow","label":"OperatingCashFlow"},{"key":"InvestingCashFlow","label":"InvestingCashFlow"},{"key":"FinancingCashFlow","label":"FinancingCashFlow"},{"key":"NetChangeCash","label":"NetChangeCash"}],"values":[[5673.7,4642.8,4543.3,5887.5,2810.8,3570.3,2984.1,2870.4,1803,2144.4,3262.6,2523.5],[-6425.2,-5785.3,-4034.2,-4108.7,-2565.4,-2254.7,-494.8,-769.2,-1482.6,-1889.6,-1609.9,-2369.8],[829,1891.1,-376.3,-2686.1,-242.2,-29.8,-2515.9,-2132.6,-444,-369.1,-1700.1,-433.2],[77.5,748.6,132.8,-907.3,3.2,1285.8,-26.6,-31.4,-123.6,-114.3,-47.4,-279.5]]},"CashflowStandalone":{"periods":["FY26","FY25","FY24","FY23","FY22","FY21","FY20","FY19","FY18","FY17","FY16","FY15"],"parameters":[{"key":"OperatingCashFlow","label":"OperatingCashFlow"},{"key":"InvestingCashFlow","label":"InvestingCashFlow"},{"key":"FinancingCashFlow","label":"FinancingCashFlow"},{"key":"NetChangeCash","label":"NetChangeCash"}],"values":[[4660.5,4225,3449.7,5052.9,1338.7,3514.2,1839.2,2762.1,1538.6,1015.9,2746.9,1786.1],[-5759.5,-5697.4,-3428.7,-3403.2,-1990.1,-1453.6,-1689.2,-546.5,-1180.2,1430.5,-1919.3,-2031.1],[1116.8,1590.7,68.1,-2696.9,505.5,-794.3,-224.1,-2223.1,-304.4,-2581.8,-693,189.4],[17.8,118.3,89.1,-1047.2,-145.9,1266.3,-74.1,-7.5,54,-135.4,134.6,-55.6]]}},"CHART_DATA":{"2025-09-03":{"open":1250,"high":1265.9,"low":1247.6,"close":1262.2,"volume":1294925,"delivery_per":0},"2025-09-04":{"open":1268,"high":1274.7,"low":1249,"close":1253,"volume":1230934,"delivery_per":0},"2025-09-05":{"open":1254.3,"high":1271.7,"low":1253.6,"close":1268.1,"volume":769861,"delivery_per":0},"2025-09-08":{"open":1269,"high":1277,"low":1248.7,"close":1250.6,"volume":969297,"delivery_per":0},"2025-09-09":{"open":1257.5,"high":1295.8,"low":1256.8,"close":1291.3,"volume":1643726,"delivery_per":0},"2025-09-10":{"open":1294.4,"high":1310,"low":1293.7,"close":1304.2,"volume":1232984,"delivery_per":0},"2025-09-11":{"open":1304,"high":1311,"low":1283,"close":1303.1,"volume":1349391,"delivery_per":0},"2025-09-12":{"open":1303.1,"high":1321,"low":1302.8,"close":1316.7,"volume":1042942,"delivery_per":0},"2025-09-15":{"open":1308.9,"high":1311.8,"low":1292.5,"close":1300.8,"volume":1331182,"delivery_per":0},"2025-09-16":{"open":1300,"high":1312.5,"low":1296.4,"close":1310.4,"volume":1034369,"delivery_per":0},"2025-09-17":{"open":1317,"high":1318.2,"low":1305.2,"close":1311.4,"volume":716840,"delivery_per":0},"2025-09-18":{"open":1312.1,"high":1325.8,"low":1305.7,"close":1322.7,"volume":822010,"delivery_per":0},"2025-09-19":{"open":1324.7,"high":1326.8,"low":1312,"close":1321.7,"volume":1409571,"delivery_per":0},"2025-09-22":{"open":1320.9,"high":1320.9,"low":1293.5,"close":1301.4,"volume":1399531,"delivery_per":0},"2025-09-23":{"open":1300,"high":1311.9,"low":1295.2,"close":1308.4,"volume":1271238,"delivery_per":0},"2025-09-24":{"open":1303.3,"high":1308.3,"low":1294.4,"close":1298.1,"volume":750456,"delivery_per":0},"2025-09-25":{"open":1298.3,"high":1307.3,"low":1268,"close":1275.2,"volume":1241492,"delivery_per":0},"2025-09-26":{"open":1250,"high":1278.5,"low":1246.2,"close":1253.1,"volume":2284377,"delivery_per":0},"2025-09-29":{"open":1265,"high":1270,"low":1231,"close":1234.6,"volume":3899164,"delivery_per":0},"2025-09-30":{"open":1235.1,"high":1240.3,"low":1217.5,"close":1223.7,"volume":2635047,"delivery_per":0},"2025-10-01":{"open":1227.9,"high":1250.7,"low":1226,"close":1244.7,"volume":4083180,"delivery_per":0},"2025-10-03":{"open":1243.9,"high":1265.4,"low":1240,"close":1248.1,"volume":2742600,"delivery_per":0},"2025-10-06":{"open":1248.2,"high":1251.3,"low":1234.2,"close":1248.6,"volume":1880910,"delivery_per":0},"2025-10-07":{"open":1250.3,"high":1256.1,"low":1244.4,"close":1248.5,"volume":1380941,"delivery_per":0},"2025-10-08":{"open":1248.3,"high":1251,"low":1231.4,"close":1234.5,"volume":1496744,"delivery_per":0},"2025-10-09":{"open":1245,"high":1264.9,"low":1240.3,"close":1246.1,"volume":2699135,"delivery_per":0},"2025-10-10":{"open":1249.6,"high":1267.7,"low":1244.7,"close":1264.4,"volume":1680920,"delivery_per":0},"2025-10-13":{"open":1257,"high":1265.1,"low":1248.3,"close":1262.4,"volume":1188201,"delivery_per":0},"2025-10-14":{"open":1262.4,"high":1262.4,"low":1232.3,"close":1237.3,"volume":1944911,"delivery_per":0},"2025-10-15":{"open":1233,"high":1242.3,"low":1231,"close":1232.4,"volume":2150067,"delivery_per":0},"2025-10-16":{"open":1235.9,"high":1242.6,"low":1230.3,"close":1240.2,"volume":1308931,"delivery_per":0},"2025-10-17":{"open":1245,"high":1262,"low":1238.1,"close":1255.9,"volume":1473018,"delivery_per":0},"2025-10-20":{"open":1264.8,"high":1287.7,"low":1259.8,"close":1282,"volume":1368192,"delivery_per":0},"2025-10-21":{"open":1288,"high":1294,"low":1283.1,"close":1288.7,"volume":226788,"delivery_per":0},"2025-10-23":{"open":1303.6,"high":1303.6,"low":1271.6,"close":1279.4,"volume":1991213,"delivery_per":0},"2025-10-24":{"open":1280,"high":1288,"low":1265.5,"close":1283.6,"volume":1167634,"delivery_per":0},"2025-10-27":{"open":1283,"high":1293.4,"low":1264.6,"close":1284.3,"volume":1927956,"delivery_per":0},"2025-10-28":{"open":1283.9,"high":1294.9,"low":1275.3,"close":1289.4,"volume":1828290,"delivery_per":0},"2025-10-29":{"open":1299,"high":1301.5,"low":1235,"close":1250.9,"volume":2574921,"delivery_per":0},"2025-10-30":{"open":1196,"high":1207.2,"low":1180.9,"close":1202.2,"volume":8883497,"delivery_per":0},"2025-10-31":{"open":1202.5,"high":1205.5,"low":1191,"close":1197.6,"volume":4250157,"delivery_per":0},"2025-11-03":{"open":1196.9,"high":1200.8,"low":1187.9,"close":1196,"volume":1547000,"delivery_per":0},"2025-11-04":{"open":1198,"high":1204.3,"low":1193.3,"close":1200,"volume":1015516,"delivery_per":0},"2025-11-06":{"open":1202,"high":1213.9,"low":1193.2,"close":1205.2,"volume":1560897,"delivery_per":0},"2025-11-07":{"open":1208,"high":1211.9,"low":1198,"close":1205.4,"volume":1076140,"delivery_per":0},"2025-11-10":{"open":1199.4,"high":1209.5,"low":1195,"close":1198.7,"volume":3483082,"delivery_per":0},"2025-11-11":{"open":1203.6,"high":1214.8,"low":1198.6,"close":1211.5,"volume":1048552,"delivery_per":0},"2025-11-12":{"open":1220.1,"high":1235,"low":1215,"close":1229.6,"volume":1222295,"delivery_per":0},"2025-11-13":{"open":1235.8,"high":1242.4,"low":1227.3,"close":1234.9,"volume":1426984,"delivery_per":0},"2025-11-14":{"open":1235.2,"high":1249,"low":1231.8,"close":1246,"volume":827643,"delivery_per":0},"2025-11-17":{"open":1253,"high":1253,"low":1240.5,"close":1244.4,"volume":1423044,"delivery_per":0},"2025-11-18":{"open":1244.5,"high":1247,"low":1232.7,"close":1243.8,"volume":971685,"delivery_per":0},"2025-11-19":{"open":1248.7,"high":1252.7,"low":1237,"close":1250.2,"volume":830105,"delivery_per":0},"2025-11-20":{"open":1255,"high":1255,"low":1237.7,"close":1248.6,"volume":854999,"delivery_per":0},"2025-11-21":{"open":1244.8,"high":1250.7,"low":1237.1,"close":1243.9,"volume":941902,"delivery_per":0},"2025-11-24":{"open":1248,"high":1262.4,"low":1219,"close":1226.2,"volume":7611988,"delivery_per":0},"2025-11-25":{"open":1236.3,"high":1251.2,"low":1230.3,"close":1236.1,"volume":1983817,"delivery_per":0},"2025-11-26":{"open":1236.1,"high":1251,"low":1234.6,"close":1248,"volume":809816,"delivery_per":0},"2025-11-27":{"open":1248,"high":1256,"low":1241,"close":1249.3,"volume":1060956,"delivery_per":0},"2025-11-28":{"open":1250,"high":1260.3,"low":1245,"close":1258.8,"volume":809748,"delivery_per":0},"2025-12-01":{"open":1263.9,"high":1268.8,"low":1248.4,"close":1260.1,"volume":1457856,"delivery_per":0},"2025-12-02":{"open":1260.5,"high":1278.3,"low":1260.5,"close":1275.2,"volume":2361183,"delivery_per":0},"2025-12-03":{"open":1283.6,"high":1293,"low":1269.2,"close":1280.7,"volume":4969448,"delivery_per":0},"2025-12-04":{"open":1280.6,"high":1284.2,"low":1266.5,"close":1277.6,"volume":1971130,"delivery_per":0},"2025-12-05":{"open":1277.6,"high":1282.8,"low":1271.6,"close":1275.2,"volume":1036082,"delivery_per":0},"2025-12-08":{"open":1275,"high":1279,"low":1263.7,"close":1266.5,"volume":1435892,"delivery_per":0},"2025-12-09":{"open":1266.5,"high":1267.4,"low":1241.3,"close":1246.2,"volume":2118272,"delivery_per":0},"2025-12-10":{"open":1249.3,"high":1262.1,"low":1246.8,"close":1250.8,"volume":1669910,"delivery_per":0},"2025-12-11":{"open":1250.8,"high":1275.9,"low":1248,"close":1273.5,"volume":1717539,"delivery_per":0},"2025-12-12":{"open":1275,"high":1280.4,"low":1267.3,"close":1279.3,"volume":981548,"delivery_per":0},"2025-12-15":{"open":1274.9,"high":1282.8,"low":1264.1,"close":1280.6,"volume":1078613,"delivery_per":0},"2025-12-16":{"open":1285.9,"high":1285.9,"low":1272,"close":1276.9,"volume":928506,"delivery_per":0},"2025-12-17":{"open":1270,"high":1281,"low":1267.3,"close":1272,"volume":894068,"delivery_per":0},"2025-12-18":{"open":1277,"high":1283.9,"low":1262,"close":1280,"volume":889699,"delivery_per":0},"2025-12-19":{"open":1277,"high":1292.9,"low":1268.9,"close":1278.2,"volume":1209487,"delivery_per":0},"2025-12-22":{"open":1278.2,"high":1286.3,"low":1276.7,"close":1283.4,"volume":614138,"delivery_per":0},"2025-12-23":{"open":1288.6,"high":1288.6,"low":1277.8,"close":1283.5,"volume":408490,"delivery_per":0},"2025-12-24":{"open":1281.1,"high":1285.1,"low":1252.4,"close":1265.8,"volume":1265233,"delivery_per":0},"2025-12-26":{"open":1265,"high":1275,"low":1261.1,"close":1269.3,"volume":594744,"delivery_per":0},"2025-12-29":{"open":1269.3,"high":1275.9,"low":1260,"close":1268.6,"volume":811488,"delivery_per":0},"2025-12-30":{"open":1268,"high":1272.9,"low":1256.4,"close":1265.8,"volume":1123996,"delivery_per":0},"2025-12-31":{"open":1270,"high":1273.9,"low":1260,"close":1271.4,"volume":658106,"delivery_per":0},"2026-01-01":{"open":1270,"high":1270,"low":1248,"close":1253.4,"volume":553856,"delivery_per":0},"2026-01-02":{"open":1249,"high":1257.6,"low":1236,"close":1256.1,"volume":1591218,"delivery_per":0},"2026-01-05":{"open":1256,"high":1262.3,"low":1245,"close":1250,"volume":1184386,"delivery_per":0},"2026-01-06":{"open":1250,"high":1258.8,"low":1245.5,"close":1256.2,"volume":540944,"delivery_per":0},"2026-01-07":{"open":1252.6,"high":1265,"low":1240,"close":1242.8,"volume":1215477,"delivery_per":0},"2026-01-08":{"open":1241.6,"high":1241.6,"low":1202.2,"close":1206.9,"volume":2000942,"delivery_per":0},"2026-01-09":{"open":1207,"high":1216.4,"low":1203.6,"close":1210.1,"volume":1390935,"delivery_per":0},"2026-01-12":{"open":1210,"high":1218.7,"low":1199.9,"close":1215.5,"volume":707317,"delivery_per":0},"2026-01-13":{"open":1215.6,"high":1215.9,"low":1185.5,"close":1191.3,"volume":2071117,"delivery_per":0},"2026-01-14":{"open":1191.1,"high":1195,"low":1176.1,"close":1186.5,"volume":2834908,"delivery_per":0},"2026-01-16":{"open":1184,"high":1197,"low":1171.5,"close":1175.5,"volume":2214792,"delivery_per":0},"2026-01-19":{"open":1170,"high":1177.5,"low":1164.7,"close":1167.2,"volume":1253443,"delivery_per":0},"2026-01-20":{"open":1168.4,"high":1192.8,"low":1161.4,"close":1166.7,"volume":2790934,"delivery_per":0},"2026-01-21":{"open":1170,"high":1193.8,"low":1148.4,"close":1157.2,"volume":2322066,"delivery_per":0},"2026-01-22":{"open":1195,"high":1225,"low":1187.7,"close":1217.5,"volume":6464461,"delivery_per":0},"2026-01-23":{"open":1230,"high":1250.8,"low":1225,"close":1235.6,"volume":3888860,"delivery_per":0},"2026-01-27":{"open":1251,"high":1252.3,"low":1233.5,"close":1239.8,"volume":2159137,"delivery_per":0},"2026-01-28":{"open":1241.9,"high":1243.2,"low":1219,"close":1222.5,"volume":1740662,"delivery_per":0},"2026-01-29":{"open":1215.3,"high":1218,"low":1191.2,"close":1208.9,"volume":1626394,"delivery_per":0},"2026-01-30":{"open":1200,"high":1224.8,"low":1200,"close":1218.1,"volume":1672460,"delivery_per":0},"2026-02-01":{"open":1220.2,"high":1235.6,"low":1169,"close":1178.7,"volume":555385,"delivery_per":0},"2026-02-02":{"open":1189.5,"high":1195,"low":1167.1,"close":1182.5,"volume":1207638,"delivery_per":0},"2026-02-03":{"open":1265,"high":1265.9,"low":1218.1,"close":1235.4,"volume":1521425,"delivery_per":0},"2026-02-04":{"open":1235.5,"high":1248.3,"low":1230.1,"close":1240.2,"volume":947684,"delivery_per":0},"2026-02-05":{"open":1242,"high":1253.6,"low":1237,"close":1244.9,"volume":953241,"delivery_per":0},"2026-02-06":{"open":1244.9,"high":1248.9,"low":1225,"close":1241.2,"volume":1324651,"delivery_per":0},"2026-02-09":{"open":1260,"high":1278.8,"low":1243.5,"close":1275.5,"volume":2111316,"delivery_per":0},"2026-02-10":{"open":1279,"high":1283.5,"low":1253,"close":1256,"volume":1412804,"delivery_per":0},"2026-02-11":{"open":1263.9,"high":1273.5,"low":1253.2,"close":1270.3,"volume":855888,"delivery_per":0},"2026-02-12":{"open":1268.9,"high":1277.6,"low":1261.5,"close":1274.9,"volume":981247,"delivery_per":0},"2026-02-13":{"open":1274,"high":1279.3,"low":1263.6,"close":1268.1,"volume":838946,"delivery_per":0},"2026-02-16":{"open":1257.1,"high":1275.2,"low":1257.1,"close":1269.4,"volume":469592,"delivery_per":0},"2026-02-17":{"open":1266,"high":1286.8,"low":1258.2,"close":1284.8,"volume":687326,"delivery_per":0},"2026-02-18":{"open":1289,"high":1291.5,"low":1276.6,"close":1280.3,"volume":689997,"delivery_per":0},"2026-02-19":{"open":1290,"high":1295.7,"low":1276.5,"close":1282.3,"volume":1333838,"delivery_per":0},"2026-02-20":{"open":1281.9,"high":1292.4,"low":1275,"close":1280.4,"volume":1753200,"delivery_per":0},"2026-02-23":{"open":1290,"high":1313.5,"low":1282.1,"close":1307.4,"volume":1849756,"delivery_per":0},"2026-02-24":{"open":1307.5,"high":1315,"low":1297.1,"close":1300.2,"volume":1803242,"delivery_per":0},"2026-02-25":{"open":1281,"high":1324,"low":1266.9,"close":1306.5,"volume":2296240,"delivery_per":0},"2026-02-26":{"open":1311.2,"high":1327,"low":1305,"close":1319.3,"volume":1511598,"delivery_per":0},"2026-02-27":{"open":1313.8,"high":1317.2,"low":1278.2,"close":1286.3,"volume":3510396,"delivery_per":0},"2026-03-02":{"open":1252.6,"high":1300,"low":1221.2,"close":1294.4,"volume":1052234,"delivery_per":0},"2026-03-04":{"open":1274.4,"high":1299.2,"low":1272.1,"close":1291.2,"volume":1890939,"delivery_per":0},"2026-03-05":{"open":1292.5,"high":1322.1,"low":1292.5,"close":1313.5,"volume":1060509,"delivery_per":0},"2026-03-06":{"open":1313.5,"high":1316.4,"low":1290.8,"close":1303.8,"volume":963701,"delivery_per":0},"2026-03-09":{"open":1285.5,"high":1294.9,"low":1273.6,"close":1287,"volume":1597730,"delivery_per":0},"2026-03-10":{"open":1288,"high":1329.6,"low":1288,"close":1314.6,"volume":2329349,"delivery_per":0},"2026-03-11":{"open":1311.1,"high":1336,"low":1311.1,"close":1325.5,"volume":2454389,"delivery_per":0},"2026-03-12":{"open":1321,"high":1337.3,"low":1303.6,"close":1319,"volume":1969692,"delivery_per":0},"2026-03-13":{"open":1310,"high":1319.9,"low":1280.9,"close":1292.3,"volume":1574522,"delivery_per":0},"2026-03-16":{"open":1292.1,"high":1297,"low":1264,"close":1276.9,"volume":1294975,"delivery_per":0},"2026-03-17":{"open":1279.9,"high":1291.4,"low":1265,"close":1283.8,"volume":1003677,"delivery_per":0},"2026-03-18":{"open":1283.8,"high":1299.3,"low":1280.1,"close":1294.8,"volume":849938,"delivery_per":0},"2026-03-19":{"open":1278.7,"high":1286.4,"low":1266.7,"close":1274.5,"volume":1035491,"delivery_per":0},"2026-03-20":{"open":1289,"high":1307.5,"low":1288.2,"close":1298.9,"volume":3359706,"delivery_per":0},"2026-03-23":{"open":1293,"high":1293,"low":1244.2,"close":1253.3,"volume":2112613,"delivery_per":0},"2026-03-24":{"open":1267.2,"high":1279.8,"low":1248.4,"close":1259.6,"volume":3166135,"delivery_per":0},"2026-03-25":{"open":1268.9,"high":1309,"low":1260.1,"close":1300.7,"volume":1577150,"delivery_per":0},"2026-03-27":{"open":1297,"high":1302.9,"low":1278.2,"close":1281.7,"volume":2165113,"delivery_per":0},"2026-03-30":{"open":1265,"high":1276.2,"low":1251.1,"close":1254.9,"volume":1991442,"delivery_per":0},"2026-04-01":{"open":1280,"high":1284.8,"low":1206.1,"close":1209.6,"volume":2240507,"delivery_per":0},"2026-04-02":{"open":1187.5,"high":1222.6,"low":1167.5,"close":1217.3,"volume":3560727,"delivery_per":0},"2026-04-06":{"open":1220.1,"high":1223.2,"low":1196.3,"close":1217.8,"volume":1099471,"delivery_per":0},"2026-04-07":{"open":1208,"high":1211,"low":1179,"close":1196.1,"volume":2330512,"delivery_per":0},"2026-04-08":{"open":1210,"high":1219.9,"low":1185.4,"close":1191.4,"volume":2063229,"delivery_per":0},"2026-04-09":{"open":1189,"high":1214.7,"low":1189,"close":1211.9,"volume":2746602,"delivery_per":0},"2026-04-10":{"open":1212.8,"high":1236.8,"low":1208.8,"close":1232.2,"volume":1931448,"delivery_per":0},"2026-04-13":{"open":1218,"high":1239.1,"low":1204,"close":1235.9,"volume":1463269,"delivery_per":0},"2026-04-15":{"open":1220,"high":1222,"low":1195.4,"close":1217.8,"volume":4693413,"delivery_per":0},"2026-04-16":{"open":1222,"high":1227.6,"low":1214.1,"close":1221.4,"volume":2014236,"delivery_per":0},"2026-04-17":{"open":1215.2,"high":1242,"low":1212.4,"close":1235.7,"volume":2564061,"delivery_per":0},"2026-04-20":{"open":1235,"high":1243,"low":1223,"close":1232.6,"volume":1605279,"delivery_per":0},"2026-04-21":{"open":1232.6,"high":1234.9,"low":1218.4,"close":1220.6,"volume":1230733,"delivery_per":0},"2026-04-22":{"open":1214.1,"high":1226,"low":1208.1,"close":1217,"volume":1573272,"delivery_per":0},"2026-04-23":{"open":1230,"high":1357,"low":1217.5,"close":1331,"volume":16407707,"delivery_per":0},"2026-04-24":{"open":1293,"high":1348.8,"low":1293,"close":1317.1,"volume":5638719,"delivery_per":0},"2026-04-27":{"open":1320.4,"high":1350,"low":1309,"close":1334.5,"volume":1940454,"delivery_per":0},"2026-04-28":{"open":1342.4,"high":1367.9,"low":1327.4,"close":1354.6,"volume":2336352,"delivery_per":0},"2026-04-29":{"open":1367,"high":1375.9,"low":1321.5,"close":1329.8,"volume":4545837,"delivery_per":0},"2026-04-30":{"open":1327,"high":1340.3,"low":1313.6,"close":1322.9,"volume":1227007,"delivery_per":0},"2026-05-04":{"open":1320,"high":1320,"low":1280.6,"close":1287.2,"volume":2285506,"delivery_per":0},"2026-05-05":{"open":1287.6,"high":1292.4,"low":1268.5,"close":1271.2,"volume":986348,"delivery_per":0},"2026-05-06":{"open":1282,"high":1328.6,"low":1277.1,"close":1311,"volume":3340410,"delivery_per":0},"2026-05-07":{"open":1309.1,"high":1315.7,"low":1297.3,"close":1307.6,"volume":2530096,"delivery_per":0},"2026-05-08":{"open":1303.5,"high":1310.2,"low":1290,"close":1293.9,"volume":964903,"delivery_per":0},"2026-05-11":{"open":1288,"high":1299.9,"low":1272.5,"close":1279.9,"volume":1506740,"delivery_per":0},"2026-05-12":{"open":1278.9,"high":1288.3,"low":1264.5,"close":1270,"volume":1946195,"delivery_per":0},"2026-05-13":{"open":1245.6,"high":1303.8,"low":1230,"close":1265.3,"volume":9276074,"delivery_per":0},"2026-05-14":{"open":1265.3,"high":1307.7,"low":1255,"close":1303.6,"volume":2362951,"delivery_per":0},"2026-05-15":{"open":1303.6,"high":1344.9,"low":1303.6,"close":1336.7,"volume":3982549,"delivery_per":0},"2026-05-18":{"open":1336.5,"high":1341.9,"low":1322,"close":1331.2,"volume":1926791,"delivery_per":0},"2026-05-19":{"open":1332,"high":1345,"low":1318.9,"close":1335.2,"volume":2488019,"delivery_per":0},"2026-05-20":{"open":1323.6,"high":1336,"low":1319.6,"close":1321.9,"volume":1277182,"delivery_per":0},"2026-05-21":{"open":1325,"high":1331.6,"low":1314.2,"close":1318.5,"volume":2183121,"delivery_per":0},"2026-05-22":{"open":1319,"high":1329.6,"low":1305.1,"close":1307.2,"volume":2002451,"delivery_per":0},"2026-05-25":{"open":1320,"high":1340.5,"low":1298.7,"close":1331.4,"volume":4659781,"delivery_per":0},"2026-05-26":{"open":1333,"high":1341,"low":1321.6,"close":1327.9,"volume":1909354,"delivery_per":0},"2026-05-27":{"open":1329.6,"high":1346.8,"low":1316.7,"close":1319,"volume":959327,"delivery_per":0},"2026-05-29":{"open":1318.8,"high":1328.6,"low":1297.5,"close":1303.5,"volume":5424483,"delivery_per":0},"2026-06-01":{"open":1310.1,"high":1319.6,"low":1284.8,"close":1290.4,"volume":1379034,"delivery_per":0},"2026-06-02":{"open":1280.2,"high":1284.7,"low":1264.1,"close":1274,"volume":2021793,"delivery_per":0},"2026-06-03":{"open":1269.5,"high":1275.2,"low":1256.9,"close":1263.3,"volume":1226407,"delivery_per":0},"2026-06-04":{"open":1257.3,"high":1274.9,"low":1248.4,"close":1267.5,"volume":944045,"delivery_per":0},"2026-06-05":{"open":1273,"high":1289.4,"low":1268.5,"close":1278.2,"volume":774687,"delivery_per":0},"2026-06-08":{"open":1270,"high":1293.7,"low":1270,"close":1275.6,"volume":862999,"delivery_per":0},"2026-06-09":{"open":1277,"high":1287.6,"low":1261.4,"close":1268.5,"volume":871896,"delivery_per":0},"2026-06-10":{"open":1268.6,"high":1283.7,"low":1266.7,"close":1271.7,"volume":1172155,"delivery_per":0},"2026-06-11":{"open":1271.1,"high":1285.7,"low":1266.4,"close":1276,"volume":1057772,"delivery_per":0},"2026-06-12":{"open":1291,"high":1291,"low":1266,"close":1275.4,"volume":1645027,"delivery_per":0},"2026-06-15":{"open":1296.2,"high":1296.2,"low":1275.3,"close":1279.5,"volume":1178640,"delivery_per":0},"2026-06-16":{"open":1279,"high":1286,"low":1269.1,"close":1276.9,"volume":430918,"delivery_per":0},"2026-06-17":{"open":1276,"high":1277.4,"low":1260.9,"close":1269,"volume":683616,"delivery_per":0},"2026-06-18":{"open":1269,"high":1279.9,"low":1261.7,"close":1267.5,"volume":774093,"delivery_per":0},"2026-06-19":{"open":1267,"high":1275,"low":1261,"close":1272.1,"volume":1312877,"delivery_per":0},"2026-06-22":{"open":1278.1,"high":1306,"low":1271.2,"close":1290.7,"volume":1618251,"delivery_per":0},"2026-06-23":{"open":1297.2,"high":1329.5,"low":1294.9,"close":1301.3,"volume":2878800,"delivery_per":0},"2026-06-24":{"open":1310,"high":1343,"low":1306.2,"close":1328.4,"volume":3346371,"delivery_per":0},"2026-06-25":{"open":1331.9,"high":1363,"low":1331.9,"close":1350.5,"volume":1699744,"delivery_per":0},"2026-06-29":{"open":1388.4,"high":1414.9,"low":1355.8,"close":1375.7,"volume":8857211,"delivery_per":0},"2026-06-30":{"open":1375,"high":1375,"low":1347.1,"close":1357.1,"volume":2446438,"delivery_per":0},"2026-07-01":{"open":1351,"high":1362.7,"low":1330,"close":1339.9,"volume":1423120,"delivery_per":0},"2026-07-02":{"open":1339.9,"high":1360.8,"low":1329,"close":1345.7,"volume":808598,"delivery_per":0},"2026-07-03":{"open":1356,"high":1390.4,"low":1350.3,"close":1374.1,"volume":1296170,"delivery_per":0},"2026-07-06":{"open":1375.9,"high":1380.7,"low":1357.4,"close":1367.9,"volume":810266,"delivery_per":0},"2026-07-07":{"open":1362,"high":1380.2,"low":1351.5,"close":1354.6,"volume":1043736,"delivery_per":0},"2026-07-08":{"open":1357,"high":1383,"low":1338.6,"close":1349,"volume":1561612,"delivery_per":0},"2026-07-09":{"open":1340,"high":1349,"low":1261.1,"close":1269.5,"volume":8410883,"delivery_per":0},"2026-07-10":{"open":1244.9,"high":1251.8,"low":1222,"close":1244.3,"volume":8106606,"delivery_per":0},"2026-07-13":{"open":1244.3,"high":1249.1,"low":1226.3,"close":1234.5,"volume":2437935,"delivery_per":0},"2026-07-14":{"open":1234.5,"high":1248,"low":1231.2,"close":1246.2,"volume":1984818,"delivery_per":0},"2026-07-15":{"open":1249.1,"high":1249.1,"low":1226.4,"close":1229.5,"volume":1685660,"delivery_per":0},"2026-07-16":{"open":1227.5,"high":1235,"low":1221.8,"close":1224.4,"volume":1935887,"delivery_per":0},"2026-07-17":{"open":1227.5,"high":1229.9,"low":1201.2,"close":1211.2,"volume":2075149,"delivery_per":0},"2026-07-20":{"open":1213.3,"high":1231.3,"low":1209.6,"close":1223.1,"volume":2212191,"delivery_per":0},"2026-07-21":{"open":1224.7,"high":1230,"low":1203,"close":1206,"volume":2182513,"delivery_per":0},"2026-07-22":{"open":1191,"high":1202.3,"low":1169,"close":1182.8,"volume":2528082,"delivery_per":0},"2026-07-23":{"open":1101,"high":1171.6,"low":1101,"close":1166.3,"volume":6693935,"delivery_per":0},"2026-07-24":{"open":1147,"high":1166.3,"low":1131.4,"close":1151.7,"volume":4750512,"delivery_per":0},"2026-07-27":{"open":1154.7,"high":1159.3,"low":1147.2,"close":1150.8,"volume":1053461,"delivery_per":0},"2026-07-28":{"open":1145,"high":1149,"low":1130.2,"close":1135.6,"volume":2157306,"delivery_per":0},"2026-07-29":{"open":1144,"high":1147.8,"low":1131.1,"close":1142.3,"volume":1280586,"delivery_per":0},"2026-07-30":{"open":1143,"high":1151,"low":1139,"close":1144.8,"volume":1350714,"delivery_per":0},"2026-07-31":{"open":1152,"high":1154.3,"low":1141.7,"close":1148.1,"volume":1085841,"delivery_per":0},"2026-08-03":{"open":1166.2,"high":1182,"low":1160.3,"close":1180,"volume":2150927,"delivery_per":0},"2026-08-04":{"open":1174,"high":1174,"low":1154.4,"close":1172.6,"volume":2165315,"delivery_per":0},"2026-08-05":{"open":1171.8,"high":1178.4,"low":1157.7,"close":1176,"volume":1883679,"delivery_per":0},"2026-08-06":{"open":1174,"high":1174.4,"low":1163,"close":1171,"volume":1329196,"delivery_per":0},"2026-08-07":{"open":1166,"high":1172,"low":1162.1,"close":1172,"volume":1072438,"delivery_per":0},"2026-08-10":{"open":1172,"high":1178.8,"low":1156,"close":1158.8,"volume":1770609,"delivery_per":0},"2026-08-11":{"open":1159.1,"high":1206.6,"low":1155.1,"close":1205,"volume":3936813,"delivery_per":0},"2026-08-12":{"open":1206.8,"high":1206.8,"low":1190,"close":1200,"volume":2366909,"delivery_per":0},"2026-08-13":{"open":1194,"high":1208.1,"low":1182.1,"close":1206,"volume":1799813,"delivery_per":0},"2026-08-14":{"open":1205.9,"high":1205.9,"low":1192.4,"close":1200,"volume":2136998,"delivery_per":0},"2026-08-17":{"open":1204.4,"high":1204.4,"low":1178.2,"close":1192,"volume":2183094,"delivery_per":0},"2026-08-18":{"open":1185,"high":1189.3,"low":1176.1,"close":1178.8,"volume":805633,"delivery_per":0},"2026-08-19":{"open":1171.9,"high":1187.2,"low":1168,"close":1170,"volume":1150424,"delivery_per":0},"2026-08-20":{"open":1171.2,"high":1183.8,"low":1171.2,"close":1180,"volume":1031107,"delivery_per":0},"2026-08-21":{"open":1179,"high":1185.1,"low":1174,"close":1174.7,"volume":1246756,"delivery_per":0},"2026-08-24":{"open":1179.4,"high":1195.9,"low":1168.6,"close":1190,"volume":2248634,"delivery_per":0},"2026-08-25":{"open":1189,"high":1193.5,"low":1175,"close":1193.5,"volume":1569853,"delivery_per":0},"2026-08-26":{"open":1189.9,"high":1197.2,"low":1180.1,"close":1182,"volume":1993156,"delivery_per":0},"2026-08-27":{"open":1182,"high":1191.9,"low":1169.4,"close":1177,"volume":1044405,"delivery_per":0},"2026-08-28":{"open":1175,"high":1186.6,"low":1172.5,"close":1178,"volume":682712,"delivery_per":0},"2026-08-31":{"open":1178,"high":1178.1,"low":1154.4,"close":1154.4,"volume":2001757,"delivery_per":0},"2026-09-01":{"open":1166.5,"high":1179.9,"low":1166.5,"close":1171,"volume":556259,"delivery_per":0},"2026-09-02":{"open":1165,"high":1170.9,"low":1156.5,"close":1156.5,"volume":486542,"delivery_per":0}},"COMPANY_INSIGHTS":{"message":"No insights found for this stock","success":false},"COMPANY_PROFILE":{"BALANCE_SHEET_AND_CASH_FLOWS":{"BOOK_VALUE":456.14},"FINANCIAL_RATIOS":{"DEBT_TO_EQUITY":0.17,"PB_RATIO":2.55,"PE_BY_SECTOR_PE":1.3855257168866637,"PE_RATIO":30.44},"INCOME_STATEMENT":{"DIVIDEND_YIELD":0.69,"EBITDA":1186.1,"EPS":38.14},"INDUSTRY_AND_SECTOR":{"INDUSTRY_CURRENT_RATIO":2.42,"INDUSTRY_DEBT_TO_EQUITY":0.4,"INDUSTRY_DIVIDEND_YIELD":0.31,"INDUSTRY_EPS":15.83,"INDUSTRY_OPERATING_MARGIN":14.26,"INDUSTRY_PB_RATIO":3.74},"PERFORMANCE_AND_GROWTH":{"RETURN_ON_CAPITAL":14.16,"RETURN_ON_EQUITY":11.64},"PRICE_AND_VOLUME_ACTIONS":{"52_WEEK_HIGH":1414.9,"52_WEEK_LOW":1101},"SHAREHOLDING_CHANGES":{"CHANGE_IN_DII":5,"CHANGE_IN_FII":-4.29,"DII_HOLDING":31.74,"FII_HOLDING":32.07,"PROMOTER_HOLDING":26.64,"PUBLIC_RETAIL_HOLDING":7.42},"UNIVERSE":{"INDUSTRY":"Pharmaceuticals","MARKET_CAP":96529.5,"SECTOR":"Healthcare"}},"CORPORATE_ACTIONS":{"past":[{"ActionType":"DIVIDEND","ExDate":"2021-07-09","Note":25},{"ActionType":"DIVIDEND","ExDate":"2022-07-11","Note":30},{"ActionType":"DIVIDEND","ExDate":"2023-07-11","Note":40},{"ActionType":"DIVIDEND","ExDate":"2024-07-16","Note":40},{"ActionType":"DIVIDEND","ExDate":"2025-07-10","Note":8},{"ActionType":"DIVIDEND","ExDate":"2026-07-10","Note":8},{"ActionType":"SPLIT","ExDate":"2024-10-28","Note":"1:5"}],"upcoming":[]},"FOLLOW_UP_QUESTIONS":["What's the current financial health & valuation of Dr Reddys Laboratories?","What did management say in recent earnings calls for Dr Reddys Laboratories?","How has Dr Reddys Laboratories stock performed vs. peers/market?","What are the key business risks & opportunities for Dr Reddys Laboratories?","What's the promoter holding & corporate governance status of Dr Reddys Laboratories?"],"GROWTH_FORECAST":{"AVG_EBITDA_MARGIN":22.28,"NET_INCOME_GROWTH":0.1,"REVENUE_GROWTH":-7.86,"ROCE":14.16,"ROE":11.64},"LODR":[{"news_object":{"overall_sentiment":"positive","text":"Dr. Reddy's Laboratories secures U.S. FDA approval for its rituximab biosimilar, a key oncology drug. Fresenius Kabi will exclusively commercialize the product in the United States.","title":"Dr. Reddy's Wins U.S. FDA Nod for Rituximab"},"publish_date":1785558022651},{"news_object":{"overall_sentiment":"positive","text":"Dr Reddys Laboratories shareholders approved a ₹8 dividend and re-appointed key directors at its 42nd AGM on July 23, 2026. Deloitte was named statutory auditor for five years.","title":"Dr Reddys AGM: Dividend, Auditors & Directors Approved"},"publish_date":1784829188263},{"news_object":{"overall_sentiment":"neutral","text":"Dr Reddy's Laboratories reported a 6% YoY decline in Q1FY27 revenue to ₹8,071 Cr, impacted by semaglutide API costs. EBITDA fell 56% to ₹1,009 Cr, while PAT dropped 69% to ₹443 Cr.","title":"Dr Reddy's Q1FY27 revenue dips 6% to ₹8,071 Cr"},"publish_date":1784724228591},{"news_object":{"overall_sentiment":"negative","text":"Dr Reddy's Laboratories reported a 69% YoY decline in Q1FY27 net profit to ₹4,435 million, impacted by a ₹2,397 million provision for semaglutide API issues. Revenue fell 5.6% YoY to ₹80,705 million.","title":"Dr Reddy's Q1FY27 net profit falls 69%"},"publish_date":1784721532102},{"news_object":{"overall_sentiment":"neutral","text":"Dr Reddy's Laboratories will announce Q1FY27 results on July 22, 2026, followed by an earnings call at 19:30 IST.","title":"Dr Reddy's sets Q1FY27 results date"},"publish_date":1783934616296},{"news_object":{"overall_sentiment":"negative","text":"Dr Reddy's Laboratories Ltd reported API issues delaying semaglutide commercial supplies. An analyst call is scheduled for July 9, 2026.","title":"Dr Reddy's delays semaglutide supplies"},"publish_date":1783569818187},{"news_object":{"overall_sentiment":"neutral","text":"Dr Reddy's Laboratories filed its BRSR for FY26, reporting a turnover of ₹20,102 crore and outlining ESG goals including net zero by FY2045.","title":"Dr Reddy's FY26 BRSR details ESG goals"},"publish_date":1782836243477},{"news_object":{"overall_sentiment":"positive","text":"Dr Reddy's Laboratories Ltd has announced a final dividend of ₹8 per share for FY26. The AGM is scheduled for July 23, 2026, via video conferencing.","title":"Dr Reddy's declares ₹8 dividend for FY26"},"publish_date":1782835589786},{"news_object":{"overall_sentiment":"positive","text":"Dr Reddy's Laboratories announced its 42nd AGM on July 23, 2026, via video conference. The Board recommended a final dividend of Rs.8 per share.","title":"Dr Reddy's sets July 23 AGM, final dividend"},"publish_date":1781944160043},{"news_object":{"overall_sentiment":"positive","text":"Dr Reddy's Laboratories Ltd announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States on June 13, 2026.","title":"Dr Reddy's launches Bosutinib in US market"},"publish_date":1781336229708}],"NEWS":[{"id":"6a3eb8bc436449ea139d4fa9","card_variant":"primary","web_results_preview":{"total_count":12,"url_list":[{"article_title":"Pharma audits explained: Process, types, and how to stay audit ready","article_url":"https://www.scilife.io/blog/pharma-audit","source_domain":"www.scilife.io","source_main_domain":"scilife","source_name":""},{"article_title":"Biosimilars Market Size, Share, Trends | Industry Report – 2035","article_url":"https://www.gminsights.com/industry-analysis/biosimilars-market","source_domain":"www.gminsights.com","source_main_domain":"gminsights","source_name":""},{"article_title":"Dr. Reddy's Labs Live Share Price Today, Share Analysis and Chart","article_url":"https://trendlyne.com/equity/346/DRREDDY/dr-reddy-s-laboratories-ltd/","source_domain":"trendlyne.com","source_main_domain":"trendlyne","source_name":""},{"article_title":"Cipla Shares Fall 5% After USFDA Observations on Partner","article_url":"https://www.swastika.co.in/blog/cipla-shares-slide-5-as-usfda-observations-on-key-partner-dent-investor-sentiment","source_domain":"www.swastika.co.in","source_main_domain":"swastika","source_name":""},{"article_title":"FDA cites Dr. Reddy's for quality control problems at a biologics plant","article_url":"https://www.statnews.com/pharmalot/2023/11/16/fda-reddy-india-manufacturing-violation-pharmaceuticals-biologics/","source_domain":"www.statnews.com","source_main_domain":"statnews","source_name":""},{"article_title":"U.S. FDA issues seven observations to Dr. Reddy's biologics ...","article_url":"https://www.thehindu.com/business/Industry/us-fda-issues-seven-observations-to-dr-reddys-biologics-manufacturing-facility-in-hyderabad/article71149469.ece","source_domain":"www.thehindu.com","source_main_domain":"thehindu","source_name":""},{"article_title":"Biosimilars Market Size & Share | Forecast Report [2033]","article_url":"https://www.skyquestt.com/report/biosimilars-market","source_domain":"www.skyquestt.com","source_main_domain":"skyquestt","source_name":""},{"article_title":"Dr. Reddy's Laboratories Limited (RDY) Stock Analysis & Key Metrics","article_url":"https://koalagains.com/stocks/NYSE/RDY","source_domain":"koalagains.com","source_main_domain":"koalagains","source_name":""},{"article_title":"Dr. Reddy's Hyderabad Plant Flags 7 USFDA Observations, Risking ...","article_url":"https://www.sahi.com/news/dr-reddy-s-hyderabad-plant-flags-7-usfda-observations-risking-biologics-approval-timelines-545961-PE1_C","source_domain":"www.sahi.com","source_main_domain":"sahi","source_name":""},{"article_title":"USFDA Completes Pre-License Inspection at Dr. Reddy's Biologics ...","article_url":"https://innovacia.in/usfda-completes-pre-license-inspection-at-dr-reddys-biologics-facility-issues-form-483-with-seven-observations/","source_domain":"innovacia.in","source_main_domain":"innovacia","source_name":""},{"article_title":"Biosimilars Market Trends, Share, Size & Forecast, 2026-2033","article_url":"https://www.coherentmarketinsights.com/market-insight/biosimilars-market-750","source_domain":"www.coherentmarketinsights.com","source_main_domain":"coherentmarketinsights","source_name":""},{"article_title":"USFDA flags cleanliness, procedural issues at Dr Reddy's ...","article_url":"https://www.moneycontrol.com/news/business/markets/usfda-flags-cleanliness-procedural-issues-at-dr-reddys-bachupally-unit-in-hyderabad-11742531.html","source_domain":"www.moneycontrol.com","source_main_domain":"moneycontrol","source_name":""}]},"title":"Dr. Reddy's Biologics Facility: Three Years of USFDA Scrutiny","description":"Dr. Reddy's Hyderabad biologics facility faces its third consecutive USFDA Form 483, raising questions about corrective action effectiveness and competitive positioning in the global biosimilars market.","text_content":"$29","image_link":"https://images.askfuzz.ai/article_images/5505da45-563f-4bc3-9d20-e3c256fa97e6.png","image_source":"","slug":"dr-reddys-biologics-facility-three-years-of-usfda-scrutiny","last_updated":"2026-06-26T23:07:00.661+05:30","created_at":"2026-06-26T23:07:00.661+05:30","view_count":403,"follow_up_questions":["What specific timeline has Dr. Reddy's management provided for resolving the seven June 2026 observations, and what milestones should investors monitor in the coming quarters?","How does Dr. Reddy's cost of capital and valuation multiple compare to Indian pharma peers with clean USFDA inspection records, and what is the estimated valuation discount attributable to regulatory risk?","What is the competitive landscape for Dr. Reddy's key biosimilar pipeline products, and which competitors are best positioned to gain market share if Dr. Reddy's faces further delays?"],"read_time":"6 min","reading_time":417,"isin":["INE089A01031"],"category":["Connect the Dots"],"llm_info":{"model":""},"lodr":[{"name":"TR Q3FY26","type":"Transcripts","code":"C725500"},{"name":"TR Q3FY26","type":"Transcripts","code":"C725505"},{"name":"TR Q2FY26","type":"Transcripts","code":"C683470"},{"name":"TR Q3FY26","type":"Transcripts","code":"C725556"},{"name":"TR Q2FY26","type":"Transcripts","code":"C683460"},{"name":"TR Q3FY26","type":"Transcripts","code":"C725523"},{"name":"TR Q3FY26","type":"Transcripts","code":"C725503"},{"name":"TR Q2FY26","type":"Transcripts","code":"C683436"},{"name":"TR Q4FY22","type":"Transcripts","code":"C74469"},{"name":"TR Q2FY26","type":"Transcripts","code":"C683473"},{"name":"GNR FY26","type":"Others","code":"M1096096"},{"name":"TR Q3FY26","type":"Transcripts","code":"C725497"},{"name":"TR Q2FY26","type":"Transcripts","code":"C683422"},{"name":"TR Q2FY26","type":"Transcripts","code":"C683440"}]},{"id":"6a2f9188b70326ce81e846fc","card_variant":"primary","web_results_preview":{"total_count":16,"url_list":[{"article_title":"Nestle India shares in spotlight on rejecting claims of infestation in ...","article_url":"https://upstox.com/news/market-news/stocks/nestle-india-shares-in-spotlight-on-rejecting-claims-of-infestation-in-maggi-noodles-key-details/article-195274/","source_domain":"upstox.com","source_main_domain":"upstox","source_name":""},{"article_title":"Dr. Reddy's Launches First-to-Market Generic Bosutinib Tablets ...","article_url":"https://innovacia.in/dr-reddys-launches-first-to-market-generic-bosutinib-tablets-400mg-in-the-united-states/","source_domain":"innovacia.in","source_main_domain":"innovacia","source_name":""},{"article_title":"NLC emerges as preferred bidder for a critical mineral block in ...","article_url":"https://www.thehindu.com/business/nlc-emerges-as-preferred-bidder-for-a-critical-mineral-block-in-telangana/article71094780.ece","source_domain":"www.thehindu.com","source_main_domain":"thehindu","source_name":""},{"article_title":"JSW Energy Signs Agreement to Acquire 300 MW Maruti Clean ...","article_url":"https://innovacia.in/jsw-energy-signs-agreement-to-acquire-300-mw-maruti-clean-coal-power-limited-for-enterprise-value-of-%E2%82%B91410-crore/","source_domain":"innovacia.in","source_main_domain":"innovacia","source_name":""},{"article_title":"JSW Energy to acquire Maruti Clean Coal & Power for ₹1,410 crore","article_url":"https://www.fortuneindia.com/business-news/jsw-energy-to-acquire-maruti-clean-coal-power-for-1410-crore/142944","source_domain":"www.fortuneindia.com","source_main_domain":"fortuneindia","source_name":""},{"article_title":"Adani Green Commissions 3.37 GWh Battery Storage System in ...","article_url":"https://www.mercomindia.com/adani-green-commissions-3-37-gwh-battery-storage-system-in-gujarat","source_domain":"www.mercomindia.com","source_main_domain":"mercomindia","source_name":""},{"article_title":"Acquisition of Maruti Clean Coal and Power Limited - JSW Energy","article_url":"https://www.jswenergy.in/newsroom/press-release/jsw-energy-to-acquire-300-mw-maruti-clean-coal-power-limited-strengthening-thermal-portfolio/","source_domain":"www.jswenergy.in","source_main_domain":"jswenergy","source_name":""},{"article_title":"Nestle's Maggi Row - The Aftermath and Implications on the Instant ...","article_url":"https://insideiim.com/nestles-maggi-row-the-aftermath-and-implications-on-the-instant-noodle-industry","source_domain":"insideiim.com","source_main_domain":"insideiim","source_name":""},{"article_title":"The 180-Day Gold Rush: Why First Generic Launches Win Billions ...","article_url":"https://www.drugpatentwatch.com/blog/first-generic-launch-has-significant-first-mover-advantage-over-later-generic-drug-entrants/","source_domain":"www.drugpatentwatch.com","source_main_domain":"drugpatentwatch","source_name":""},{"article_title":"KIMS Board Approves ₹599.99 Crore Warrant Allotment to Promoters","article_url":"https://scanx.trade/stock-market-news/companies/kims-board-to-meet-on-june-13-to-consider-fund-raising/42648898","source_domain":"scanx.trade","source_main_domain":"scanx","source_name":""},{"article_title":"Adani Green to commission 14 GWh battery storage at Khavda by ...","article_url":"https://m.economictimes.com/industry/renewables/adani-green-to-commission-14-gwh-battery-storage-at-khavda-by-fiscal-year-end-to-cut-clean-energy-wastage/articleshow/131710052.cms","source_domain":"m.economictimes.com","source_main_domain":"economictimes","source_name":""},{"article_title":"NLC India Wins Preferred Bidder Status for 1 Critical Mineral Block ...","article_url":"https://www.sahi.com/news/nlc-india-wins-preferred-bidder-status-for-1-critical-mineral-block-in-telangana-933-PE1_CORP","source_domain":"www.sahi.com","source_main_domain":"sahi","source_name":""},{"article_title":"Nestle India rejects allegations over Maggi infestation, says tests ...","article_url":"https://www.newindianexpress.com/business/2026/Jun/13/nestle-india-rejects-allegations-over-maggi-infestation-says-tests-confirm-product-quality-2","source_domain":"www.newindianexpress.com","source_main_domain":"newindianexpress","source_name":""},{"article_title":"Rethinking Environmental Clearance for Critical Mineral Mining","article_url":"https://www.orfonline.org/expert-speak/rethinking-environmental-clearance-for-critical-mineral-mining","source_domain":"www.orfonline.org","source_main_domain":"orfonline","source_name":""},{"article_title":"adani green energy","article_url":"https://connect.adani.com/media/2026/may26/agel/","source_domain":"connect.adani.com","source_main_domain":"adani","source_name":""},{"article_title":"Top 10 Insurance Companies in India 2026... - IcyPluto","article_url":"https://www.icypluto.com/blog/top-10-insurance-companies-in-india-2026","source_domain":"www.icypluto.com","source_main_domain":"icypluto","source_name":""}]},"title":"Corporate Developments: Dr Reddy's, Adani Green, JSW Energy, KIMS, Nestlé, NLC India, LIC","description":"Analysis of major corporate moves including Dr Reddy's Bosutinib launch, Adani Green's battery storage expansion, JSW Energy's thermal acquisition, KIMS' warrant issuance, Nestlé's quality response, NLC India's mineral blocks, and LIC's competitive strategy.","text_content":"$2a","image_link":"https://images.askfuzz.ai/article_images/e0072a9d-42cd-49cb-9e5c-0c008307bb80.png","image_source":"","slug":"corporate-developments-dr-reddys-adani-green-jsw-energy-kims-nestl-nlc-india-lic","last_updated":"2026-06-15T11:15:44.009+05:30","created_at":"2026-06-15T11:15:44.009+05:30","view_count":571,"follow_up_questions":["How will Dr Reddy's maintain its first-to-file success rate as US generic competition intensifies?","What financing strategy will Adani Green employ to fund ₹15,000 crore BESS expansion given current leverage?","Can JSW Energy achieve similar PLF improvements at MCCPL as demonstrated at KSK Mahanadi?","How will KIMS' margin recovery trajectory validate the premium warrant pricing over next 18 months?","What are the key regulatory milestones NLC India must achieve for Telangana mineral block commercial production?"],"read_time":"5 min","reading_time":323,"isin":["INE089A01031","INE364U01010","INE121E01018","INE967H01025","INE239A01024","INE589A01014","INE0J1Y01017"],"category":["Connect the Dots"],"llm_info":{"model":""},"lodr":[{"name":"TR Q2FY23","type":"Transcripts","code":"C74755"},{"name":"TR Q4FY22","type":"Transcripts","code":"C74444"},{"name":"TR Q4FY22","type":"Transcripts","code":"C74462"}]},{"id":"6a032d5931a2b28ef968e45b","card_variant":"primary","web_results_preview":{"total_count":11,"url_list":[{"article_title":"Dr. Reddy Q4 net profit rises 22% but price erosion in US hit yearly ...","article_url":"https://pharma.economictimes.indiatimes.com/news/financial-performance/dr-reddy-q4-net-profit-rises-22-but-price-erosion-in-us-hit-yearly-earrings/121082986","source_domain":"pharma.economictimes.indiatimes.com","source_main_domain":"indiatimes","source_name":""},{"article_title":"Semaglutide Market Size, Share and Analysis, 2026-2033","article_url":"https://www.coherentmarketinsights.com/market-insight/semaglutide-market-3314","source_domain":"www.coherentmarketinsights.com","source_main_domain":"coherentmarketinsights","source_name":""},{"article_title":"Dr Reddy's Laboratories Projects 25% EBITDA Margin After ... - ScanX","article_url":"https://scanx.trade/stock-market-news/earnings/dr-reddy-s-laboratories-projects-25-ebitda-margin-after-one-time-adjustments/30597776","source_domain":"scanx.trade","source_main_domain":"scanx","source_name":""},{"article_title":"Dr. Reddy's Q3 FY26 profit falls as growth shifts | RDY SEC Filing","article_url":"https://www.stocktitan.net/sec-filings/RDY/6-k-dr-reddys-laboratories-ltd-current-report-foreign-issuer-949dd18141b9.html","source_domain":"www.stocktitan.net","source_main_domain":"stocktitan","source_name":""},{"article_title":"Biosimilars & innovation are Dr. Reddy's growth pill: Generics to ...","article_url":"https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/biosimilars-innovation-are-dr-reddys-growth-pill-generics-to-remain-core-business-says-co-chairman-md-gv-prasad/articleshow/128687416.cms","source_domain":"m.economictimes.com","source_main_domain":"economictimes","source_name":""},{"article_title":"Dr Reddy's targets new launches, potential M&A as gRevlimid ...","article_url":"https://www.moneycontrol.com/news/business/stocks/dr-reddy-s-targets-new-launches-potential-m-a-as-grevlimid-tapers-off-in-america-13070438.html","source_domain":"www.moneycontrol.com","source_main_domain":"moneycontrol","source_name":""},{"article_title":"What is Growth Strategy and Future Prospects of Dr. Reddy's ...","article_url":"https://matrixbcg.com/blogs/growth-strategy/drreddys","source_domain":"matrixbcg.com","source_main_domain":"matrixbcg","source_name":""},{"article_title":"Dr. Reddy's Laboratories still awaiting approval for a major near ...","article_url":"https://www.cnbctv18.com/market/dr-reddys-laboratories-share-price-key-trigger-canada-approval-semaglutide-market-size-competition-timeline-19891766.htm","source_domain":"www.cnbctv18.com","source_main_domain":"cnbctv18","source_name":""},{"article_title":"Dr Reddy's To Come With Low-Cost Generic In 87 Countries By 2026","article_url":"https://www.bwhealthcareworld.com/article/dr-reddys-to-come-with-low-cost-generic-in-87-countries-by-2026-564798","source_domain":"www.bwhealthcareworld.com","source_main_domain":"bwhealthcareworld","source_name":""},{"article_title":"Dr Reddy's Q4 profit crashes 86% as Revlimid competition and ...","article_url":"https://www.cnbctv18.com/market/earnings/dr-reddys-q4-profit-crashes-as-cancer-drug-revlimid-competition-margin-erosion-hurts-generic-pharma-co-ws-l-19904059.htm","source_domain":"www.cnbctv18.com","source_main_domain":"cnbctv18","source_name":""},{"article_title":"Dr Reddy's Q4 net profit misses estimates, slumps 86% to Rs 221 ...","article_url":"https://www.moneycontrol.com/news/business/earnings/dr-reddy-s-q4-net-profit-misses-estimates-slumps-86-to-rs-221-crore-on-cancer-therapy-impairments-13916741.html","source_domain":"www.moneycontrol.com","source_main_domain":"moneycontrol","source_name":""}]},"title":"Dr Reddy's Q4 FY26: Navigating R&D Setbacks and US Market Headwinds","description":"Dr Reddy's reported an 86% plunge in Q4 net profit to Rs 221 crore, hit by cancer therapy impairments, US pricing pressure, and one-time provisions. The company is strategically pivoting toward semaglutide and biosimilars to offset declining lenalidomide sales.","text_content":"$2b","image_link":"https://images.askfuzz.ai/article_images/8c990ac9-8745-436b-bba7-603c11ae834e.jpg","image_source":"","slug":"dr-reddys-q4-fy26-navigating-r-d-setbacks-and-us-market-headwinds","last_updated":"2026-05-12T19:08:33.607+05:30","created_at":"2026-05-12T19:08:33.607+05:30","view_count":227,"follow_up_questions":["What are the specific revenue milestones Dr Reddy's has set for its semaglutide launches in Canada and Brazil for FY27?","How does Dr Reddy's plan to regain market share in the US generics segment amid ongoing pricing pressure?","What is the expected timeline for the abatacept biosimilar launch in the US following the European rollout in 2027?"],"read_time":"3 min","reading_time":238,"isin":["INE089A01031"],"category":["Connect the Dots"],"llm_info":{"model":""},"lodr":[{"name":"AR FY26","type":"AnnualReports","code":"B16960724"},{"name":"TR Q3FY26","type":"Transcripts","code":"C725532"},{"name":"TR Q3FY26","type":"Transcripts","code":"C725526"},{"name":"AR FY26","type":"AnnualReports","code":"B16960649"},{"name":"IP Q4FY26","type":"InvestorPresentations","code":"A2568460"},{"name":"TR Q3FY26","type":"Transcripts","code":"C725525"},{"name":"AR FY26","type":"AnnualReports","code":"B16960456"},{"name":"TR Q3FY26","type":"Transcripts","code":"C725534"},{"name":"TR Q3FY26","type":"Transcripts","code":"C725503"},{"name":"AR FY26","type":"AnnualReports","code":"B16960455"}]},{"id":"69f17f0dd757dc0b14912c32","card_variant":"primary","web_results_preview":{"total_count":20,"url_list":[{"article_title":"Dr. Reddy's weight-loss drug Semaglutide rollout in Canada suffers ...","article_url":"https://www.thehindu.com/business/Industry/dr-reddys-weight-loss-drug-semaglutide-rollout-in-canada-delayed-over-compliance-notice/article70220441.ece","source_domain":"www.thehindu.com","source_main_domain":"thehindu","source_name":""},{"article_title":"Dr Reddy's Shares Slip as Semaglutide Woes Weigh - HDFC Sky","article_url":"https://hdfcsky.com/news/dr-reddys-slides-against-market-rally-assemaglutide-concerns-weigh-on-stock","source_domain":"hdfcsky.com","source_main_domain":"hdfcsky","source_name":""},{"article_title":"The semaglutide saga continues: navigating generic entry and ...","article_url":"https://patentlawyermagazine.com/the-semaglutide-saga-continues-navigating-generic-entry-and-reinforcing-patent-strategies-in-canada/","source_domain":"patentlawyermagazine.com","source_main_domain":"patentlawyermagazine","source_name":""},{"article_title":"Novo Nordisk Canada considers renamed lower-price Ozempic","article_url":"https://www.bnnbloomberg.ca/business/company-news/2026/01/07/novo-nordisk-considers-competing-with-generics-through-renamed-lower-price-ozempic/","source_domain":"www.bnnbloomberg.ca","source_main_domain":"bnnbloomberg","source_name":""},{"article_title":"A diabetes treatment drug can change Dr. Reddy's fortunes, HSBC ...","article_url":"https://www.cnbctv18.com/market/dr-reddys-laboratories-share-price-hsbc-upgrades-buy-target-upside-diabetes-treatment-drug-key-trigger-19615870.htm","source_domain":"www.cnbctv18.com","source_main_domain":"cnbctv18","source_name":""},{"article_title":"Generic drugs - pan-Canadian Pharmaceutical Alliance (pCPA)","article_url":"https://www.pcpacanada.ca/generic-drug-framework","source_domain":"www.pcpacanada.ca","source_main_domain":"pcpacanada","source_name":""},{"article_title":"Generic Drug Sector Study - Competition Bureau Canada","article_url":"https://competition-bureau.canada.ca/en/generic-drug-sector-study","source_domain":"competition-bureau.canada.ca","source_main_domain":"canada","source_name":""},{"article_title":"Dr Reddy's Laboratories Share Price Target 2026: Analyst Forecast","article_url":"https://univest.in/blogs/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case","source_domain":"univest.in","source_main_domain":"univest","source_name":""},{"article_title":"The 2026 GLP-1 Patent Cliff: Generics, Global Competition, and the ...","article_url":"https://www.geneonline.com/the-2026-glp-1-patent-cliff-generics-global-competition-and-the-100-billion-ma-race/","source_domain":"www.geneonline.com","source_main_domain":"geneonline","source_name":""},{"article_title":"HSBC upgrades Dr Reddy's on weight loss drug semaglutide-driven ...","article_url":"https://finance.yahoo.com/news/hsbc-upgrades-dr-reddy-weight-142057344.html","source_domain":"finance.yahoo.com","source_main_domain":"yahoo","source_name":""},{"article_title":"Generic Semaglutide in Canada (2026): Timeline, Pricing, and What ...","article_url":"https://thehypna.app/articles/generic-semaglutide-canada-2026","source_domain":"thehypna.app","source_main_domain":"thehypna","source_name":""},{"article_title":"Generic Semaglutide Canada 2026 — Timeline & Price Tracker","article_url":"https://glp1prices.ca/generic-alert","source_domain":"glp1prices.ca","source_main_domain":"glp1prices","source_name":""},{"article_title":"Dr Reddy's Labs falls 6% after firm gets non-compliance notice for ...","article_url":"https://www.tradingview.com/news/moneycontrol:f080c0d3e094b:0-dr-reddy-s-labs-falls-6-after-firm-gets-non-compliance-notice-for-semaglutide-in-canada/","source_domain":"www.tradingview.com","source_main_domain":"tradingview","source_name":""},{"article_title":"Dr. Reddy's Laboratories still awaiting approval for a major near ...","article_url":"https://www.cnbctv18.com/market/dr-reddys-laboratories-share-price-key-trigger-canada-approval-semaglutide-market-size-competition-timeline-19891766.htm","source_domain":"www.cnbctv18.com","source_main_domain":"cnbctv18","source_name":""},{"article_title":"Dr. Reddy's gets one step closer to Semaglutide approval in Canada ...","article_url":"https://www.cnbctv18.com/market/dr-reddys-laboratories-share-price-semaglutide-injection-approval-health-canada-din-goldman-downgrade-19892580.htm","source_domain":"www.cnbctv18.com","source_main_domain":"cnbctv18","source_name":""},{"article_title":"Health Canada approves 1st generic version of Novo Nordisk's ...","article_url":"https://www.cbc.ca/lite/story/9.7180566","source_domain":"www.cbc.ca","source_main_domain":"cbc","source_name":""},{"article_title":"Dr Reddy's Shares Decline Amidst Goldman Sachs Downgrade and ...","article_url":"https://www.ainvest.com/news/dr-reddy-shares-decline-goldman-sachs-downgrade-citi-cautionary-note-2604/","source_domain":"www.ainvest.com","source_main_domain":"ainvest","source_name":""},{"article_title":"Dr. Reddy's updates on Health Canada review | RDY SEC Filing","article_url":"https://www.stocktitan.net/sec-filings/RDY/6-k-dr-reddys-laboratories-ltd-current-report-foreign-issuer-6483f832bffa.html","source_domain":"www.stocktitan.net","source_main_domain":"stocktitan","source_name":""},{"article_title":"Canada GLP-1 Receptor Agonist Market Size & Outlook, 2033","article_url":"https://www.grandviewresearch.com/horizon/outlook/glp-1-receptor-agonist-market/canada","source_domain":"www.grandviewresearch.com","source_main_domain":"grandviewresearch","source_name":""},{"article_title":"Dr Reddy's expects to launch Semaglutide generic in Canada by May","article_url":"https://pharma.economictimes.indiatimes.com/news/pharma-industry/dr-reddys-expects-to-launch-semaglutide-generic-in-canada-by-may/127139141","source_domain":"pharma.economictimes.indiatimes.com","source_main_domain":"indiatimes","source_name":""}]},"title":"Dr. Reddy's Generic Semaglutide: A Canadian First-Mover Advantage","description":"Health Canada's approval of Dr. Reddy's Laboratories' generic semaglutide marks the first G7 authorization, positioning the company for $80-280 million in annual revenue. With 6-9 months of competitive advantage and 12-15 million pens ready, Dr. Reddy's faces pricing pressure from mandatory discounts but gains first-mover benefits. Analysts remain divided on execution risks.","text_content":"$2c","image_link":"https://images.askfuzz.ai/article_images/2b2ff25e-73ac-4711-86fd-09d5af2244ac.jpg","image_source":"","slug":"dr-reddys-generic-semaglutide-a-canadian-first-mover-advantage","last_updated":"2026-04-29T09:16:21.51+05:30","created_at":"2026-04-29T09:16:21.51+05:30","view_count":757,"follow_up_questions":["What specific execution milestones should investors monitor over the next 6-9 months to assess whether Dr. Reddy's can achieve HSBC's bullish $280 million revenue projection?","How will the entry of additional generic manufacturers like Sandoz and Apotex impact Dr. Reddy's market share and margin assumptions in analyst valuation models?","What regulatory and competitive developments in Brazil and other emerging markets could provide additional upside or downside to current analyst price targets?"],"read_time":"5 min","reading_time":340,"isin":["INE089A01031"],"category":["Connect the Dots"],"llm_info":{"model":""}},{"id":"01KDWKPD129J4MQ7HJAKJW9ATD","card_variant":"primary","web_results_preview":{"total_count":2,"url_list":[{"article_title":"Dr. Reddy's Laboratories Receives GST Orders Worth ₹8.38 Crores in Penalties for FY 2018-19 to FY 2022-23","article_url":"https://scanx.trade/stock-market-news/normal_news/dr-reddy-s-laboratories-receives-gst-orders-worth-8-38-crores-in-penalties-for-fy-2018-19-to-fy-2022-23/28809020","source_domain":"scanx.trade","source_main_domain":"scanx","source_name":"Scanx"},{"article_title":"कल्पतरु प्रोजेक्ट्स को मिला ₹719 करोड़ का बड़ा ठेका, ठाणे मेट्रो के लिए शेयर में उछाल!","article_url":"https://www.whalesbook.com/news/Hindi/Industrial-GoodsServices/%E0%A4%95%E0%A4%B2%E0%A5%8D%E0%A4%AA%E0%A4%A4%E0%A4%B0%E0%A5%81-%E0%A4%AA%E0%A5%8D%E0%A4%B0%E0%A5%8B%E0%A4%9C%E0%A5%87%E0%A4%95%E0%A5%8D%E0%A4%9F%E0%A5%8D%E0%A4%B8-%E0%A4%95%E0%A5%8B-%E0%A4%AE%E0%A4%BF%E0%A4%B2%E0%A4%BE-indian-rupee719-%E0%A4%95%E0%A4%B0%E0%A5%8B%E0%A4%A1%E0%A4%BC-%E0%A4%95%E0%A4%BE-%E0%A4%AC%E0%A4%A1%E0%A4%BC%E0%A4%BE-%E0%A4%A0%E0%A5%87%E0%A4%95%E0%A4%BE-%E0%A4%A0%E0%A4%BE%E0%A4%A3%E0%A5%87-%E0%A4%AE%E0%A5%87%E0%A4%9F%E0%A5%8D%E0%A4%B0%E0%A5%8B-%E0%A4%95%E0%A5%87-%E0%A4%B2%E0%A4%BF%E0%A4%8F-%E0%A4%B6%E0%A5%87%E0%A4%AF%E0%A4%B0-%E0%A4%AE%E0%A5%87%E0%A4%82-%E0%A4%89%E0%A4%9B%E0%A4%BE%E0%A4%B2/6955f6f44342f77179f3f02a","source_domain":"www.whalesbook.com","source_main_domain":"whalesbook","source_name":"Whalesbook"}]},"title":"Dr. Reddy's Hit with ₹8.38 Cr GST Penalties","description":"Dr. Reddy's Laboratories received five GST penalty orders totaling ₹8.38 crores for alleged excess input tax credit violations from FY 2018-19 to 2022-23, with the company planning to file appeals while maintaining no material impact on operations.","text_content":"**Dr. Reddy's Laboratories** has received five separate GST orders imposing penalties totaling **₹8.38 crores** for alleged tax violations spanning financial years 2018-19 to 2022-23. According to the company's regulatory disclosure, the Joint Commissioner, Office of Principal Commissioner of Central Tax, Visakhapatnam issued all orders on **December 31, 2025**, which were received by the pharmaceutical company on the same date. The orders allege that *Dr. Reddy's Laboratories* availed excess input tax credit during the specified period under the APGST Act 2017.","image_link":"https://images.askfuzz.ai/article_images/dr-reddys-hit-with-8-38-cr-gst-penalties.jpg","image_source":"","slug":"dr-reddys-hit-with-8-38-cr-gst-penalties","last_updated":"2026-01-01T18:36:59.666+05:30","created_at":"2026-01-01T16:00:26+05:30","view_count":896,"follow_up_questions":["What will be the outcome of Dr. Reddy's appeal against the GST penalty orders?","How might this GST scrutiny affect Dr. Reddy's future tax compliance costs and operational expenses?","Will this penalty impact Dr. Reddy's credit rating or borrowing costs in the near term?","Could similar GST audits be extended to other pharmaceutical companies, creating sector-wide financial risks?","How will Dr. Reddy's handle the interest accumulation on the ₹8.38 crore penalty during the appeal process?"],"read_time":"1 min 22 sec","reading_time":82,"isin":["INE089A01031"],"category":["Companies"],"category_l2":["Litigation"],"category_l3":["Tax Disputes"],"llm_info":{"model":""}}],"PEERS":[{"CHAIRMAN_NAME":"Dilip S Shanghvi","DISPLAY_SYMBOL":"Sun Pharmaceutical","HIGH":1936.8,"ISIN":"INE044A01036","LISTING_DATE":"","LOW":1913,"LTP":1916,"MARKET_CAPITALISATION":463479.54,"PE_RATIO":38.28,"PREV_CLOSE":1931.7,"SEO_SYMBOL":"sun-pharmaceutical-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SUNPHARMA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SUNPHARMA.png","VOLUME":1205188},{"CHAIRMAN_NAME":"Ramesh B V Nimmagadda","DISPLAY_SYMBOL":"Divis Laboratories","HIGH":9282,"ISIN":"INE361B01024","LISTING_DATE":"2003-03-12","LOW":9184,"LTP":9250,"MARKET_CAPITALISATION":244762,"PE_RATIO":83.79,"PREV_CLOSE":9220,"SEO_SYMBOL":"divis-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"DIVISLAB","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/DIVISLAB.png","VOLUME":497269},{"CHAIRMAN_NAME":"Sudhir Mehta","DISPLAY_SYMBOL":"Torrent Pharmaceuticals","HIGH":5025,"ISIN":"INE685A01028","LISTING_DATE":"","LOW":4886.5,"LTP":4905.5,"MARKET_CAPITALISATION":190640.37,"PE_RATIO":88.29,"PREV_CLOSE":5012,"SEO_SYMBOL":"torrent-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"TORNTPHARM","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/TORNTPHARM.png","VOLUME":328448},{"CHAIRMAN_NAME":"Pankaj R Patel","DISPLAY_SYMBOL":"Zydus Life Science","HIGH":1157.8,"ISIN":"INE010B01027","LISTING_DATE":"2000-04-27","LOW":1130.5,"LTP":1143,"MARKET_CAPITALISATION":116139.53,"PE_RATIO":25,"PREV_CLOSE":1154.2,"SEO_SYMBOL":"cadila-healthcare-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ZYDUSLIFE","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ZYDUSLIFE.png","VOLUME":962097},{"CHAIRMAN_NAME":"Y K Hamied","DISPLAY_SYMBOL":"Cipla","HIGH":1415.4,"ISIN":"INE059A01026","LISTING_DATE":"","LOW":1389.4,"LTP":1394.7,"MARKET_CAPITALISATION":114132.4,"PE_RATIO":34.02,"PREV_CLOSE":1412.8,"SEO_SYMBOL":"cipla-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"CIPLA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/CIPLA.png","VOLUME":549645},{"CHAIRMAN_NAME":"Ravindranath Kancherla","DISPLAY_SYMBOL":"Laurus Labs","HIGH":1876.6,"ISIN":"INE947Q01028","LISTING_DATE":"2016-12-19","LOW":1852.6,"LTP":1868.5,"MARKET_CAPITALISATION":100629.27,"PE_RATIO":92.32,"PREV_CLOSE":1864,"SEO_SYMBOL":"laurus-labs-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"LAURUSLABS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/LAURUSLABS.png","VOLUME":1506361},{"CHAIRMAN_NAME":"RAMESH CHAND JUNEJA","DISPLAY_SYMBOL":"Mankind Pharma","HIGH":2390,"ISIN":"INE634S01028","LISTING_DATE":"2023-05-09","LOW":2355.4,"LTP":2368.8,"MARKET_CAPITALISATION":98768,"PE_RATIO":47.54,"PREV_CLOSE":2391.5,"SEO_SYMBOL":"mankind-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"MANKIND","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/MANKIND.png","VOLUME":98805},{"CHAIRMAN_NAME":"M D Gupta","DISPLAY_SYMBOL":"Lupin","HIGH":2159.9,"ISIN":"INE326A01037","LISTING_DATE":"","LOW":2132,"LTP":2132,"MARKET_CAPITALISATION":98542.8,"PE_RATIO":17.73,"PREV_CLOSE":2155.2,"SEO_SYMBOL":"lupin-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"LUPIN","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/LUPIN.png","VOLUME":474595},{"CHAIRMAN_NAME":"Satish Reddy","DISPLAY_SYMBOL":"Dr Reddys Laboratories","HIGH":1164.3,"ISIN":"INE089A01031","LISTING_DATE":"","LOW":1155,"LTP":1155,"MARKET_CAPITALISATION":96529.5,"PE_RATIO":30.44,"PREV_CLOSE":1156.5,"SEO_SYMBOL":"dr-reddys-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"DRREDDY","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/DRREDDY.png","VOLUME":338167},{"CHAIRMAN_NAME":"M R Kumar","DISPLAY_SYMBOL":"Aurobindo Pharma","HIGH":1666.6,"ISIN":"INE406A01037","LISTING_DATE":"","LOW":1626.6,"LTP":1637.3,"MARKET_CAPITALISATION":94833.78,"PE_RATIO":25.68,"PREV_CLOSE":1648.2,"SEO_SYMBOL":"aurobindo-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"AUROPHARMA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/AUROPHARMA.png","VOLUME":920206},{"CHAIRMAN_NAME":"Glenn Saldanha","DISPLAY_SYMBOL":"Glenmark Pharmaceuticals","HIGH":2471.8,"ISIN":"INE935A01035","LISTING_DATE":"","LOW":2425.1,"LTP":2459,"MARKET_CAPITALISATION":69421.4,"PE_RATIO":38.49,"PREV_CLOSE":2460,"SEO_SYMBOL":"glenmark-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"GLENMARK","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/GLENMARK.png","VOLUME":481342},{"CHAIRMAN_NAME":"Kiran Mazumdar Shaw","DISPLAY_SYMBOL":"Biocon","HIGH":405.7,"ISIN":"INE376G01013","LISTING_DATE":"2004-04-07","LOW":400.6,"LTP":402,"MARKET_CAPITALISATION":64998.4,"PE_RATIO":156.76,"PREV_CLOSE":401,"SEO_SYMBOL":"biocon-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"BIOCON","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/BIOCON.png","VOLUME":1279896},{"CHAIRMAN_NAME":"Basudeo N Singh","DISPLAY_SYMBOL":"Alkem Laboratories","HIGH":5233.5,"ISIN":"INE540L01014","LISTING_DATE":"2015-12-23","LOW":5157,"LTP":5193,"MARKET_CAPITALISATION":62293.36,"PE_RATIO":28.26,"PREV_CLOSE":5210,"SEO_SYMBOL":"alkem-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ALKEM","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ALKEM.png","VOLUME":95991},{"CHAIRMAN_NAME":"Munir Shaikh","DISPLAY_SYMBOL":"Abbott","HIGH":26175,"ISIN":"INE358A01014","LISTING_DATE":"","LOW":25905,"LTP":25945,"MARKET_CAPITALISATION":55343.81,"PE_RATIO":34.25,"PREV_CLOSE":26045,"SEO_SYMBOL":"abbott-india-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ABBOTINDIA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ABBOTINDIA.png","VOLUME":3151},{"CHAIRMAN_NAME":"Renu S. Karnad","DISPLAY_SYMBOL":"GlaxoSmithKline Pharmaceuticals","HIGH":2998,"ISIN":"INE159A01016","LISTING_DATE":"","LOW":2930.4,"LTP":2937.5,"MARKET_CAPITALISATION":49973.1,"PE_RATIO":46.73,"PREV_CLOSE":2949.9,"SEO_SYMBOL":"glaxosmithkline-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"GLAXO","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/GLAXO.png","VOLUME":56012},{"CHAIRMAN_NAME":"Premchand Godha","DISPLAY_SYMBOL":"IPCA Laboratories","HIGH":1978.2,"ISIN":"INE571A01038","LISTING_DATE":"","LOW":1907.9,"LTP":1956.1,"MARKET_CAPITALISATION":49637.23,"PE_RATIO":36.1,"PREV_CLOSE":1956.5,"SEO_SYMBOL":"ipca-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"IPCALAB","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/IPCALAB.png","VOLUME":301804},{"CHAIRMAN_NAME":"SRINIVAS SADU","DISPLAY_SYMBOL":"Gland Pharma","HIGH":2948,"ISIN":"INE068V01023","LISTING_DATE":"2020-11-20","LOW":2847.6,"LTP":2907.9,"MARKET_CAPITALISATION":47317,"PE_RATIO":41.87,"PREV_CLOSE":2868.4,"SEO_SYMBOL":"gland-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"GLAND","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/GLAND.png","VOLUME":189288},{"CHAIRMAN_NAME":"Mannalal B Agrawal","DISPLAY_SYMBOL":"Ajanta Pharma","HIGH":3536.7,"ISIN":"INE031B01049","LISTING_DATE":"2000-06-05","LOW":3456.1,"LTP":3521.1,"MARKET_CAPITALISATION":43498.84,"PE_RATIO":38.33,"PREV_CLOSE":3481.7,"SEO_SYMBOL":"ajanta-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"AJANTPHARM","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/AJANTPHARM.png","VOLUME":42779},{"CHAIRMAN_NAME":"SATISH RAMANLAL MEHTA","DISPLAY_SYMBOL":"Emcure Pharmaceuticals","HIGH":1874.9,"ISIN":"INE168P01015","LISTING_DATE":"2024-07-10","LOW":1838.4,"LTP":1854.7,"MARKET_CAPITALISATION":35246.33,"PE_RATIO":34.58,"PREV_CLOSE":1858.4,"SEO_SYMBOL":"emcure-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"EMCURE","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/EMCURE.png","VOLUME":91443},{"CHAIRMAN_NAME":"Ranga Raju Kanumuri","DISPLAY_SYMBOL":"Sai Life Sciences","HIGH":1630,"ISIN":"INE570L01029","LISTING_DATE":"2024-12-18","LOW":1559.9,"LTP":1574.8,"MARKET_CAPITALISATION":33662.7,"PE_RATIO":93.16,"PREV_CLOSE":1587,"SEO_SYMBOL":"sai-life-sciences-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SAILIFE","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SAILIFE.png","VOLUME":1633705},{"CHAIRMAN_NAME":"H F Khorakiwala","DISPLAY_SYMBOL":"Wockhardt","HIGH":1982,"ISIN":"INE049B01025","LISTING_DATE":"","LOW":1891.4,"LTP":1950.6,"MARKET_CAPITALISATION":30943.4,"PE_RATIO":74.75,"PREV_CLOSE":1904.3,"SEO_SYMBOL":"wockhardt-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"WOCKPHARMA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/WOCKPHARMA.png","VOLUME":1056401},{"CHAIRMAN_NAME":"CHANGAVALLI VENKAT","DISPLAY_SYMBOL":"Rubicon Research","HIGH":1839.7,"ISIN":"INE506V01022","LISTING_DATE":"2025-10-16","LOW":1765,"LTP":1775.7,"MARKET_CAPITALISATION":30245.2,"PE_RATIO":104.93,"PREV_CLOSE":1828.8,"SEO_SYMBOL":"rubicon-research-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"RUBICON","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/RUBICON.png","VOLUME":233208},{"CHAIRMAN_NAME":"D R Rao","DISPLAY_SYMBOL":"Neuland Laboratories","HIGH":23295,"ISIN":"INE794A01010","LISTING_DATE":"","LOW":22810,"LTP":22890,"MARKET_CAPITALISATION":29457.4,"PE_RATIO":59.17,"PREV_CLOSE":22960,"SEO_SYMBOL":"neuland-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"NEULANDLAB","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/NEULANDLAB.png","VOLUME":32650},{"CHAIRMAN_NAME":"Nandini Piramal","DISPLAY_SYMBOL":"Piramal Pharma","HIGH":216.9,"ISIN":"INE0DK501011","LISTING_DATE":"","LOW":211.81,"LTP":214.49,"MARKET_CAPITALISATION":28461.6,"PE_RATIO":-90.53,"PREV_CLOSE":213.78,"SEO_SYMBOL":"piramal-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"PPLPHARMA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/PPLPHARMA.png","VOLUME":2539339},{"CHAIRMAN_NAME":"Nareshbhai Ramjibhai Patel","DISPLAY_SYMBOL":"Acutaas Chemicals","HIGH":3211.6,"ISIN":"INE00FF01025","LISTING_DATE":"2021-09-14","LOW":3149.7,"LTP":3201,"MARKET_CAPITALISATION":25665.8,"PE_RATIO":66.33,"PREV_CLOSE":3134.9,"SEO_SYMBOL":"acutaas-chemicals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ACUTAAS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ACUTAAS.png","VOLUME":211896},{"CHAIRMAN_NAME":"Pradip Shah","DISPLAY_SYMBOL":"Pfizer","HIGH":4695,"ISIN":"INE182A01018","LISTING_DATE":"","LOW":4601,"LTP":4643.7,"MARKET_CAPITALISATION":21170.22,"PE_RATIO":28.79,"PREV_CLOSE":4627.6,"SEO_SYMBOL":"pfizer-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"PFIZER","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/PFIZER.png","VOLUME":10609},{"CHAIRMAN_NAME":"C C Paarthipan","DISPLAY_SYMBOL":"Caplin Point Laboratories","HIGH":2877.3,"ISIN":"INE475E01026","LISTING_DATE":"","LOW":2663.1,"LTP":2845,"MARKET_CAPITALISATION":20679,"PE_RATIO":30.43,"PREV_CLOSE":2720.5,"SEO_SYMBOL":"caplin-point-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"CAPLIPOINT","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/CAPLIPOINT.png","VOLUME":840705},{"CHAIRMAN_NAME":"C Krishna Prasad","DISPLAY_SYMBOL":"Granules","HIGH":873.5,"ISIN":"INE101D01020","LISTING_DATE":"","LOW":834,"LTP":853.85,"MARKET_CAPITALISATION":20610.51,"PE_RATIO":31.1,"PREV_CLOSE":831.75,"SEO_SYMBOL":"granules-india-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"GRANULES","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/GRANULES.png","VOLUME":2829036},{"CHAIRMAN_NAME":"Omprakash Inani","DISPLAY_SYMBOL":"Shilpa Medicare","HIGH":966.45,"ISIN":"INE790G01031","LISTING_DATE":"","LOW":923.6,"LTP":956.15,"MARKET_CAPITALISATION":18160.7,"PE_RATIO":61.07,"PREV_CLOSE":928.55,"SEO_SYMBOL":"shilpa-medicare-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SHILPAMED","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SHILPAMED.png","VOLUME":1865298},{"CHAIRMAN_NAME":"Amit Indubhushan Bakshi","DISPLAY_SYMBOL":"Eris Lifesciences","HIGH":1336.7,"ISIN":"INE406M01024","LISTING_DATE":"2017-06-29","LOW":1288.9,"LTP":1303.5,"MARKET_CAPITALISATION":17859.9,"PE_RATIO":26.92,"PREV_CLOSE":1288.9,"SEO_SYMBOL":"eris-lifesciences-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ERIS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ERIS.png","VOLUME":74372},{"CHAIRMAN_NAME":"Arun Kumar","DISPLAY_SYMBOL":"Onesource Specialty Pharma","HIGH":1596.6,"ISIN":"INE013P01021","LISTING_DATE":"","LOW":1546,"LTP":1575.7,"MARKET_CAPITALISATION":17705.9,"PE_RATIO":-364.35,"PREV_CLOSE":1544.4,"SEO_SYMBOL":"onesource-specialty-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ONESOURCE","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ONESOURCE.png","VOLUME":118656},{"CHAIRMAN_NAME":"Vivek Sharma","DISPLAY_SYMBOL":"Cohance Lifesciences","HIGH":464.75,"ISIN":"INE03QK01018","LISTING_DATE":"","LOW":457.8,"LTP":460.85,"MARKET_CAPITALISATION":17533.05,"PE_RATIO":299.97,"PREV_CLOSE":458.3,"SEO_SYMBOL":"suven-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"COHANCE","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/COHANCE.png","VOLUME":540229},{"CHAIRMAN_NAME":"HIREN KARSANBHAI PATEL","DISPLAY_SYMBOL":"Alivus Life Sciences","HIGH":1439.4,"ISIN":"INE03Q201024","LISTING_DATE":"2021-08-06","LOW":1405,"LTP":1418.8,"MARKET_CAPITALISATION":17403.2,"PE_RATIO":28.88,"PREV_CLOSE":1417.9,"SEO_SYMBOL":"glenmark-life-science-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ALIVUS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ALIVUS.png","VOLUME":79310},{"CHAIRMAN_NAME":"Shilpa Divekar Nirula","DISPLAY_SYMBOL":"AstraZeneca Pharma","HIGH":6960,"ISIN":"INE203A01020","LISTING_DATE":"","LOW":6835.5,"LTP":6940.5,"MARKET_CAPITALISATION":17170,"PE_RATIO":101.26,"PREV_CLOSE":6868,"SEO_SYMBOL":"astrazeneca-pharma-india-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ASTRAZEN","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ASTRAZEN.png","VOLUME":4139},{"CHAIRMAN_NAME":"C R Amin","DISPLAY_SYMBOL":"Alembic Pharmaceuticals","HIGH":833.5,"ISIN":"INE901L01018","LISTING_DATE":"","LOW":801.1,"LTP":803.65,"MARKET_CAPITALISATION":16253.8,"PE_RATIO":23.55,"PREV_CLOSE":826.9,"SEO_SYMBOL":"alembic-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"APLLTD","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/APLLTD.png","VOLUME":163761},{"CHAIRMAN_NAME":"SUDHIR JAIRAM VAID","DISPLAY_SYMBOL":"Concord Biotech","HIGH":1461.8,"ISIN":"INE338H01029","LISTING_DATE":"2023-08-18","LOW":1435,"LTP":1447.7,"MARKET_CAPITALISATION":15114.9,"PE_RATIO":55.31,"PREV_CLOSE":1444.8,"SEO_SYMBOL":"concord-biotech-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"CONCORDBIO","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/CONCORDBIO.png","VOLUME":69958},{"CHAIRMAN_NAME":"V C Nannapaneni","DISPLAY_SYMBOL":"Natco Pharma","HIGH":849.95,"ISIN":"INE987B01026","LISTING_DATE":"","LOW":835.8,"LTP":838.3,"MARKET_CAPITALISATION":15103.4,"PE_RATIO":13.19,"PREV_CLOSE":843.25,"SEO_SYMBOL":"natco-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"NATCOPHARM","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/NATCOPHARM.png","VOLUME":217919},{"CHAIRMAN_NAME":"Mark Saldanha","DISPLAY_SYMBOL":"Marksans Pharma","HIGH":341,"ISIN":"INE750C01026","LISTING_DATE":"","LOW":331,"LTP":332.2,"MARKET_CAPITALISATION":15071.8,"PE_RATIO":28.91,"PREV_CLOSE":332.5,"SEO_SYMBOL":"marksans-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"MARKSANS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/MARKSANS.png","VOLUME":2726314},{"CHAIRMAN_NAME":"Shyam S Bhartia","DISPLAY_SYMBOL":"Jubilant Pharmova","HIGH":910.8,"ISIN":"INE700A01033","LISTING_DATE":"","LOW":891.2,"LTP":907.9,"MARKET_CAPITALISATION":14340.1,"PE_RATIO":41.05,"PREV_CLOSE":900.3,"SEO_SYMBOL":"jubilant-life-sciences-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"JUBLPHARMA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/JUBLPHARMA.png","VOLUME":125392},{"CHAIRMAN_NAME":"Sujit J Bhayani","DISPLAY_SYMBOL":"Sudeep Pharma","HIGH":1295.7,"ISIN":"INE0QPI01025","LISTING_DATE":"2025-11-28","LOW":1238,"LTP":1292.8,"MARKET_CAPITALISATION":13937.9,"PE_RATIO":75.93,"PREV_CLOSE":1234,"SEO_SYMBOL":"sudeep-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SUDEEPPHRM","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SUDEEPPHRM.png","VOLUME":369818},{"CHAIRMAN_NAME":"KIRTIKUMAR LAXMIDAS MEHTA","DISPLAY_SYMBOL":"Corona Remedies","HIGH":2138,"ISIN":"INE02ZQ01018","LISTING_DATE":"2025-12-15","LOW":2041.8,"LTP":2127.8,"MARKET_CAPITALISATION":12563.5,"PE_RATIO":63.03,"PREV_CLOSE":2054.2,"SEO_SYMBOL":"corona-remedies-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"CORONA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/CORONA.png","VOLUME":23122},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Akums Drugs & Pharma","HIGH":788,"ISIN":"INE09XN01023","LISTING_DATE":"2024-08-06","LOW":760.5,"LTP":780.55,"MARKET_CAPITALISATION":12123.27,"PE_RATIO":41.4,"PREV_CLOSE":770.25,"SEO_SYMBOL":"akums-drugs-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"AKUMS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/AKUMS.png","VOLUME":335921},{"CHAIRMAN_NAME":"Kamal K Sharma","DISPLAY_SYMBOL":"Viyash Scientific","HIGH":263.9,"ISIN":"INE807F01027","LISTING_DATE":"","LOW":259.1,"LTP":260.45,"MARKET_CAPITALISATION":11319.4,"PE_RATIO":42.69,"PREV_CLOSE":259.1,"SEO_SYMBOL":"sequent-scientific-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"VIYASH","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/VIYASH.png","VOLUME":2922487},{"CHAIRMAN_NAME":"Akshay Bansarilal Arora","DISPLAY_SYMBOL":"Blue Jet Healthcare","HIGH":586.25,"ISIN":"INE0KBH01020","LISTING_DATE":"2023-11-01","LOW":577,"LTP":579,"MARKET_CAPITALISATION":10984.6,"PE_RATIO":46.8,"PREV_CLOSE":580.35,"SEO_SYMBOL":"blue-jet-healthcare-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"BLUEJET","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/BLUEJET.png","VOLUME":186895},{"CHAIRMAN_NAME":"Arun Kumar","DISPLAY_SYMBOL":"Strides Pharma Science","HIGH":1073,"ISIN":"INE939A01011","LISTING_DATE":"","LOW":1043.1,"LTP":1053.6,"MARKET_CAPITALISATION":9657.86,"PE_RATIO":15.22,"PREV_CLOSE":1047.8,"SEO_SYMBOL":"strides-pharma-science-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"STAR","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/STAR.png","VOLUME":189317},{"CHAIRMAN_NAME":"Amit Jain","DISPLAY_SYMBOL":"Sanofi Consumer Healthcare","HIGH":4287.9,"ISIN":"INE0UOS01011","LISTING_DATE":"","LOW":4145,"LTP":4205.4,"MARKET_CAPITALISATION":9632.3,"PE_RATIO":36.36,"PREV_CLOSE":4182.4,"SEO_SYMBOL":"sanofi-consumer-healthcare-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SANOFICONR","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SANOFICONR.png","VOLUME":7444},{"CHAIRMAN_NAME":"MADHAVAN SAMPATH","DISPLAY_SYMBOL":"Procter & Gamble Health","HIGH":5773,"ISIN":"INE199A01012","LISTING_DATE":"","LOW":5646,"LTP":5757.5,"MARKET_CAPITALISATION":9411.02,"PE_RATIO":26.41,"PREV_CLOSE":5669.5,"SEO_SYMBOL":"procter-gamble-health-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"PGHL","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/PGHL.png","VOLUME":7533},{"CHAIRMAN_NAME":"Rashesh C Gogri","DISPLAY_SYMBOL":"Aarti Pharma Labs","HIGH":886.95,"ISIN":"INE0LRU01027","LISTING_DATE":"","LOW":854.5,"LTP":868.1,"MARKET_CAPITALISATION":7862.3,"PE_RATIO":36.91,"PREV_CLOSE":867.25,"SEO_SYMBOL":"aarti-pharma-labs-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"AARTIPHARM","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/AARTIPHARM.png","VOLUME":378950},{"CHAIRMAN_NAME":"Rahul Bhatnagar","DISPLAY_SYMBOL":"Sanofi","HIGH":3220,"ISIN":"INE058A01010","LISTING_DATE":"","LOW":3160,"LTP":3190.8,"MARKET_CAPITALISATION":7271.7,"PE_RATIO":20.14,"PREV_CLOSE":3157.4,"SEO_SYMBOL":"sanofi-india-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SANOFI","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SANOFI.png","VOLUME":14906},{"CHAIRMAN_NAME":"Nandkumar Kashinath Chodankar","DISPLAY_SYMBOL":"Bliss GVS Pharma","HIGH":665,"ISIN":"INE416D01022","LISTING_DATE":"","LOW":635,"LTP":639.35,"MARKET_CAPITALISATION":6862,"PE_RATIO":48.65,"PREV_CLOSE":648.65,"SEO_SYMBOL":"bliss-gvs-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"BLISSGVS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/BLISSGVS.png","VOLUME":124902},{"CHAIRMAN_NAME":"Satish Waman Wagh","DISPLAY_SYMBOL":"Supriya Lifescience","HIGH":852.9,"ISIN":"INE07RO01027","LISTING_DATE":"2021-12-28","LOW":834,"LTP":842.7,"MARKET_CAPITALISATION":6770.21,"PE_RATIO":34.14,"PREV_CLOSE":841.2,"SEO_SYMBOL":"supriya-lifescience-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SUPRIYA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SUPRIYA.png","VOLUME":195663},{"CHAIRMAN_NAME":"Sanjay Majmudar","DISPLAY_SYMBOL":"Senores Pharmaceuticals","HIGH":1462.4,"ISIN":"INE0RB801010","LISTING_DATE":"2024-12-30","LOW":1424,"LTP":1430.4,"MARKET_CAPITALISATION":6675.47,"PE_RATIO":51.05,"PREV_CLOSE":1449.5,"SEO_SYMBOL":"senores-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SENORES","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SENORES.png","VOLUME":111646},{"CHAIRMAN_NAME":"Dilip S Shanghvi","DISPLAY_SYMBOL":"Sun Pharma Advanced Research Co","HIGH":205.9,"ISIN":"INE232I01014","LISTING_DATE":"","LOW":198.5,"LTP":202.54,"MARKET_CAPITALISATION":6476.36,"PE_RATIO":4.09,"PREV_CLOSE":199.58,"SEO_SYMBOL":"sun-pharma-advanced-research-company-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SPARC","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SPARC.png","VOLUME":1047061},{"CHAIRMAN_NAME":"Manish Grover","DISPLAY_SYMBOL":"Jeena Sikho Lifecare","HIGH":509.8,"ISIN":"INE0J5801029","LISTING_DATE":"2022-04-19","LOW":500,"LTP":501.45,"MARKET_CAPITALISATION":6384.7,"PE_RATIO":27.01,"PREV_CLOSE":513.65,"SEO_SYMBOL":"jeena-sikho-lifecare-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"JSLL","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/JSLL.png","VOLUME":606645},{"CHAIRMAN_NAME":"Manoj Kumar Lohariwala","DISPLAY_SYMBOL":"Innova Captab","HIGH":1155.8,"ISIN":"INE0DUT01020","LISTING_DATE":"2023-12-29","LOW":1101.9,"LTP":1125.4,"MARKET_CAPITALISATION":6344,"PE_RATIO":41.37,"PREV_CLOSE":1108.6,"SEO_SYMBOL":"innova-captab-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"INNOVACAP","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/INNOVACAP.png","VOLUME":168214},{"CHAIRMAN_NAME":"Sushil Suri","DISPLAY_SYMBOL":"Morepen Laboratories","HIGH":118.55,"ISIN":"INE083A01026","LISTING_DATE":"","LOW":109.6,"LTP":117.45,"MARKET_CAPITALISATION":6135.44,"PE_RATIO":43.93,"PREV_CLOSE":111.97,"SEO_SYMBOL":"morepen-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"MOREPENLAB","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/MOREPENLAB.png","VOLUME":33820381},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"FDC","HIGH":344.05,"ISIN":"INE258B01022","LISTING_DATE":"","LOW":339.05,"LTP":341.6,"MARKET_CAPITALISATION":5545.3,"PE_RATIO":18.92,"PREV_CLOSE":340.6,"SEO_SYMBOL":"fdc-fairdeal-corporation-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"FDC","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/FDC.png","VOLUME":92294},{"CHAIRMAN_NAME":"R M Malla","DISPLAY_SYMBOL":"IOL Chemicals & Pharmaceuticals","HIGH":202.99,"ISIN":"INE485C01029","LISTING_DATE":"","LOW":189.7,"LTP":196.43,"MARKET_CAPITALISATION":5529.47,"PE_RATIO":32.86,"PREV_CLOSE":188.38,"SEO_SYMBOL":"iol-chemicals-and-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"IOLCP","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/IOLCP.png","VOLUME":8448743},{"CHAIRMAN_NAME":"R G Agarwal","DISPLAY_SYMBOL":"Orchid Pharma","HIGH":954.75,"ISIN":"INE191A01027","LISTING_DATE":"","LOW":931.1,"LTP":934.65,"MARKET_CAPITALISATION":4757.71,"PE_RATIO":524.3,"PREV_CLOSE":938.05,"SEO_SYMBOL":"orchid-chemicals-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ORCHPHARMA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ORCHPHARMA.png","VOLUME":33332},{"CHAIRMAN_NAME":"Dinesh S Patel","DISPLAY_SYMBOL":"Gujarat Themis Biosyn","HIGH":435,"ISIN":"INE942C01045","LISTING_DATE":"","LOW":412.85,"LTP":425.1,"MARKET_CAPITALISATION":4500.8,"PE_RATIO":114.93,"PREV_CLOSE":413.05,"SEO_SYMBOL":"gujarat-themis-biosyn-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"GUJTHEM","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/GUJTHEM.png","VOLUME":1355432},{"CHAIRMAN_NAME":"Jayesh P Choksi","DISPLAY_SYMBOL":"Gufic BioSciences","HIGH":447.9,"ISIN":"INE742B01025","LISTING_DATE":"","LOW":436.15,"LTP":439.35,"MARKET_CAPITALISATION":4400.4,"PE_RATIO":60.01,"PREV_CLOSE":438.8,"SEO_SYMBOL":"gufic-biosciences-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"GUFICBIO","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/GUFICBIO.png","VOLUME":106608},{"CHAIRMAN_NAME":"H V Goenka","DISPLAY_SYMBOL":"RPG Life Sciences","HIGH":2698.9,"ISIN":"INE105J01010","LISTING_DATE":"","LOW":2583.1,"LTP":2652.4,"MARKET_CAPITALISATION":4242.09,"PE_RATIO":35.56,"PREV_CLOSE":2564.9,"SEO_SYMBOL":"rpg-life-sciences-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"RPGLIFE","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/RPGLIFE.png","VOLUME":25736},{"CHAIRMAN_NAME":"C Snook","DISPLAY_SYMBOL":"Novartis","HIGH":1620.8,"ISIN":"INE234A01025","LISTING_DATE":"","LOW":1585.6,"LTP":1614.1,"MARKET_CAPITALISATION":3954.2,"PE_RATIO":40.46,"PREV_CLOSE":1601.5,"SEO_SYMBOL":"novartis-india-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"NOVARTIND","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/NOVARTIND.png","VOLUME":16580},{"CHAIRMAN_NAME":"Prakash A Mody","DISPLAY_SYMBOL":"Unichem Laboratories","HIGH":569.25,"ISIN":"INE351A01035","LISTING_DATE":"","LOW":542.85,"LTP":547.95,"MARKET_CAPITALISATION":3940.26,"PE_RATIO":12.89,"PREV_CLOSE":559.65,"SEO_SYMBOL":"unichem-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"UNICHEMLAB","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/UNICHEMLAB.png","VOLUME":73499},{"CHAIRMAN_NAME":"Chandrakant V. Gogri","DISPLAY_SYMBOL":"Aarti Drugs","HIGH":440.6,"ISIN":"INE767A01016","LISTING_DATE":"","LOW":419.5,"LTP":425.85,"MARKET_CAPITALISATION":3813.26,"PE_RATIO":19.93,"PREV_CLOSE":417.8,"SEO_SYMBOL":"aarti-drugs-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"AARTIDRUGS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/AARTIDRUGS.png","VOLUME":379786},{"CHAIRMAN_NAME":"Ketankumar Zota","DISPLAY_SYMBOL":"Zota Healthcare","HIGH":1105,"ISIN":"INE358U01012","LISTING_DATE":"2017-05-10","LOW":1071.9,"LTP":1101.2,"MARKET_CAPITALISATION":3733.39,"PE_RATIO":-35.81,"PREV_CLOSE":1078,"SEO_SYMBOL":"zota-healthcare-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"ZOTA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ZOTA.png","VOLUME":40807},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Kwality Pharmaceuticals","HIGH":3445,"ISIN":"INE552U01010","LISTING_DATE":"2016-07-18","LOW":3290.2,"LTP":3351.7,"MARKET_CAPITALISATION":3517.6,"PE_RATIO":43.41,"PREV_CLOSE":3390.1,"SEO_SYMBOL":"kwality-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"KPL","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/KPL.png","VOLUME":21875},{"CHAIRMAN_NAME":"P Ramesh Babu","DISPLAY_SYMBOL":"SMS Pharmaceuticals","HIGH":376.4,"ISIN":"INE812G01025","LISTING_DATE":"2007-02-28","LOW":368.55,"LTP":374.15,"MARKET_CAPITALISATION":3493.7,"PE_RATIO":34.13,"PREV_CLOSE":373.05,"SEO_SYMBOL":"sms-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SMSPHARMA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SMSPHARMA.png","VOLUME":57593},{"CHAIRMAN_NAME":"N R Munjal","DISPLAY_SYMBOL":"Ind Swift Laboratories","HIGH":376,"ISIN":"INE915B01019","LISTING_DATE":"","LOW":363,"LTP":372.7,"MARKET_CAPITALISATION":3185.6,"PE_RATIO":55.7,"PREV_CLOSE":366.85,"SEO_SYMBOL":"ind-swift-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"INDSWFTLAB","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/INDSWFTLAB.png","VOLUME":536113},{"CHAIRMAN_NAME":"RAJAGOPALAN RAMAKRISHNAN","DISPLAY_SYMBOL":"Solara Active Pharma Sciences","HIGH":647.6,"ISIN":"INE624Z01016","LISTING_DATE":"","LOW":625.1,"LTP":629.85,"MARKET_CAPITALISATION":3055.23,"PE_RATIO":-1887.21,"PREV_CLOSE":640.35,"SEO_SYMBOL":"solara-active-pharma-sciences-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SOLARA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SOLARA.png","VOLUME":226118},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Dishman Carbogen Amcis","HIGH":179.9,"ISIN":"INE385W01011","LISTING_DATE":"","LOW":175.4,"LTP":176.99,"MARKET_CAPITALISATION":2772.71,"PE_RATIO":171.84,"PREV_CLOSE":176.85,"SEO_SYMBOL":"dishman-carbogen-amcis-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"DCAL","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/DCAL.png","VOLUME":137643},{"CHAIRMAN_NAME":"Suresh G Kare","DISPLAY_SYMBOL":"Indoco Remedies","HIGH":283.5,"ISIN":"INE873D01024","LISTING_DATE":"2005-01-14","LOW":266.38,"LTP":272.56,"MARKET_CAPITALISATION":2527,"PE_RATIO":805.15,"PREV_CLOSE":273.77,"SEO_SYMBOL":"indoco-remedies-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"INDOCO","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/INDOCO.png","VOLUME":1489787},{"CHAIRMAN_NAME":"Daulat N Medhora","DISPLAY_SYMBOL":"Fredun Pharmaceuticals","HIGH":1525.9,"ISIN":"INE194R01017","LISTING_DATE":"","LOW":1480,"LTP":1488.3,"MARKET_CAPITALISATION":2490.3,"PE_RATIO":56.84,"PREV_CLOSE":1505.8,"SEO_SYMBOL":"fredun-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"FREDUN","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/FREDUN.png","VOLUME":9559},{"CHAIRMAN_NAME":"J Hiremath","DISPLAY_SYMBOL":"Hikal","HIGH":240.72,"ISIN":"INE475B01022","LISTING_DATE":"","LOW":201.15,"LTP":240.36,"MARKET_CAPITALISATION":2473.4,"PE_RATIO":-73.38,"PREV_CLOSE":200.6,"SEO_SYMBOL":"hikal-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"HIKAL","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/HIKAL.png","VOLUME":20195810},{"CHAIRMAN_NAME":"Rahul Batra","DISPLAY_SYMBOL":"Beta Drugs","HIGH":2285,"ISIN":"INE351Y01019","LISTING_DATE":"2017-10-12","LOW":2145,"LTP":2258.9,"MARKET_CAPITALISATION":2369.05,"PE_RATIO":51.2,"PREV_CLOSE":2137,"SEO_SYMBOL":"beta-drugs-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"BETA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/BETA.png","VOLUME":27003},{"CHAIRMAN_NAME":"Rajesh Jain","DISPLAY_SYMBOL":"Panacea Biotec","HIGH":394,"ISIN":"INE922B01023","LISTING_DATE":"","LOW":383.45,"LTP":389.05,"MARKET_CAPITALISATION":2341.9,"PE_RATIO":-261.64,"PREV_CLOSE":382.35,"SEO_SYMBOL":"panacea-biotec-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"PANACEABIO","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/PANACEABIO.png","VOLUME":97503},{"CHAIRMAN_NAME":"ANIL KUMAR KARUSALA","DISPLAY_SYMBOL":"Sai Parenteral's","HIGH":522.8,"ISIN":"INE0H9F01037","LISTING_DATE":"2026-04-02","LOW":515.55,"LTP":518.15,"MARKET_CAPITALISATION":2277.66,"PE_RATIO":109.91,"PREV_CLOSE":515.55,"SEO_SYMBOL":"","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SAIPARENT","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SAIPARENT.png","VOLUME":35674},{"CHAIRMAN_NAME":"Vivek Dhariwal","DISPLAY_SYMBOL":"Windlas Biotech","HIGH":1148,"ISIN":"INE0H5O01029","LISTING_DATE":"2021-08-16","LOW":1090,"LTP":1127.1,"MARKET_CAPITALISATION":2262.97,"PE_RATIO":33.96,"PREV_CLOSE":1096.6,"SEO_SYMBOL":"windlas.ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"WINDLAS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/WINDLAS.png","VOLUME":418192},{"CHAIRMAN_NAME":"Sanjay S Shah.","DISPLAY_SYMBOL":"Sakar Healthcare","HIGH":1017,"ISIN":"INE732S01012","LISTING_DATE":"2016-10-14","LOW":960.05,"LTP":1006.95,"MARKET_CAPITALISATION":2193.4,"PE_RATIO":60.78,"PREV_CLOSE":985.8,"SEO_SYMBOL":"sakar-healthcare-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"SAKAR","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SAKAR.png","VOLUME":168154},{"CHAIRMAN_NAME":"Pawan Chaudhary","DISPLAY_SYMBOL":"Venus Remedies","HIGH":1701.9,"ISIN":"INE411B01019","LISTING_DATE":"","LOW":1620,"LTP":1701.9,"MARKET_CAPITALISATION":2166.66,"PE_RATIO":18.74,"PREV_CLOSE":1620.9,"SEO_SYMBOL":"venus-remedies-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"VENUSREM","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/VENUSREM.png","VOLUME":28866},{"CHAIRMAN_NAME":"Dakshesh Shah","DISPLAY_SYMBOL":"Shukra Pharmaceuticals","HIGH":54.9,"ISIN":"INE551C01044","LISTING_DATE":"","LOW":47.1,"LTP":51.93,"MARKET_CAPITALISATION":2056.96,"PE_RATIO":60.77,"PREV_CLOSE":46.79,"SEO_SYMBOL":"shukra-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SHUKRAPHAR","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SHUKRAPHAR.png","VOLUME":8949079},{"CHAIRMAN_NAME":"ANKIT KEDARMAL BANKDA","DISPLAY_SYMBOL":"Syncom Formulations","HIGH":22.59,"ISIN":"INE312C01025","LISTING_DATE":"","LOW":20.66,"LTP":21.36,"MARKET_CAPITALISATION":2010.7,"PE_RATIO":23.51,"PREV_CLOSE":21.39,"SEO_SYMBOL":"syncom-formulations-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SYNCOMF","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SYNCOMF.png","VOLUME":24798161},{"CHAIRMAN_NAME":"Bhupendra V Gandhi","DISPLAY_SYMBOL":"Hester Biosciences","HIGH":2225,"ISIN":"INE782E01017","LISTING_DATE":"","LOW":2176.5,"LTP":2201.7,"MARKET_CAPITALISATION":1851.5,"PE_RATIO":13.56,"PREV_CLOSE":2176.5,"SEO_SYMBOL":"hester-biosciences-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"HESTERBIO","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/HESTERBIO.png","VOLUME":1969},{"CHAIRMAN_NAME":"Dhananjay N Mungale","DISPLAY_SYMBOL":"NGL Fine Chem","HIGH":2999.8,"ISIN":"INE887E01022","LISTING_DATE":"","LOW":2676,"LTP":2940.8,"MARKET_CAPITALISATION":1661.1,"PE_RATIO":29.05,"PREV_CLOSE":2688.7,"SEO_SYMBOL":"ngl-fine-chem-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"NGLFINE","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/NGLFINE.png","VOLUME":69056},{"CHAIRMAN_NAME":"Harsha Raghavan","DISPLAY_SYMBOL":"Jagsonpal Pharmaceuticals","HIGH":249.57,"ISIN":"INE048B01035","LISTING_DATE":"","LOW":237.01,"LTP":243.02,"MARKET_CAPITALISATION":1560.5,"PE_RATIO":34.4,"PREV_CLOSE":237.03,"SEO_SYMBOL":"jagsonpal-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"JAGSNPHARM","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/JAGSNPHARM.png","VOLUME":300344},{"CHAIRMAN_NAME":"Pradeep Manjunath Chandan","DISPLAY_SYMBOL":"Fermenta Biotech","HIGH":537.75,"ISIN":"INE225B01021","LISTING_DATE":"","LOW":495.2,"LTP":502.3,"MARKET_CAPITALISATION":1532.32,"PE_RATIO":26.44,"PREV_CLOSE":520.65,"SEO_SYMBOL":"dil-fermenta-biotech-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"FERMENTA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/FERMENTA.png","VOLUME":102470},{"CHAIRMAN_NAME":"S Sambhuprasad","DISPLAY_SYMBOL":"Amrutanjan Health Care","HIGH":515.45,"ISIN":"INE098F01031","LISTING_DATE":"","LOW":502.75,"LTP":507.35,"MARKET_CAPITALISATION":1446.25,"PE_RATIO":26.88,"PREV_CLOSE":500.25,"SEO_SYMBOL":"amrutajan-health-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"AMRUTANJAN","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/AMRUTANJAN.png","VOLUME":67870},{"CHAIRMAN_NAME":"Rabindra Prasad Sinha","DISPLAY_SYMBOL":"Sigachi Industries","HIGH":33.55,"ISIN":"INE0D0K01022","LISTING_DATE":"2021-11-15","LOW":32.3,"LTP":32.55,"MARKET_CAPITALISATION":1243.03,"PE_RATIO":47.17,"PREV_CLOSE":32.53,"SEO_SYMBOL":"sigachi-industries-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SIGACHI","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SIGACHI.png","VOLUME":2065385},{"CHAIRMAN_NAME":"Kishorbhai M Shah","DISPLAY_SYMBOL":"Lincoln Pharmaceuticals","HIGH":627.35,"ISIN":"INE405C01035","LISTING_DATE":"","LOW":619,"LTP":622.65,"MARKET_CAPITALISATION":1238.5,"PE_RATIO":12.82,"PREV_CLOSE":618.35,"SEO_SYMBOL":"lincoln-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"LINCOLN","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/LINCOLN.png","VOLUME":22964},{"CHAIRMAN_NAME":"Dinesh S Patel","DISPLAY_SYMBOL":"Themis Medicare","HIGH":126.9,"ISIN":"INE083B01024","LISTING_DATE":"","LOW":123.72,"LTP":124.87,"MARKET_CAPITALISATION":1143.4,"PE_RATIO":28.59,"PREV_CLOSE":124.15,"SEO_SYMBOL":"themis-medicare-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"THEMISMED","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/THEMISMED.png","VOLUME":81469},{"CHAIRMAN_NAME":"Sanjankumar R Bajaj","DISPLAY_SYMBOL":"Bajaj HealthCare","HIGH":339.9,"ISIN":"INE411U01027","LISTING_DATE":"2016-05-10","LOW":324.6,"LTP":325.2,"MARKET_CAPITALISATION":1107.5,"PE_RATIO":62.79,"PREV_CLOSE":329,"SEO_SYMBOL":"bajaj-healthcare-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"BAJAJHCARE","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/BAJAJHCARE.png","VOLUME":159404},{"CHAIRMAN_NAME":"Surendra Somani","DISPLAY_SYMBOL":"Kopran","HIGH":239.6,"ISIN":"INE082A01010","LISTING_DATE":"","LOW":218.84,"LTP":232.24,"MARKET_CAPITALISATION":1056.6,"PE_RATIO":42.35,"PREV_CLOSE":218.81,"SEO_SYMBOL":"kopran-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"KOPRAN","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/KOPRAN.png","VOLUME":1456374},{"CHAIRMAN_NAME":"Bharat Kumar R Desai","DISPLAY_SYMBOL":"Bharat Parenterals","HIGH":1568.3,"ISIN":"INE365Y01019","LISTING_DATE":"","LOW":1512.4,"LTP":1520.8,"MARKET_CAPITALISATION":1046.34,"PE_RATIO":-35.64,"PREV_CLOSE":1518.2,"SEO_SYMBOL":"bplpharma.ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"BPLPHARMA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/BPLPHARMA.png","VOLUME":897},{"CHAIRMAN_NAME":"SWAPNIL JATINBHAI SHAH","DISPLAY_SYMBOL":"Remus Pharmaceuticals","HIGH":921.95,"ISIN":"INE0O5T01011","LISTING_DATE":"2023-05-29","LOW":891,"LTP":894.1,"MARKET_CAPITALISATION":1043.24,"PE_RATIO":22.6,"PREV_CLOSE":885.3,"SEO_SYMBOL":"remus-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"REMUS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/REMUS.png","VOLUME":8600},{"CHAIRMAN_NAME":"Chandubhai Kothia","DISPLAY_SYMBOL":"Shree Ganesh Remedies","HIGH":699.95,"ISIN":"INE414Y01015","LISTING_DATE":"","LOW":678,"LTP":684.1,"MARKET_CAPITALISATION":880.03,"PE_RATIO":56.9,"PREV_CLOSE":685.65,"SEO_SYMBOL":"shree-ganesh-remedies-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SGRL","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SGRL.png","VOLUME":21215},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Wanbury","HIGH":249.5,"ISIN":"INE107F01022","LISTING_DATE":"","LOW":241,"LTP":243.35,"MARKET_CAPITALISATION":856.02,"PE_RATIO":19.94,"PREV_CLOSE":245,"SEO_SYMBOL":"wanbury-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"WANBURY","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/WANBURY.png","VOLUME":91104},{"CHAIRMAN_NAME":"Punitkumar R Rasadia","DISPLAY_SYMBOL":"Anlon Healthcare","HIGH":16.25,"ISIN":"INE0Y8W01025","LISTING_DATE":"2025-09-03","LOW":15.47,"LTP":15.6,"MARKET_CAPITALISATION":827.04,"PE_RATIO":24.25,"PREV_CLOSE":15.56,"SEO_SYMBOL":"anlon-healthcare-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"AHCL","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/AHCL.png","VOLUME":5112726},{"CHAIRMAN_NAME":"Arun Todarwal","DISPLAY_SYMBOL":"Anuh Pharma","HIGH":81.7,"ISIN":"INE489G01022","LISTING_DATE":"","LOW":78.1,"LTP":79.68,"MARKET_CAPITALISATION":791.17,"PE_RATIO":17.96,"PREV_CLOSE":78.94,"SEO_SYMBOL":"anuh-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ANUHPHR","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ANUHPHR.png","VOLUME":93225},{"CHAIRMAN_NAME":"Ravichandran Chitra","DISPLAY_SYMBOL":"Bafna Pharmaceuticals","HIGH":307.5,"ISIN":"INE878I01022","LISTING_DATE":"2008-06-27","LOW":301.85,"LTP":301.85,"MARKET_CAPITALISATION":728.6,"PE_RATIO":0,"PREV_CLOSE":308,"SEO_SYMBOL":"bafna-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"BAFNAPH","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/BAFNAPH.png","VOLUME":4454},{"CHAIRMAN_NAME":"Bhavesh Patel","DISPLAY_SYMBOL":"Amanta Healthcare","HIGH":190.23,"ISIN":"INE084K01015","LISTING_DATE":"2025-09-09","LOW":190.23,"LTP":190.23,"MARKET_CAPITALISATION":724.17,"PE_RATIO":49.55,"PREV_CLOSE":186.5,"SEO_SYMBOL":"amanta-healthcare-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"AMANTA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/AMANTA.png","VOLUME":19977},{"CHAIRMAN_NAME":"Anwar Daud","DISPLAY_SYMBOL":"Zim Laboratories","HIGH":134.49,"ISIN":"INE518E01015","LISTING_DATE":"","LOW":127,"LTP":128.02,"MARKET_CAPITALISATION":717.29,"PE_RATIO":193.62,"PREV_CLOSE":133.95,"SEO_SYMBOL":"zim-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ZIMLAB","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ZIMLAB.png","VOLUME":139007},{"CHAIRMAN_NAME":"Munir Abdul Ganee Chandniwala","DISPLAY_SYMBOL":"Influx Healthtech","HIGH":298.4,"ISIN":"INE0MYZ01012","LISTING_DATE":"2025-06-25","LOW":283,"LTP":290.4,"MARKET_CAPITALISATION":657.12,"PE_RATIO":32,"PREV_CLOSE":283.85,"SEO_SYMBOL":"influx-healthtech-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"INFLUX","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/INFLUX.png","VOLUME":16200},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"KRM Ayurveda","HIGH":293.9,"ISIN":"INE1MTV01019","LISTING_DATE":"2026-01-29","LOW":279.1,"LTP":284.4,"MARKET_CAPITALISATION":619.01,"PE_RATIO":0,"PREV_CLOSE":291.15,"SEO_SYMBOL":"krm-ayurveda-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"KRMAYURVED","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/KRMAYURVED.png","VOLUME":142000},{"CHAIRMAN_NAME":"Mukund P Mehta","DISPLAY_SYMBOL":"Kilitch Drugs","HIGH":173.71,"ISIN":"INE729D01010","LISTING_DATE":"","LOW":167,"LTP":173.4,"MARKET_CAPITALISATION":599.1,"PE_RATIO":20.53,"PREV_CLOSE":171.37,"SEO_SYMBOL":"kilitch-drugs-india-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"KILITCH","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/KILITCH.png","VOLUME":8770},{"CHAIRMAN_NAME":"Mulesh Manilal Savla","DISPLAY_SYMBOL":"Valiant Laboratories","HIGH":100.93,"ISIN":"INE0JWS01017","LISTING_DATE":"2023-10-06","LOW":99,"LTP":100.93,"MARKET_CAPITALISATION":522.1,"PE_RATIO":32.99,"PREV_CLOSE":96.13,"SEO_SYMBOL":"valiant-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"VALIANTLAB","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/VALIANTLAB.png","VOLUME":44968},{"CHAIRMAN_NAME":"A K Kothari","DISPLAY_SYMBOL":"Albert David","HIGH":883.9,"ISIN":"INE155C01010","LISTING_DATE":"","LOW":865,"LTP":870.15,"MARKET_CAPITALISATION":497.5,"PE_RATIO":22.12,"PREV_CLOSE":871.7,"SEO_SYMBOL":"albert-david-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ALBERTDAVD","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ALBERTDAVD.png","VOLUME":1783},{"CHAIRMAN_NAME":"Ashish U Bhuta","DISPLAY_SYMBOL":"Jenburkt Pharmaceuticals","HIGH":1049.7,"ISIN":"INE354A01013","LISTING_DATE":"","LOW":1027.3,"LTP":1031.5,"MARKET_CAPITALISATION":460.7,"PE_RATIO":13.92,"PREV_CLOSE":1043.9,"SEO_SYMBOL":"jenburkt-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"JENBURPH","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/JENBURPH.png","VOLUME":2668},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Haleos","HIGH":1512.9,"ISIN":"INE320X01016","LISTING_DATE":"","LOW":1475,"LTP":1482.1,"MARKET_CAPITALISATION":447.87,"PE_RATIO":29.35,"PREV_CLOSE":1481.4,"SEO_SYMBOL":"sms-lifesciences-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"HALEOSLABS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/HALEOSLABS.png","VOLUME":193},{"CHAIRMAN_NAME":"Sanjaykumar Viththalbhai Patel","DISPLAY_SYMBOL":"Infinium Pharmachem","HIGH":255,"ISIN":"INE0MRE01011","LISTING_DATE":"2023-04-17","LOW":245.5,"LTP":250,"MARKET_CAPITALISATION":405.08,"PE_RATIO":28.53,"PREV_CLOSE":259.95,"SEO_SYMBOL":"infinium-pharmachem-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"INFINIUM","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/INFINIUM.png","VOLUME":6000},{"CHAIRMAN_NAME":"Rahul Bishnoi","DISPLAY_SYMBOL":"Medicamen Biotech","HIGH":273,"ISIN":"INE646B01010","LISTING_DATE":"","LOW":258,"LTP":259.4,"MARKET_CAPITALISATION":359.75,"PE_RATIO":35.61,"PREV_CLOSE":265.25,"SEO_SYMBOL":"medicamen-biotech-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"MEDICAMEQ","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/MEDICAMEQ.png","VOLUME":33679},{"CHAIRMAN_NAME":"Ashwin Hathi","DISPLAY_SYMBOL":"Ambalal Sarabhai Enterprises","HIGH":45.5,"ISIN":"INE432A01017","LISTING_DATE":"","LOW":43.51,"LTP":43.67,"MARKET_CAPITALISATION":338,"PE_RATIO":25.31,"PREV_CLOSE":44.1,"SEO_SYMBOL":"ambalal-sarabhai-enterprises-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"AMBALALSA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/AMBALALSA.png","VOLUME":24304},{"CHAIRMAN_NAME":"Haresh Mehta","DISPLAY_SYMBOL":"Medico Remedies","HIGH":40.3,"ISIN":"INE630Y01024","LISTING_DATE":"2018-02-08","LOW":39.11,"LTP":39.5,"MARKET_CAPITALISATION":326.4,"PE_RATIO":23.78,"PREV_CLOSE":39.33,"SEO_SYMBOL":"medico-remedies-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"MEDICO","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/MEDICO.png","VOLUME":60839},{"CHAIRMAN_NAME":"Babulal Jain","DISPLAY_SYMBOL":"Lyka Labs","HIGH":76.83,"ISIN":"INE933A01014","LISTING_DATE":"","LOW":73.9,"LTP":76.83,"MARKET_CAPITALISATION":268.9,"PE_RATIO":-29.23,"PREV_CLOSE":75.33,"SEO_SYMBOL":"lyka-labs-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"LYKALABS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/LYKALABS.png","VOLUME":23070},{"CHAIRMAN_NAME":"Mihir R Ghatalia","DISPLAY_SYMBOL":"Aarey Drugs & Pharmaceuticals","HIGH":95,"ISIN":"INE198H01019","LISTING_DATE":"","LOW":91.91,"LTP":94.44,"MARKET_CAPITALISATION":260.07,"PE_RATIO":67.84,"PREV_CLOSE":91.72,"SEO_SYMBOL":"aarey-drugs-pharm-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"AAREYDRUGS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/AAREYDRUGS.png","VOLUME":146325},{"CHAIRMAN_NAME":"Sanjiv Goyal","DISPLAY_SYMBOL":"Nectar Lifesciences","HIGH":12.65,"ISIN":"INE023H01027","LISTING_DATE":"2005-07-18","LOW":12.1,"LTP":12.17,"MARKET_CAPITALISATION":239.14,"PE_RATIO":-0.97,"PREV_CLOSE":12.31,"SEO_SYMBOL":"nectar-lifesciences-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"NECLIFE","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/NECLIFE.png","VOLUME":274924},{"CHAIRMAN_NAME":"Harshad Nanubhai Rathod","DISPLAY_SYMBOL":"Accretion Pharmaceuticals","HIGH":210,"ISIN":"INE0T8T01010","LISTING_DATE":"2025-05-21","LOW":202,"LTP":202,"MARKET_CAPITALISATION":227.88,"PE_RATIO":23.56,"PREV_CLOSE":205,"SEO_SYMBOL":"accretion-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"ACCPL","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ACCPL.png","VOLUME":7200},{"CHAIRMAN_NAME":"T Y Prabhu","DISPLAY_SYMBOL":"Natural Capsules","HIGH":226.98,"ISIN":"INE936B01015","LISTING_DATE":"","LOW":218.5,"LTP":226.98,"MARKET_CAPITALISATION":225.07,"PE_RATIO":-9.03,"PREV_CLOSE":216.18,"SEO_SYMBOL":"natural-capsules-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"NATCAPSUQ","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/NATCAPSUQ.png","VOLUME":18619},{"CHAIRMAN_NAME":"FALGUN VALLABHBHAI SAVANI","DISPLAY_SYMBOL":"Par Drugs & Chemical","HIGH":180,"ISIN":"INE04LG01015","LISTING_DATE":"2019-05-16","LOW":155.1,"LTP":164.95,"MARKET_CAPITALISATION":207.03,"PE_RATIO":14.28,"PREV_CLOSE":168.25,"SEO_SYMBOL":"par-drugs-chemical-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"PAR","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/PAR.png","VOLUME":726278},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Bio Medica Laboratories","HIGH":166.65,"ISIN":"INE1BKA01015","LISTING_DATE":"2026-05-29","LOW":155.15,"LTP":162.3,"MARKET_CAPITALISATION":202.33,"PE_RATIO":17.03,"PREV_CLOSE":160.9,"SEO_SYMBOL":"","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"BMLL","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/BMLL.png","VOLUME":73000},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Sat Kartar Life","HIGH":126,"ISIN":"INE0NB801022","LISTING_DATE":"2025-01-17","LOW":117.55,"LTP":118.2,"MARKET_CAPITALISATION":192.23,"PE_RATIO":11.24,"PREV_CLOSE":121.7,"SEO_SYMBOL":"sat-kartar-shopping-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"SATKARTAR","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SATKARTAR.png","VOLUME":38400},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Brooks Laboratories","HIGH":65.95,"ISIN":"INE650L01011","LISTING_DATE":"2011-09-05","LOW":64,"LTP":64.15,"MARKET_CAPITALISATION":191.8,"PE_RATIO":14.85,"PREV_CLOSE":65.1,"SEO_SYMBOL":"brooks-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"BROOKS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/BROOKS.png","VOLUME":24891},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Parnax Lab","HIGH":144.95,"ISIN":"INE383L01019","LISTING_DATE":"","LOW":134.8,"LTP":135,"MARKET_CAPITALISATION":157.6,"PE_RATIO":17.46,"PREV_CLOSE":137.23,"SEO_SYMBOL":"parnax-lab-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"PARNAXLAB","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/PARNAXLAB.png","VOLUME":7999},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Balaxi Pharmaceuticals","HIGH":26.99,"ISIN":"INE618N01022","LISTING_DATE":"","LOW":24.41,"LTP":25.8,"MARKET_CAPITALISATION":138.07,"PE_RATIO":56.84,"PREV_CLOSE":25.01,"SEO_SYMBOL":"balaxi-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"BALAXI","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/BALAXI.png","VOLUME":222864},{"CHAIRMAN_NAME":"Mr Anil Kumar Sabarwal","DISPLAY_SYMBOL":"Quest Laboratories","HIGH":86,"ISIN":"INE0TNW01017","LISTING_DATE":"2024-05-23","LOW":84.75,"LTP":84.8,"MARKET_CAPITALISATION":137.65,"PE_RATIO":0,"PREV_CLOSE":84,"SEO_SYMBOL":"quest-laboratories-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"QUESTLAB","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/QUESTLAB.png","VOLUME":3600},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Bal Pharma","HIGH":90.5,"ISIN":"INE083D01012","LISTING_DATE":"","LOW":85.13,"LTP":87.71,"MARKET_CAPITALISATION":136.36,"PE_RATIO":18.76,"PREV_CLOSE":85.65,"SEO_SYMBOL":"bal-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"BALPHARMA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/BALPHARMA.png","VOLUME":55480},{"CHAIRMAN_NAME":"Mahendra Singh Chawla","DISPLAY_SYMBOL":"Alpa Laboratories","HIGH":64.6,"ISIN":"INE385I01010","LISTING_DATE":"2007-08-06","LOW":63.05,"LTP":63.3,"MARKET_CAPITALISATION":132.83,"PE_RATIO":33.16,"PREV_CLOSE":63.13,"SEO_SYMBOL":"alpa-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ALPA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ALPA.png","VOLUME":5832},{"CHAIRMAN_NAME":"R T Ravi","DISPLAY_SYMBOL":"Krebs Biochemicals & Industries","HIGH":56.4,"ISIN":"INE268B01013","LISTING_DATE":"","LOW":53.65,"LTP":54.5,"MARKET_CAPITALISATION":118.4,"PE_RATIO":-8.4,"PREV_CLOSE":54.91,"SEO_SYMBOL":"krebs-biochemicals-industries-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"KREBSBIO","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/KREBSBIO.png","VOLUME":7124},{"CHAIRMAN_NAME":"Dharmesh Dasharathbhai Patel","DISPLAY_SYMBOL":"Curis Lifesciences","HIGH":147,"ISIN":"INE1BZN01016","LISTING_DATE":"2025-11-14","LOW":140.6,"LTP":145.1,"MARKET_CAPITALISATION":114.76,"PE_RATIO":21.41,"PREV_CLOSE":141.95,"SEO_SYMBOL":"curis-lifesciences-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"CURIS","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/CURIS.png","VOLUME":39000},{"CHAIRMAN_NAME":"R K P Verma","DISPLAY_SYMBOL":"Makers Laboratories","HIGH":200.97,"ISIN":"INE987A01010","LISTING_DATE":"","LOW":182.06,"LTP":200.77,"MARKET_CAPITALISATION":107.8,"PE_RATIO":9.59,"PREV_CLOSE":182.7,"SEO_SYMBOL":"makers-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"MAKERSL","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/MAKERSL.png","VOLUME":9968},{"CHAIRMAN_NAME":"Atul Vasani","DISPLAY_SYMBOL":"Vaishali Pharma","HIGH":8.48,"ISIN":"INE972X01022","LISTING_DATE":"2017-08-22","LOW":8.02,"LTP":8.36,"MARKET_CAPITALISATION":105.15,"PE_RATIO":23.71,"PREV_CLOSE":8.06,"SEO_SYMBOL":"vaishali-pharma-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"VAISHALI","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/VAISHALI.png","VOLUME":92138},{"CHAIRMAN_NAME":"Sharadkumar Dashrathbhai Patel","DISPLAY_SYMBOL":"Sotac Pharmaceuticals","HIGH":0,"ISIN":"INE0O2D01012","LISTING_DATE":"2023-04-13","LOW":0,"LTP":90.05,"MARKET_CAPITALISATION":99.51,"PE_RATIO":17.25,"PREV_CLOSE":90.05,"SEO_SYMBOL":"sotac-pharmaceuticals-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"SOTAC","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SOTAC.png","VOLUME":0},{"CHAIRMAN_NAME":"Anil Kumar Khaitan","DISPLAY_SYMBOL":"Sunil Healthcare","HIGH":80,"ISIN":"INE671C01016","LISTING_DATE":"","LOW":79.58,"LTP":80,"MARKET_CAPITALISATION":81.61,"PE_RATIO":22.53,"PREV_CLOSE":79.58,"SEO_SYMBOL":"sunil-synchem-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"SUNLOC","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SUNLOC.png","VOLUME":544},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Vilin Bio Med","HIGH":51.7,"ISIN":"INE0L4V01013","LISTING_DATE":"2023-06-30","LOW":50,"LTP":51.7,"MARKET_CAPITALISATION":75.11,"PE_RATIO":39.09,"PREV_CLOSE":49.25,"SEO_SYMBOL":"vilin-bio-med-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"VILINBIO","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/VILINBIO.png","VOLUME":100000},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Onyx Biotec","HIGH":39.25,"ISIN":"INE0WVU01018","LISTING_DATE":"2024-11-22","LOW":37.95,"LTP":39.25,"MARKET_CAPITALISATION":72.35,"PE_RATIO":-332.5,"PREV_CLOSE":39.9,"SEO_SYMBOL":"onyx-biotec-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"ONYX","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ONYX.png","VOLUME":50000},{"CHAIRMAN_NAME":"Dilip V Acharekar","DISPLAY_SYMBOL":"Vineet Laboratories","HIGH":38.69,"ISIN":"INE505Y01010","LISTING_DATE":"","LOW":37.1,"LTP":37.5,"MARKET_CAPITALISATION":72.16,"PE_RATIO":64.66,"PREV_CLOSE":37.57,"SEO_SYMBOL":"vineet-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"VINEETLAB","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/VINEETLAB.png","VOLUME":49880},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Zenith Drugs","HIGH":41.4,"ISIN":"INE0QWN01013","LISTING_DATE":"2024-02-27","LOW":39.8,"LTP":39.85,"MARKET_CAPITALISATION":68.6,"PE_RATIO":7.69,"PREV_CLOSE":40,"SEO_SYMBOL":"zenith-drugs-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"ZENITHDRUG","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ZENITHDRUG.png","VOLUME":20800},{"CHAIRMAN_NAME":"Smiral Ashwinkumar Patel","DISPLAY_SYMBOL":"JFL Life Sciences","HIGH":9.85,"ISIN":"INE0LA901015","LISTING_DATE":"","LOW":9.8,"LTP":9.8,"MARKET_CAPITALISATION":66.98,"PE_RATIO":4.95,"PREV_CLOSE":10.15,"SEO_SYMBOL":"jfl-life-sciences-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"JFLLIFE","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/JFLLIFE.png","VOLUME":66000},{"CHAIRMAN_NAME":"Juhi Sawajani","DISPLAY_SYMBOL":"Sunrest Lifescience","HIGH":38.75,"ISIN":"INE0PLZ01012","LISTING_DATE":"","LOW":35,"LTP":38.75,"MARKET_CAPITALISATION":60.08,"PE_RATIO":3.76,"PREV_CLOSE":35,"SEO_SYMBOL":"sunrest-lifescience-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"SUNREST","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/SUNREST.png","VOLUME":9600},{"CHAIRMAN_NAME":"V Manohar Rao","DISPLAY_SYMBOL":"Vivimed Labs","HIGH":6.54,"ISIN":"INE526G01021","LISTING_DATE":"2005-08-17","LOW":6.54,"LTP":6.54,"MARKET_CAPITALISATION":55.3,"PE_RATIO":-0.31,"PREV_CLOSE":6.67,"SEO_SYMBOL":"vivimed-labs-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"VIVIMEDLAB","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/VIVIMEDLAB.png","VOLUME":86192},{"CHAIRMAN_NAME":"Ketan Shah","DISPLAY_SYMBOL":"Biofil Chemicals","HIGH":32.68,"ISIN":"INE829A01014","LISTING_DATE":"","LOW":31.71,"LTP":31.97,"MARKET_CAPITALISATION":51.99,"PE_RATIO":106.33,"PREV_CLOSE":31.95,"SEO_SYMBOL":"biofil-chem-pharma-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"BIOFILCHEM","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/BIOFILCHEM.png","VOLUME":23209},{"CHAIRMAN_NAME":"Govardhan M Dhoot","DISPLAY_SYMBOL":"Mangalam Drugs & Organics","HIGH":31.4,"ISIN":"INE584F01014","LISTING_DATE":"2005-05-23","LOW":29.73,"LTP":30.3,"MARKET_CAPITALISATION":48,"PE_RATIO":-1.25,"PREV_CLOSE":30.33,"SEO_SYMBOL":"mangalam-drugs-and-organics-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"MANGALAM","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/MANGALAM.png","VOLUME":25497},{"CHAIRMAN_NAME":"Omkar P Herlekar","DISPLAY_SYMBOL":"Lasa Supergenerics","HIGH":6.98,"ISIN":"INE670X01014","LISTING_DATE":"","LOW":6.81,"LTP":6.82,"MARKET_CAPITALISATION":33.97,"PE_RATIO":-2.11,"PREV_CLOSE":6.78,"SEO_SYMBOL":"lasa-supergenerics-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"LASA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/LASA.png","VOLUME":25647},{"CHAIRMAN_NAME":"R C Mittal","DISPLAY_SYMBOL":"Medi Caps","HIGH":27,"ISIN":"INE442D01010","LISTING_DATE":"","LOW":24,"LTP":25.08,"MARKET_CAPITALISATION":33.3,"PE_RATIO":-19.17,"PREV_CLOSE":26.7,"SEO_SYMBOL":"medi-caps-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"MEDICAPQ","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/MEDICAPQ.png","VOLUME":2755},{"CHAIRMAN_NAME":"B K Gupta","DISPLAY_SYMBOL":"Medicamen Organics","HIGH":0,"ISIN":"INE0PE401018","LISTING_DATE":"2024-06-28","LOW":0,"LTP":25.65,"MARKET_CAPITALISATION":31.21,"PE_RATIO":-9.5,"PREV_CLOSE":25.65,"SEO_SYMBOL":"medicamen-organics-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"MEDIORG","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/MEDIORG.png","VOLUME":0},{"CHAIRMAN_NAME":"","DISPLAY_SYMBOL":"Walpar Nutritions","HIGH":25.9,"ISIN":"INE0G2G01015","LISTING_DATE":"2021-07-13","LOW":24.1,"LTP":24.1,"MARKET_CAPITALISATION":23.19,"PE_RATIO":7.72,"PREV_CLOSE":24.7,"SEO_SYMBOL":"walpar.ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"WALPAR","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/WALPAR.png","VOLUME":4000},{"CHAIRMAN_NAME":"Panilam Lakhatariya","DISPLAY_SYMBOL":"Mono Pharmacare","HIGH":0,"ISIN":"INE0OIP01012","LISTING_DATE":"2023-09-07","LOW":0,"LTP":8.95,"MARKET_CAPITALISATION":15.81,"PE_RATIO":44.75,"PREV_CLOSE":8.95,"SEO_SYMBOL":"mono-pharmacare-ltd","SUPPORTED_EXCHANGES":"NSE","SYMBOL":"MONOPHARMA","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/MONOPHARMA.png","VOLUME":0},{"CHAIRMAN_NAME":"Sarang Balbhimrao Patodekar","DISPLAY_SYMBOL":"Ortin Global","HIGH":15.77,"ISIN":"INE749B01020","LISTING_DATE":"","LOW":15,"LTP":15.02,"MARKET_CAPITALISATION":12.55,"PE_RATIO":-13.9,"PREV_CLOSE":15.43,"SEO_SYMBOL":"ortin-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"ORTINGLOBE","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/ORTINGLOBE.png","VOLUME":2598}],"PRICE_INFORMATION":{"CHAIRMAN_NAME":"Satish Reddy","DISPLAY_SYMBOL":"Dr Reddys Laboratories","HIGH":1164.3,"LISTING_DATE":"","LOW":1155,"LTP":1155,"MARKET_CAPITALISATION":96529.5,"PE_RATIO":30.44,"PREV_CLOSE":1156.5,"SEO_SYMBOL":"dr-reddys-laboratories-ltd","SUPPORTED_EXCHANGES":"BOTH","SYMBOL":"DRREDDY","SYMBOL_LINK":"https://images.askfuzz.ai/symbol/DRREDDY.png","VOLUME":338167},"QUATERLY_FUNDAMANETAL":{"QUARTERLY_TAGS_CONSOLIDATED_FORMATTED":{"periods":["Q1 FY27","Q4 FY26","Q3 FY26","Q2 FY26","Q1 FY26","Q4 FY25","Q3 FY25","Q2 FY25","Q1 FY25","Q4 FY24","Q3 FY24","Q2 FY24","Q1 FY24","Q4 FY23","Q3 FY23","Q2 FY23","Q1 FY23","Q4 FY22","Q3 FY22","Q2 FY22","Q1 FY22","Q4 FY21","Q3 FY21","Q2 FY21","Q1 FY21","Q4 FY20","Q3 FY20","Q2 FY20","Q1 FY20","Q4 FY19","Q3 FY19","Q2 FY19","Q1 FY19","Q4 FY18","Q3 FY18","Q2 FY18","Q1 FY18","Q4 FY17","Q3 FY17","Q2 FY17","Q1 FY17","Q4 FY16","Q3 FY16","Q2 FY16","Q1 FY16","Q4 FY15"],"parameters":[{"key":"Sales","label":"Sales"},{"key":"Expenses","label":"Expenses"},{"key":"Ebitda","label":"Ebitda"},{"key":"Depreciation","label":"Depreciation"},{"key":"Ebit","label":"Ebit"},{"key":"Interest","label":"Interest"},{"key":"ProfitBeforeTax","label":"ProfitBeforeTax"},{"key":"NetProfit","label":"NetProfit"},{"key":"Eps","label":"Eps"}],"values":[[8070.5,7516.2,8727,8804.9,8545.2,8506,8358.6,8016.1,7672.7,7083,7214.8,6880.2,6738.4,6296.8,6770,6305.7,5215.4,5436.8,5319.7,5763.2,4919.4,4728.4,4929.6,4896.7,4417.5,4431.8,4383.8,4800.8,3843.6,4016.6,3850,3797.8,3720.7,3534.9,3806,3546,3315.9,3554.2,3706.5,3585.7,3234.5,3756.1,3968,3988.9,3737.2,3870.4],[7239.9,7163.9,6865.9,6818.4,6398.5,6530.5,6108.2,5961.7,5566.2,5282.6,5213.7,4894.3,4695.8,4781.3,4851.3,4432.9,4291.7,5023.9,4122.6,4427.1,4210.6,3715,4402.6,3754.8,3305.2,3499.7,4685.8,3749,3116.5,3210.7,3060,3058.2,2967.7,2990.3,3041.4,2890.4,3010,3021.4,2858.7,2989.3,2854.5,3313.3,2995.7,2888.2,2765.2,3270.9],[1186.1,832.3,2132.2,2316.7,2437.2,2503.1,2404.8,2368,2299.6,2001.4,2220,2305.1,2220.9,1661.6,1983.3,1927.6,1787,545.3,1271.4,1566.3,833.3,1113.9,612.6,1200.4,1207.1,1016.2,-217.1,1117.5,1173.5,904.9,901.2,878.7,811.7,589.5,807.6,687.2,343.9,553.3,888.1,640.2,447,527.8,1034.1,1173.1,1047.7,616.3],[536.6,557.1,521,504.6,476.1,454.7,471.4,397,380.6,367.7,373.5,375.5,353.3,315.5,323.7,309.2,301.8,293,294.2,294.1,283.9,308.8,311.2,316.5,292.3,274.1,286.9,313.1,289,287.2,290.3,278.6,278.7,276.3,271.5,270.2,259.2,254.3,266.5,262.2,243.6,276.7,235.4,223.5,203.3,0],[649.5,275.2,1611.2,1812.1,1961.1,2048.4,1933.4,1971,1919,1633.7,1846.5,1929.6,1867.6,1346.1,1659.6,1618.4,1485.2,252.3,977.2,1272.2,549.4,805.1,301.4,883.9,914.8,742.1,-504,804.4,884.5,617.7,610.9,600.1,533,313.2,536.1,417,84.7,299,621.6,378,203.4,251.1,798.7,949.6,844.4,616.3],[125.5,105.7,94.4,90.7,83,65.6,81.7,75.7,59.8,59.3,39.4,35.3,37.1,35.4,41.8,30.9,34.7,31.5,21.6,23.4,19.3,29.7,18.8,25.2,23.3,23,15.2,30.3,29.8,24.5,24.1,20.8,19.5,17.8,17.2,22.3,21.5,19.6,16.4,12.6,14.8,17,16,21.5,28.1,23.3],[553.3,199.7,1543.2,1744.8,1905,2005.2,1874.3,1917.4,1882.6,1605.2,1829.1,1916.7,1850,1329.1,1637.7,1613.6,1468,258.9,974.2,1272.5,555.8,815.2,294.9,872.9,900.5,736.2,-505.9,786.1,869.3,606.2,601.4,599,529.3,314.4,547,408.5,80.5,337.1,621.9,396,198.8,273,732.6,959.9,831.3,593],[435.6,221.3,1189.6,1336.8,1409.9,1586.7,1404.2,1341.9,1392.4,1309.8,1380.9,1482.2,1405,960.1,1243.9,1114.2,1189,97,709.3,995.8,380.4,557.3,27.9,771.8,594.6,781.1,-538.4,1106.8,676.5,455.4,500.3,518.3,476.1,272.1,302.7,305.4,66.6,337.6,492.3,308.9,153.5,122.6,585.7,774.7,647.4,518.8],[5.33,2.65,14.53,16.18,17.04,19.12,16.97,75.4,83.61,78.66,82.94,89.09,84.55,57.79,74.91,67.13,71.64,5.84,42.75,60.03,22.95,33.61,1.68,46.54,35.87,47.12,-32.48,66.78,40.81,27.45,30.16,31.22,28.69,16.39,18.25,18.42,4.02,20.38,29.72,18.64,9.06,7.19,34.34,45.42,37.99,30.45]]},"QUARTERLY_TAGS_STANDALONE_FORMATTED":{"periods":["Q1 FY27","Q4 FY26","Q3 FY26","Q2 FY26","Q1 FY26","Q4 FY25","Q3 FY25","Q2 FY25","Q1 FY25","Q4 FY24","Q3 FY24","Q2 FY24","Q1 FY24","Q4 FY23","Q3 FY23","Q2 FY23","Q1 FY23","Q4 FY22","Q3 FY22","Q2 FY22","Q1 FY22","Q4 FY21","Q3 FY21","Q2 FY21","Q1 FY21","Q4 FY20","Q3 FY20","Q2 FY20","Q1 FY20","Q4 FY19","Q3 FY19","Q2 FY19","Q1 FY19","Q4 FY18","Q3 FY18","Q2 FY18","Q1 FY18","Q4 FY17","Q3 FY17","Q2 FY17","Q1 FY17","Q4 FY16","Q3 FY16","Q2 FY16","Q1 FY16","Q4 FY15"],"parameters":[{"key":"Sales","label":"Sales"},{"key":"Expenses","label":"Expenses"},{"key":"Ebitda","label":"Ebitda"},{"key":"Depreciation","label":"Depreciation"},{"key":"Ebit","label":"Ebit"},{"key":"Interest","label":"Interest"},{"key":"ProfitBeforeTax","label":"ProfitBeforeTax"},{"key":"NetProfit","label":"NetProfit"},{"key":"Eps","label":"Eps"}],"values":[[5115,3802.6,4266.4,4602.9,7788.7,5546.3,4997.8,6678.8,5823.9,5081.8,4083.1,4819.1,5420.1,4537.8,3879.6,4866.1,3615.6,3631.9,3463.8,3809.5,3410.1,3313.5,3397.5,3333.6,3236.8,2837.9,3032.2,3435.3,2508.7,2634.7,2718.2,2616.1,2603.9,2476.6,2501.3,2246.2,2078.5,2303.4,2559.1,2610.8,2154.8,2367.9,2439.2,2894.3,2512.9,2671.3],[4689.2,4321.9,4183.1,4138.3,3972.5,4119.9,3822.6,3974.7,3888.2,3726.2,3446.7,3209.6,3209.6,3492.9,3222.5,3077.5,3051.1,2998.8,2865.6,3075.1,2871.6,2747.8,2634.2,2529.2,2315.7,2330.9,2288.3,2285.2,2078,2208.6,2044.8,2066.4,2042.8,2165.9,1987.5,1940.7,1941.3,2050.8,1927.9,2080.6,1927.9,2374.6,2024.9,1976.9,1861.8,1932.6],[887.8,67.3,459.9,844.5,4235.3,1857.4,1427.8,2929.2,2170.8,1591.3,883.9,1852.2,2461.3,1175.9,726.5,1920.8,982.9,784.6,677,866.4,748.1,684.5,836.8,843.2,1573.4,648.2,825,1237.5,902.1,509.3,779.7,639.4,609.7,399.5,583.2,354,197.2,368.8,729.6,610.8,627.6,130.9,424.8,1003.1,774.6,843.4],[317.7,318.5,314.3,294.8,279.8,264.5,265.1,260,249.8,246.2,246.4,245.8,237.2,236.7,238.8,226.2,221.5,205.2,205.4,206.6,197.1,210.7,212.4,214.2,197.7,192.3,195.8,204.1,197,204.2,193.5,190.8,192.1,190,198.3,194.8,191,189.6,183.7,189.3,172.5,181.1,166.9,159.1,142.3,136.8],[570.1,-251.2,145.6,549.7,3955.5,1592.9,1162.7,2669.2,1921,1345.1,637.5,1606.4,2224.1,939.2,487.7,1694.6,761.4,579.4,471.6,659.8,551,473.8,624.4,629,1375.7,455.9,629.2,1033.4,705.1,305.1,586.2,448.6,417.6,209.5,384.9,159.2,6.2,179.2,545.9,421.5,455.1,-50.2,257.9,844,632.3,706.6],[73.1,54.3,41.4,33.4,19.2,31.1,43.3,28.4,7.1,5.9,5.6,5.8,4.5,2.6,2.8,1.7,9.8,12.7,7.7,11.1,6.5,16.9,6.5,9.3,14,11.8,11.7,12.2,12.1,8.7,15.8,15.8,16.5,14,13.3,19,16.4,15.8,16.5,12.3,12.6,14.6,13.5,14.6,21.3,18.8],[497,-305.5,104.2,516.3,3936.3,1561.8,1119.4,2640.8,1913.9,1339.2,631.9,1600.6,2219.6,936.6,484.9,1692.9,751.6,566.7,463.9,648.7,544.5,456.9,617.9,619.7,1361.7,444.1,617.5,1021.2,693,296.4,570.4,432.8,401.1,195.5,371.6,140.2,-10.2,163.4,529.4,409.2,442.5,-64.8,244.4,829.4,611,687.8],[404.7,-219.4,90.6,387.3,2961.2,1200.7,849.4,1882.1,1417.2,1034.8,475.2,1192.6,1639.4,672.4,324.6,1116.3,499.5,419.7,341.1,449,413.4,311.5,443.7,481,950.2,502.8,521.7,1365.1,548.1,202.8,399.4,346.2,328.9,176.7,296.9,100.7,-7.3,223,438.8,313.2,409.1,-38.6,237,682.6,493.4,571.4],[4.86,-2.63,1.09,4.65,35.59,14.41,10.2,113,85.1,62.14,28.55,71.68,98.66,40.49,19.54,67.25,30.1,25.29,20.55,27.07,24.94,18.78,26.74,29,57.31,30.34,31.47,82.36,33.06,12.22,24.08,20.86,19.82,10.65,17.9,6.07,-0.44,13.46,26.49,18.91,24.13,-2.26,13.89,40.02,28.95,33.54]]}},"ROI":{"1Y":-7.75,"3M":-9.22,"3Y":3.66,"5Y":18.99,"6M":-10.65},"SHARE_HOLDING":{"periods":["Q1 FY27","Q4 FY26","Q3 FY26","Q2 FY26","Q1 FY26","Q4 FY25","Q3 FY25","Q2 FY25","Q1 FY25","Q4 FY24","Q3 FY24","Q2 FY24","Q1 FY24","Q4 FY23","Q3 FY23","Q2 FY23","Q1 FY23","Q4 FY22","Q3 FY22","Q2 FY22","Q1 FY22","Q4 FY21"],"parameters":[{"key":"Dii","label":"Dii"},{"key":"Fii","label":"Fii"},{"key":"Government","label":"Government"},{"key":"Others","label":"Others"},{"key":"Promoter","label":"Promoter"},{"key":"Public","label":"Public"}],"values":[[31.74,30.72,30.44,27.98,26.74,25.62,22.9,21.48,20.73,18.31,16.21,21.04,21.99,23.05,23.38,24.47,24.95,24.46,21.95,20.92,15.08,14.25],[32.07,33.08,33.2,35.52,36.36,37.29,40.08,41.75,42.27,44.49,0,42.21,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[2.13,1.99,2.07,2.3,2.22,2.25,2.3,2.06,2.29,2.3,48.69,2.18,43.8,42.66,42.08,40.76,40.12,40.45,43.07,44.22,50.43,50.7],[26.64,26.63,26.64,26.64,26.64,26.64,26.64,26.64,26.65,26.65,26.65,26.66,26.69,26.7,26.7,26.71,26.71,26.72,26.72,26.72,26.73,26.74],[7.42,7.57,7.65,7.56,8.04,8.2,8.07,8.07,8.07,8.25,8.44,7.91,7.51,7.59,7.84,8.06,8.22,8.37,8.27,8.14,7.76,8.31]]},"TYPE":"STOCK"},"documents":{"annual":[{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/AnnualReports/a874cf2f-38fb-4700-b7a0-b7665b4f3b54.pdf","category":"AnnualReports","description":"Dr. Reddy's Laboratories Ltd submitted Integrated Annual Report for FY 2024-25 as per Regulation 34(1) of SEBI LODR","quarter":"","financial_year":"2024-25","doc_date":"2025-10-01","num_pages":"256"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/AnnualReports/DrReddysLaboratoriesLtd_INE089A01031_Annual_Report_2024.pdf","category":"AnnualReports","description":"","quarter":"","financial_year":"2023-24","doc_date":"2025-09-19","num_pages":"236"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/AnnualReports/DrReddysLaboratoriesLtd_INE089A01031_Annual_Report_2023.pdf","category":"AnnualReports","description":"","quarter":"","financial_year":"2022-23","doc_date":"2025-09-06","num_pages":"222"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/AnnualReports/2a167786-8552-4298-ba0d-e5a6f1efa6ef.pdf","category":"AnnualReports","description":"","quarter":"","financial_year":"2021-22","doc_date":"2026-06-16","num_pages":"286"}],"quarterly":[{"label":"Q1 FY2026-27","documents":[{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/Transcripts/fd1d3d9c-9c71-494e-a25a-e78639a65545.pdf","category":"Transcripts","description":"Dr Reddys Laboratories Ltd transcript of earnings call held on 22 Jul 2026","quarter":"Q1","financial_year":"2026-27","doc_date":"2026-07-28","num_pages":"22"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/QuarterlyResults/6ac125d5-bb55-4743-a830-2a7f6d269439.pdf","category":"QuarterlyResults","description":"Dr Reddys Laboratories Ltd Q1FY27 unaudited financial results","quarter":"Q1","financial_year":"2026-27","doc_date":"2026-07-23","num_pages":"3"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/InvestorPresentations/a0241001-6317-4799-91fb-d567d6e59c67.pdf","category":"InvestorPresentations","description":"Dr Reddys Laboratories Ltd investor presentation for Q1FY27","quarter":"Q1","financial_year":"2026-27","doc_date":"2026-07-22","num_pages":"16"}]},{"label":"Q4 FY2025-26","documents":[{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/Transcripts/212aa87b-af61-4ce7-9145-8c8e71cdacf5.pdf","category":"Transcripts","description":"","quarter":"Q4","financial_year":"2025-26","doc_date":"2026-07-03","num_pages":"18"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/QuarterlyResults/bd298867-6d8f-4294-980d-0e172f043475.pdf","category":"QuarterlyResults","description":"Dr. Reddy's Laboratories Limited newspaper advertisement regarding audited financial results for Q4FY26 under Regulation 47 published on May 13, 2026","quarter":"Q4","financial_year":"2025-26","doc_date":"2026-05-13","num_pages":"3"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/InvestorPresentations/d4c9ece6-34b8-4f65-a787-ca1557820a5c.pdf","category":"InvestorPresentations","description":"Dr. Reddy's Laboratories Limited investor presentation for Q4FY26 under Regulation 30 scheduled on May 12, 2026","quarter":"Q4","financial_year":"2025-26","doc_date":"2026-05-12","num_pages":"18"}]},{"label":"Q3 FY2025-26","documents":[{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/QuarterlyResults/1e229049-b4d8-4222-a2fc-b7e950cd2bf2.pdf","category":"QuarterlyResults","description":"Igarashi Motors India Limited announced Q3FY26 quarterly results for quarter ended December 31, 2025 under Regulation 33","quarter":"Q3","financial_year":"2025-26","doc_date":"2026-02-12","num_pages":"3"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/Transcripts/32a5c52d-b945-4d33-8bf9-a6c69d53e461.pdf","category":"Transcripts","description":"Dr. Reddy's Laboratories Limited Q3FY26 earnings call transcript conducted on January 21, 2026 under Regulation 30","quarter":"Q3","financial_year":"2025-26","doc_date":"2026-01-27","num_pages":"20"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/InvestorPresentations/122767b1-a4c0-42a6-a1e3-b04c789bf4d5.pdf","category":"InvestorPresentations","description":"Dr. Reddy's Laboratories Limited Q3FY26 Results Update presentation under Regulation 30 dated January 21, 2026","quarter":"Q3","financial_year":"2025-26","doc_date":"2026-01-21","num_pages":"18"}]},{"label":"Q2 FY2025-26","documents":[{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/Transcripts/e3a9f53e-522c-4721-a5e7-21155b0e6043.pdf","category":"Transcripts","description":"Dr. Reddy's Laboratories Ltd. shared transcript of Q2 FY26 earnings call conducted on October 24, 2025 for quarter and half-year ended September 30, 2025 [Reg 30]","quarter":"Q2","financial_year":"2025-26","doc_date":"2025-10-30","num_pages":"20"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/InvestorPresentations/ed038209-b1ee-4e56-a2c3-ff5818d3548d.pdf","category":"InvestorPresentations","description":"Dr. Reddy's Laboratories Ltd. submitted Q2 FY26 Unaudited Financial Results Presentation for the quarter and half-year ended September 30, 2025 [Reg 30]","quarter":"Q2","financial_year":"2025-26","doc_date":"2025-10-24","num_pages":"18"}]},{"label":"Q1 FY2025-26","documents":[{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/Transcripts/752cb28e-5170-4a25-9a3e-3113cc074f21.pdf","category":"Transcripts","description":"","quarter":"Q1","financial_year":"2025-26","doc_date":"2026-07-20","num_pages":"21"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/InvestorPresentations/9f0cb3e5-747e-4ab0-9943-fc442850f676.pdf","category":"InvestorPresentations","description":"Dr. Reddy's Laboratories Ltd. submitted Q1 FY26 unaudited financial results presentation for the quarter ended June 30, 2025 [Reg 30]","quarter":"Q1","financial_year":"2025-26","doc_date":"2025-10-01","num_pages":"14"}]},{"label":"Q4 FY2024-25","documents":[{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/Transcripts/78691f37-f474-484f-adec-a6cb694cd59a.pdf","category":"Transcripts","description":"","quarter":"Q4","financial_year":"2024-25","doc_date":"2026-07-20","num_pages":"19"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/InvestorPresentations/6f6c7b6f-4fa6-4ee4-b52b-a696f9f48a95.pdf","category":"InvestorPresentations","description":"Dr. Reddy's Laboratories Ltd. submitted Q4 FY25 and full year audited financial results presentation [Reg 30]","quarter":"Q4","financial_year":"2024-25","doc_date":"2025-10-01","num_pages":"17"}]},{"label":"Q2 FY2022-23","documents":[{"symbol":"","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/Transcripts/27eb9a78-8354-4a75-85ba-5e47fa17f992_2022-11-03.pdf","category":"Transcripts","description":"Document contains corrupted or encrypted text that cannot be properly analyzed","quarter":"Q2","financial_year":"2022-23","doc_date":"2025-07-18","num_pages":"17"}]},{"label":"Q1 FY2022-23","documents":[{"symbol":"","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/Transcripts/0ceb010b-8362-41c5-bd1f-87b550e29e0d_2022-08-03.pdf","category":"Transcripts","description":"Dr. Reddy's Laboratories Limited earnings call transcript for Q1 FY2023 under Regulation 30 conducted on July 28, 2022","quarter":"Q1","financial_year":"2022-23","doc_date":"2025-07-18","num_pages":"1"}]},{"label":"Q4 FY2021-22","documents":[{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/InvestorPresentations/bf5b070f-112f-4548-a953-b8f9091bdf98.pdf","category":"InvestorPresentations","description":"","quarter":"Q4","financial_year":"2021-22","doc_date":"2025-10-07","num_pages":"42"},{"symbol":"","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/Transcripts/91a842b7-ec20-4d58-8fcd-d14c568866a8_2022-05-24.pdf","category":"Transcripts","description":"Dr. Reddy's Laboratories Limited earnings call transcript for Q4 FY22 under Regulation 30 conducted on May 19, 2022","quarter":"Q4","financial_year":"2021-22","doc_date":"2025-07-18","num_pages":"20"}]},{"label":"Q3 FY2021-22","documents":[{"symbol":"","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/Transcripts/adeed18f-2e3d-4ab9-a53b-76fc3f2b2bf1_2022-02-01.pdf","category":"Transcripts","description":"","quarter":"Q3","financial_year":"2021-22","doc_date":"2025-07-18","num_pages":"16"}]},{"label":"Q2 FY2021-22","documents":[{"symbol":"","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/Transcripts/173b25c0-a5ba-4589-a842-9a4e6a986b4e_2021-11-05.pdf","category":"Transcripts","description":"Dr. Reddy's Laboratories Limited earnings call transcript for Q2 FY22 under Regulation 30 conducted on October 29, 2021","quarter":"Q2","financial_year":"2021-22","doc_date":"2025-07-18","num_pages":"17"}]}],"drhp":[],"others":[{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/RecordDates/184f0a2d-76d8-4cd5-a5bb-2085464fe5bf.pdf","category":"RecordDates","description":"Dr Reddys Laboratories Ltd newspaper publication regarding loss of share certificates and application for duplicate certificates on 20 Aug 2026","quarter":"","financial_year":"2026-27","doc_date":"2026-08-20","num_pages":"3"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/AuditReports/e9f15f69-f898-464f-96e8-5e60d5d70553.pdf","category":"AuditReports","description":"Dr. Reddy's Laboratories Limited Annual Secretarial Compliance Report for FY26 under Regulation 24A scheduled on May 28, 2026","quarter":"","financial_year":"2025-26","doc_date":"2026-05-28","num_pages":"6"},{"symbol":"DRREDDY","company_name":"Dr Reddys Laboratories Ltd","s3_path":"https://data.fuzz.co/LODR/RecordDates/e4a6c9404676483c.pdf","category":"RecordDates","description":"Dr. Reddy's Laboratories Limited board meeting intimation for consideration of final dividend for FY26 under Regulation 29 scheduled on April 16, 2026","quarter":"","financial_year":"2025-26","doc_date":"2026-04-23","num_pages":"1"}]},"signalsPromise":"$@2d","insightsPromise":"$@2e","insightsVerdictPromise":"$@2f"}]]